Multiplexed profiling of RNA and DNA modifications

JP2023551072A5Pending Publication Date: 2024-12-03ALIDA BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023555121
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-05-26
Filing Date
2021-11-24
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current methods for identifying and quantifying epitranscriptomic and epigenetic modifications in nucleic acids are not sensitive, prone to nucleic acid degradation, and lack single-base resolution and multiplexing capabilities, leading to inconsistent and incomplete detection of these modifications.

Method used

A method involving nucleic acid binding molecules with specific binding domains and adapters that transfer barcodes to target nucleic acids, enabling high-throughput, sensitive, and accurate profiling of multiple RNA and DNA modifications with single-base resolution, using barcode transfer and sequencing techniques.

Benefits of technology

Enables the precise identification and quantification of nucleic acid modifications across the genome and transcriptome, providing insights into health and disease mechanisms and potential therapeutic targets.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides compositions and methods for multiplexed profiling of RNA and DNA modifications across transcriptomes and genomes. The method combines molecular recognition of non-classical features (e.g., base modifications, backbone modifications, lesions, and / or structural elements) of target nucleic acids with the inscription of information from this recognition event into the target nucleic acid's adjacent genetic sequence using barcodes. The resulting barcoded nucleic acids are then converted into a sequencing library and read by DNA / RNA sequencing. This process reveals the sequence of the barcode, which correlates with the non-classical features in the target nucleic acid. The high-throughput profiling method described herein enables the localization of one or more modifications in a target nucleic acid. This method also allows for the identification of the nature and location of multiple or all DNA / RNA modifications in parallel.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Cross - Reference to Related Applications This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 193,402, filed May 26, 2021, and U.S. Provisional Patent Application No. 63 / 118,409, filed November 25, 2020, each of which is hereby incorporated by reference in its entirety for all purposes.

[0002] Technical Field The present disclosure generally relates to the identification and analysis of epitranscriptomic, epigenetic, and other modifications to the structure or non - classical features of nucleic acids, including RNA and DNA.

[0003] Terms of Federal Government Funding This invention was made with government support under Grant No. 1R43HG012170 - 01 awarded by the National Human Genome Research Institute. The U.S. government has certain rights in the invention.

[0004] Sequence Listing This application includes a sequence listing submitted electronically in ASCII format, which is hereby incorporated by reference in its entirety herein. The ASCII copy created on November 24, 2021, is named ALID_001_02WO_SeqList_ST25.txt and is 40 kilobytes in size.

Background Art

[0005] Background Epigenetic changes, including chemical changes in nucleotides, are widespread and play important roles in biological processes such as gene expression, gene silencing, and response to DNA damage. Similarly, chemical modifications of RNA, known as epitranscriptomic modifications, occur frequently in cells during or after transcription.

[0006] A wide range of diseases, behaviors, and other health indicators, including almost all types of cancer, cognitive impairment, and respiratory, circulatory, reproductive, autoimmune, and neurobehavioral disorders, are correlated with epigenetic changes in DNA. However, little is known about the distribution of epigenetic changes across the genome, particularly their association with health and disease. While some functions of epitranscriptome modifications are known, much remains unknown due to the lack of analytical methods to identify and quantify the locations of these modifications across intracellular RNA. Currently, little is known about the correlation levels of epitranscriptome RNA modifications and their intracellular transformations.

[0007] Combining chemical derivatization, molecular recognition (typically using antibodies for both enrichment and detection), and reverse transcription sequencing has provided profiling methods for a limited number of DNA and RNA modifications. However, these methods are not highly sensitive, often lead to nucleic acid degradation / fragmentation, and frequently fail to identify modification sites at single-nucleotide resolution. Furthermore, these methods are not suitable for multiplexing. Existing methods for sequencing common epitranscriptome RNA modifications often yield conflicting findings in both the number of detected modifications (which can differ by an order of magnitude or more) and their locations.

[0008] Therefore, improved compositions and methods for identifying, analyzing, quantifying, and locating DNA and RNA modifications are needed in the art. Such advances could pave the way for the discovery of key biological regulatory mechanisms in health and disease, as well as the development of new therapeutic paradigms in medicine. [Overview of the Initiative]

[0009] overview The present invention provides compositions and methods for identifying and analyzing epitranscriptome, epigenetic, and other chemical modifications to the structure of nucleic acids, including RNA and DNA. The present invention provides a highly parallelized, highly sensitive, highly accurate, and high-throughput method for simultaneously profiling a potentially unlimited number of DNA and / or RNA modifications at the single-molecule level.

[0010] In some embodiments, the present invention provides a nucleic acid binding molecule comprising a binding domain and an adapter, wherein the binding domain specifically binds to a non-classical feature of DNA or RNA, and the adapter comprises a nucleic acid barcode sequence specific to the non-classical feature to which the binding domain specifically binds.

[0011] In some embodiments, the present invention provides a method for producing nucleic acid-binding molecules, the method comprising conjugating an adapter to a binding domain to form an adapter-binding domain conjugate.

[0012] In some embodiments, the present invention provides a method for analyzing a plurality of target nucleic acids, the method comprising: (i) contacting a target nucleic acid with a nucleic acid binding molecule described herein; (i) transferring a nucleic acid barcode to the target nucleic acid in an environment that substantially prevents off-target generation of the barcoded nucleic acid to generate a barcoded target nucleic acid; or (ii) generating a barcoded copy of the target nucleic acid; modifying the barcoded target nucleic acid or barcoded target nucleic acid copy so that the locations of non-classical features can be identified based on the primary nucleic acid sequence of the barcoded target nucleic acid or barcoded target nucleic acid copy; and determining the nucleotide sequence of the barcoded target nucleic acid.

[0013] In some embodiments, the present invention provides a method for detecting and / or quantifying two or more nonclassical features in a plurality of target nucleic acids, the method comprising: contacting a target nucleic acid with at least two nucleic acid binding molecules, each nucleic acid binding molecule comprising a binding domain and an adapter, wherein the binding domain of each nucleic acid binding molecule binds to different nonclassical features of DNA or RNA, and the adapter comprises a nucleic acid barcode sequence specific to the nonclassical feature to which each binding domain is specifically bound; (i) transferring the nucleic acid barcode to the target nucleic acid to generate a barcoded target nucleic acid in an environment that substantially prevents off-target generation of the barcoded nucleic acid, or (ii) generating a barcoded copy of the target nucleic acid; modifying the barcoded target nucleic acid or the barcoded target nucleic acid copy so that the location of the nonclassical features can be identified based on the primary nucleic acid sequence of the barcoded target nucleic acid or the barcoded target nucleic acid copy; and determining the nucleotide sequence of the barcoded target nucleic acid.

[0014] In some embodiments, the present invention provides a method for detecting non-classical features in a target nucleic acid, the method comprising: contacting the target nucleic acid with a nucleic acid binding molecule described herein; (i) transferring a nucleic acid barcode to the target nucleic acid to generate a barcoded target nucleic acid, or (ii) generating a barcoded copy of the target nucleic acid, in an environment that substantially prevents off-target generation of the barcoded nucleic acid; and detecting the presence of a barcode in the target nucleic acid or the copy thereof.

[0015] In some embodiments, the Disclosure provides a method for determining the location of non-classical features in a target nucleic acid with single-nucleotide resolution, the method comprising the steps of: contacting the target nucleic acid with a nucleic acid binding molecule described herein; (i) transcribing a nucleic acid barcode onto the target nucleic acid in an environment that substantially prevents off-target generation of the barcoded nucleic acid to generate a barcoded target nucleic acid, or (ii) generating a barcoded copy of the target nucleic acid; and detecting the presence of a barcode in the target nucleic acid or a copy thereof, wherein the nucleic acid binding molecule comprises a binding domain capable of one or more of the following: inducing a mutation in the target nucleic acid or causing cleavage between copies of the target nucleic acid by preventing polymerase bypass.

[0016] In some embodiments, the present invention provides nucleic acid binding molecules comprising a base editing enzyme, wherein the base editing enzyme is a deaminase.

[0017] This specification also provides complexes comprising nucleic acid-binding molecules bound to target nucleic acids.

[0018] Furthermore, the materials provided herein are substrates bound to nucleic acid-binding molecules described herein.

[0019] Furthermore, this specification also provides polymers bonded to nucleic acid-binding molecules described herein.

[0020] These and other aspects of the present invention may become apparent by referring to the following detailed description, claims, embodiments, methods, compounds, and / or compositions, as well as relevant background information and references. [Brief explanation of the drawing]

[0021] [Figure 1]Figures 1A-1D are schematic diagrams illustrating the functional elements of various molecules described herein. Figure 1A shows a double-stranded nucleic acid and base modification (i.e., non-classical features). Figure 1B shows a base-modified single-stranded nucleic acid. Figure 1C shows a single-stranded nucleic acid having structural elements (i.e., non-classical features). Figure 1D shows a binding domain bound to an adapter (e.g., an adapter containing or consisting of a barcode sequence). Figures 1E-1G are schematic diagrams showing complexes containing different nucleic acid binding molecules described herein bound to a target nucleic acid. Figure 1E shows the binding of a nucleic acid binding molecule containing a double-stranded barcode to a double-stranded nucleic acid having modifications. Figure 1F shows the binding of a nucleic acid binding molecule containing a single-stranded barcode to a single-stranded nucleic acid having modifications. Figure 1G shows the binding of a structure-specific nucleic acid binding molecule to a single-stranded nucleic acid having non-classical structural elements. [Figure 2] Figures 2A-2G are schematic diagrams showing the structures of various DNA adapters. Figure 2A shows an adapter containing either a UFP or a URP. Figure 2B shows an adapter that can be used for library preparation by cyclization. Figure 2C shows an adapter that can be used for barcode transfer by ligation. Figure 2D shows an adapter that can be used for single or multiple barcode transfer by primer extension. Figure 2E shows an adapter containing random feet or targeted feet, as well as a stem region for internal priming and long read construction. Figure 2F shows an adapter that can be used for internal priming and short read construction. Figure 2G shows an adapter that can be used for barcoding by primer extension and targeting of the binding domain with a DNA editing enzyme via hybridization to the DNA address. As shown in the legend, "UFP" is an abbreviation for Universal Forward Primer, "URP" is an abbreviation for Universal Reverse Primer, "MBC" is an abbreviation for Modified Encoded Barcode, "UMI" is an abbreviation for Unique Molecular Identifier, and "CLS" is an abbreviation for Cleavage Site. "SP" is an abbreviation for Spacer. [Figure 3]Figures 3A-3E are schematic diagrams illustrating different adapter introduction schemes, including single-strand ligation (Figure 3A), splint ligation (Figure 3B), primer or splint extension (Figure 3C), template extension (Figure 3D), and double-strand ligation (Figure 3E). [Figure 4] Figures 4A–4D are schematic diagrams illustrating different formats for intracomplex adapter transfer, including surface immobilization of the recognition element (Figure 4A), RNA capture via a poly-A tail (Figure 4B), DNA or RNA capture via a hybridization probe (Figure 4C), and direct surface binding of a nucleic acid target (Figure 4D). [Figure 5] Figures 5A–5C are schematic diagrams showing different formats of intracomplex adapter transfer on beads and the associated bead pool compositions. The beads may be decorated with a single type of nucleic acid binding molecule (Figure 5A) or with multiple types of nucleic acid binding molecules (Figure 5B). Alternatively, the beads may present oligonucleotides for capturing RNA molecules by hybridization (Figure 5C). [Figure 6] Figures 6A–6D are schematic diagrams showing different architectures for targeting nucleic acid modification sites with nucleic acid modifying enzymes (deaminase in this example). These approaches include conjugating deaminase to a secondary antibody that binds to a primary antibody (Figure 6A), conjugating deaminase to an oligonucleotide that hybridizes to a complementary oligonucleotide (DNA address) bound to a nucleic acid binding domain (Figure 6B), and genetically fusing deaminase to a SpyCatcher protein that spontaneously forms a covalent bond with a peptide SpyTag bound to a nucleic acid binding domain (Figure 6C). Alternatively, deaminase can be conjugated to protein G that binds to a primary antibody (Figure 6D). Nucleotide sequences are provided as exemplary barcode sites (SEQ ID NOs. 52–54).

[0022] [Figure 7]Figure 7 is a schematic diagram illustrating an exemplary RNA-seq workflow involving modification analysis for the purpose of measuring the stoichiometry and abundance of RNA modifications. [Figure 8] Figure 8 is a schematic diagram illustrating exemplary methods of RNA profiling by barcode ligation and cDNA cleavage. After cDNA cleavage, the sample is amplified by PCR and prepared for sequencing. [Figure 9] Figure 9 is a schematic diagram illustrating exemplary methods of DNA profiling by barcode ligation and cytosine deaminase-mediated base editing. [Figure 10] Figure 10 is a schematic diagram illustrating an exemplary method of RNA profiling by base editing and sample splitting using adenosine deaminase. [Figure 11] Figure 11 is a schematic diagram illustrating an exemplary method of RNA profiling by barcode ligation and base editing using a secondary antibody-adenosine deaminase conjugate, preserving strand information. [Figure 12] Figure 12 is a schematic diagram illustrating an exemplary method for RNA profiling, where the target RNA fragment contains two or more modifications. After eluting the cDNA, the sample is amplified by PCR and prepared for analysis. [Figure 13] Figure 13 is a schematic diagram illustrating an exemplary method for periodic profiling of multiple RNA modifications. After performing the illustrated steps, the resulting DNA construct can be reverse transcribed and used for library preparation. [Figure 14] Figure 14A is a schematic diagram illustrating an exemplary method for periodic profiling that combines primer extension and base editing for barcoding. Figure 14B also illustrates an exemplary method for periodic profiling that uses differential base editing directed by different DNA addresses (address 1, address 1', address 2, address 2'). [Figure 15] Figures 15A-15D are a series of schematic diagrams illustrating exemplary methods of RNA profiling using tagmentation. [Figure 16] Figure 16 is a schematic diagram illustrating an exemplary method of RNA profiling using long-read construction. [Figure 17] Figure 17A is a schematic diagram comparing the size of a nanoantibody with the size of a primary antibody bound to a secondary antibody. Figure 17B shows the three-dimensional structure of the nanobody. The DNA adapter, deaminase, and surface coupling site are shown in the figure. Figure 17C shows an exemplary method for site-specific coupling of the adapter (i.e., DNA barcoding) and immobilization of the antibody onto the substrate surface. [Figure 18] Figures 18A-18B are schematic diagrams illustrating an exemplary method for measuring barcode crosstalk in a model system. [Figure 19] Figure 19 shows binding curves of several exemplary RNA modification-specific antibodies and their targets obtained by ELISA. Biotinylated RNA targets were immobilized at high density on streptavidin plates, and antibodies were bound at various concentrations. The binding curves were fitted using a 1:1 binding model to derive the key-dissociation (KD) values. The RNA targets were either single-stranded RNA (ss-RNA) or double-stranded RNA / DNA heteroduplexes (dsRNA / DNA) containing one modification flanked by degenerate sequences. Undenatured sequences were used as negative controls (non-denatured). Ab01 to Ab19 are antibody IDs, and the antibody sources are shown in Example 1. The antibodies bound to the RNA targets with high affinity and specificity.

[0023] [Figure 20] Figures 20A and 20B show experimental data for generating nucleic acid binding molecules. RNA modification-specific antibodies were randomly labeled with HyNic (hydrazinonicotinamide) compounds using DNA adapters. In Figure 20A, exemplary antibodies were labeled with 10 to 50 molar excess HyNic relative to the antibody. Analysis by non-reducing SDS gel electrophoresis revealed the relevant labeling stoichiometry. Figure 20B shows the results of labeling several RNA modification-specific antibodies with 20-fold excess HyNic using the same DNA adapters. The resulting labeling stoichiometry varied depending on the antibody isotype. [Figure 21]Figures 21A-21E show the functional effects of different antibody labeling methods and labeling stoichiometry. Figures 21A-21C show ELISA binding curves before and after random labeling of antibodies with HyNic compounds. The affinity of nucleic acid binding molecules decreases 10-15 times compared to unlabeled antibodies. Figures 21D-21E compare labeling of anti-m6A antibodies with random HyNic compounds or site-selective glycochemistry. Figure 21D shows the SDS gel of nucleic acid binding molecules, showing the attachment of 1 or 2 adapters to the antibody. Figure 21E shows the retention of binding activity by glycosylation as measured by ELISA. [Figure 22] Figure 22 shows experimental data on pull-down of modified or unmodified (N30) RNA targets with different antibodies. In this experiment, antibodies were immobilized on protein G beads and incubated with a mixture of four different RNA targets. Each antibody preferred its respective target, with specificities ranging from 3 to 44 compared to the N30 control. Specificity was sequence-dependent. [Figure 23]Figures 23A–23D illustrate an experimental approach to preparing RNA libraries for barcoding by primer extension with the addition of a universal sequence to the 3' end. Figure 23A provides an overview of a method for introducing a spacer of a known sequence (e.g., SEQ ID NO: 55) by homopolymer tailing or ligation. Figures 23B–23C provide experimental results for enzymatic A-tailing of RNA targets. Figure 23B illustrates the concept of regulating A-tail size by adding a polydT competitor oligonucleotide ((dT)20) to the reaction. In the absence of a polydT competitor, the A-tail has a wide size distribution between 100–200b. With a polydT competitor, the A-tail length is approximately 25b. Figure 23C shows experimental results of A-tailing at different temperatures and with different lengths of polydT competitors ((dT)10=10b, (dT)20=20b, (dT)30=30b). Figure 23D shows data on the addition of a universal sequence to the 3' end of RNA by single-strand ligation. A 30b degenerate RNA library is ligated to 10b, 20b, 30b, and 50b universal sequences. Plotting the formation of the ligation product as a function of time shows that the reaction rate is faster with intermediate length universal sequences (20 and 30b). Figures 23E-23F show experimental examples of barcoding by primer extension in the absence of nucleic acid binding molecules. We test whether the spacer length (universal sequence), the secondary structure of the target nucleic acid, and the reaction conditions affect the completeness of the barcode. Figure 23E compares the barcoding yield using DNA adapters with 8b (adapid-SP8), 10b (adapid-SP10), or 12b (adapid-SP12) spacers. Barcoding yields are low for 50b RNA targets (long RNAs) regardless of spacer length, while 50b DNA targets and 15b RNA targets are readily extended with an 8b spacer (adapt-SP8). This finding suggests that barcoding yield depends on the accessibility of the target spacer, and that the stable secondary structure common to long RNAs may hinder access.Increasing the spacer length from 8b to 12b is not sufficient to compete with the intramolecular secondary structure. Figure 23F shows generally improved barcoding yields with higher reaction temperatures and times, as well as with the addition of DMSO. Nearly perfect barcoding is possible with the use of an 18b spacer adapter (adapt-18SP). [Figure 24] Figures 24A-24C show experimental results of barcoding DNA and RNA targets using nucleic acid-binding molecules. The nucleic acid-binding molecule contains the RNA-specific antibody described in Example 1 and is bound to a barcoding DNA adapter. The nucleic acid-binding molecule is immobilized on protein G beads and incubated with an equimolar mixture of two nucleic acid targets. In Figures 24A-24B, the nucleic acid-binding molecule precipitates its homogeneous targets, and barcoding transfer is induced by the addition of a primer extension mix. This result indicates that barcoding is more efficient when using nucleic acid-binding molecules than when using free adapters. Figure 24A highlights the importance of appropriate spacer length. Since Ab05 and Ab10 are functionally affected by labeling, a 12b spacer is required to restore binding activity. With the randomly labeled m6A antibody (Ab05), the 12b spacer supports barcoding of the correct target, while the wrong target is barcoded with the anti-inosine antibody (Ab10). Figure 24B shows that on-target barcoding is possible via the 8b spacer when both antibodies are site-selectively labeled. Figure 24C shows an example of barcoding by ligation using a protein G bead assay format. The m6A antibody (Ab01) is site-specifically labeled with an adapter to obtain a nucleic acid binding molecule (BAC01). Barcoding with BAC01 is more efficient than ligation with a free adapter.

[0024] [Figure 25]Figure 25 describes the preparation of beads in which the density of capture molecules (e.g., capture probes) can be controlled. Beads with capture molecules spaced one molecule apart provide an assay format for barcoding using freely diffused nucleic acid-binding molecules. The nucleic acid hybridization probe (capture molecule) is co-immobilized with a passivating molecule. The graph shows the number of molecules per bead obtained by varying the ratio of grafting molecule to passivation molecule, as determined by qPCR. [Figure 26] Figures 26A–26C show the results of barcoding in solution and on single-molecule beads (see Figure 25), highlighting the importance of controlling intermolecular distance. Figure 26A shows the preparation of a nucleic acid binding molecule consisting of streptavidin and a biotinylated DNA adapter. Depending on the ratio of streptavidin to adapter, nucleic acid binding molecules with 1, 2, 3, or 4 adapter morphologies are formed, as identified by natural gel electrophoresis. A nucleic acid molecule with a streptavidin:adapter ratio of 1:2 is selected for the barcoding experiment. Figure 26B shows the results of barcoding in solution. The biotin-specific nucleic acid binding molecule is incubated with a mixture of biotin and m6A-modified RNA. Barcoding by ligation is initiated by adding T4 RNA ligase I (T4 Rnl1). The intermolecular distance is gradually reduced by adding 0–25% polyethylene glycol (PEG8k). Barcoding is specific at low concentrations of PEG8k, but gradually becomes nonspecific at higher concentrations due to intermolecular crosstalk. Figure 26C shows the reaction of the same assay components, but with the RNA target immobilized on beads by sequence-specific hybridization. In this experiment, the intermolecular distance was varied by using beads with different graft molecule:passivation molecule ratios (see Figure 25). This data shows that beads with a graft molecule:passivation molecule ratio of 1:100 exhibit crosstalk, while those with a ratio of 1:1,000 are specific to biotin. [Figure 27]Figure 27 is a schematic diagram of the protein domain structure of a fusion protein designed for the positional labeling of RNA modifications by targeted deamination. APOBEC1 = cytidine deaminase, YTH = m6A leader protein, Spytag = covalent targeting peptide, Spycatcher = covalent targeting protein, TEV = cleavage site of TEV protease, His-tag = affinity tag for purification, MBD = maltose-binding domain, affinity purification tag to improve protein solubility. [Figure 28] Figure 28 shows the results of analyzing the size, quantity, and cellular localization of expression products of different fusion proteins by SDS gel electrophoresis. [Figure 29] Figures 29A and 29B show the successful results of purification of the MBD-TEV-APOBEC1-Spycatcher fusion protein using a Ni-column (Figure 29A) and an MBD-column (Figure 29B). [Figure 30] Figure 30 is a schematic diagram of the protein domain composition and amino acid sequence of fusion proteins (SEQ ID NOs. 42 and 43) designed for site-specific labeling of nucleic acid modifications by targeted deamidation. [Figure 31] Figure 31 shows the deamination activity of APOBEC fusion protein expressed in vitro. Top figure: Schematic diagram of the USER assay used for APOBEC activity testing. Bottom figure: Data on deamination activity of cell-free extracts containing APOBEC enzyme using serial dilutions (1:1, 1:2, 1:4, 1:8, 1:16). The first two lanes are controls showing the detection of 100% cytidine or 100% uracil by USER cleavage. [Figure 32] Figure 32 is a schematic diagram of the poisoned primer assay (PPA). The PPA assay is designed to measure the size of the deaminase activity window. The template used as a probe for deaminase activity contains a series of cytidines separated by the AGAA sequence. "U" = uracil is produced by deamination. The gray dashed line = polymerization or reverse transcript product extended from the primer oligo. "ddA" = dideoxyadenosine (reaction termination product). The dark gray band in the schematic gel shows the expected gel analysis results. [Figure 33] Figure 33 shows an example of using a PPA assay to measure the activity of a commercially available APOBEC3A enzyme. PPA experiments were performed on both RNA and DNA targets, using reverse transcriptase (MuLV) and DNA polymerase (Klenow exo-) as the PPA enzymes, respectively. APOBEC3A showed high activity against DNA but weak activity against RNA. [Figure 34] Figure 34 shows the PPA assay used to measure the size of the deaminase activity window after targeting the enzyme with the Spytag peptide. Spytag rapidly reacts with Spycatcher, tethering the APOBEC3A-Spycatcher fusion protein to a specific site on the DNA template (e.g., SEQ ID NO: 50). Top figure: Schematic diagram of the assay design. "C" = cytidine as the editing site. Arrows = deamination activity at different sites. Darker colors indicate stronger deamination activity, and lighter colors indicate weaker deamination activity. Bottom figure: Target oligo sequences used in the assay and FAM-labeled primers used for analysis (SEQ ID NO: 51). SpyTag labeling sites (distal and proximal, SEQ ID NOs: 48 and 49, respectively) are shown.

[0025] [Figure 35] Figure 35 shows targeted deamination by hAPOBEC3A(E109Q)-SpyCatcher. In the presence of Spytag, the cytidine closest to the Spytag is preferably edited, indicating successful targeting. hAPOBEC3A(E109Q) alone, or hAPOBEC3A(E109Q)-SpyCatcher without SpyTag control, showed nonspecific editing at all available sites. D: Oligonucleotide with SpyTag distal to the first cytidine. P: Oligonucleotide with SpyTag proximal to the first cytidine. Bands appearing near the bottom of the gel (i.e., small bands) represent editing at the first cytidine, and bands appearing at the top of the gel (i.e., large bands) represent editing at the later cytidine. [Figure 36]Figure 36 is a schematic diagram showing barcoding facilitated by targeted tagmentation. The sequence is captured on magnetic beads via a sequence-specific hybridization probe (Step A). ​​The captured RNA is reverse transcribed (Step B). A pool of i5-ME antibody conjugates, each individually or with different barcodes, is added to the immobilized RNA / DNA double helix and incubated until saturation binding is reached (Step C). Next, a functional transposome is constructed from in situ. In the first step, free Tn5 transposase and ME' oligo are added to the surface-bound i5-ME- antibody conjugate to produce an antibody-bound i5-Tn5 monomer (Step D). Tn5 binds to the double-stranded i5-ME / ME' adapter. In the second step, Tn5 with a pre-attached i7-ME / ME' adapter is added to obtain an i5- / i7-Tn5 dimer (Step E). After transposome assembly, tagmentation is initiated by adding a MgCl2-containing buffer (step F), forming a product with a barcode adapter. [Modes for carrying out the invention]

[0026] Detailed explanation This invention provides compositions and methods for multiple profiling of RNA and DNA modifications across the transcriptome and genome, respectively. The method combines molecular recognition of non-classical features of a target nucleic acid (e.g., base modifications, skeletal modifications, damage, and / or structural elements) with the process of writing information from this recognition event to adjacent gene sequences of the target nucleic acid using barcodes. The resulting barcoded nucleic acid is then converted into a sequencing library and read by, for example, DNA / RNA sequencing or other methods. This process reveals the barcode sequence, which correlates with the non-classical features of the target nucleic acid. Base sequencing can also confirm the localization of the non-classical features in the target nucleic acid. The high-throughput profiling methods described herein enable the parallel identification of the nature and location of multiple or all DNA / RNA modifications. These methods can also determine the abundance and stoichiometry of DNA / RNA modifications.

[0027] In some embodiments, the methods described herein can be used not only to identify modifications on target nucleic acids but also to localize modifications on target nucleic acids with a high resolution of about one base.

[0028] The present invention will be described below in more detail in illustrative and non-limiting embodiments and with reference to the accompanying drawings. However, the present invention can be embodied in many different forms and should not be construed as being limited to the embodiments shown below. Rather, these embodiments are provided to complete the description herein and to convey to those skilled in the art the scope described herein.

[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art in which the present invention pertains. Terms used in the detailed description herein are for the purpose of describing specific embodiments only and are not intended to limit them.

[0030] All publications, patent applications, patents, GenBank / Uniprot or other accession numbers, and other references cited herein are incorporated herein in their entirety by citation for all purposes.

[0031] definition The following terms are used herein and in the appended claims.

[0032] The singular forms "a," "an," and "the" include the plural forms unless it is clear from the context.

[0033] Furthermore, when referring to measurable values ​​such as the amount, dose, time, or temperature of a polynucleotide or polypeptide sequence, the term “about” as used herein means encompassing variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified amount.

[0034] Furthermore, as used herein, “and / or” means any one or more possible combinations of the related enumerated items, and, when interpreted alternatively, the absence of a combination (“or”), and encompasses them all.

[0035] Unless otherwise stated, the various features described herein are particularly intended to be used in any combination. Furthermore, in some embodiments, any of the features or combinations of features described herein can be excluded or omitted. To further explain, for example, where it is indicated herein that a particular DNA base may be selected from A, T, G, and / or C, this term also indicates that the base may be selected from any subset of these bases, e.g., A, T, G, or C; A, T, or C; T, G, or C only, etc., and such subcombinations are described as if each of them were explicitly described herein. Furthermore, such term also indicates that one or more of the specified bases may be excluded. For example, in some embodiments, each of such possible exclusions is described as if it were explicitly described herein, such as the nucleic acid is not A, T, or G; not A; not G, or C, etc.

[0036] As used herein, the terms “decrease,” “reduction,” “decrease,” and similar terms mean a decrease of at least about 10%, about 15%, about 20%, about 25%, about 35%, about 50%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, or more.

[0037] As used herein, the terms “increase,” “improvement,” “enhancement,” “strengthen,” and similar terms refer to increases of at least about 10%, about 15%, about 20%, about 25%, about 50%, about 75%, about 100%, about 150%, about 200%, about 300%, about 400%, about 500%, or more.

[0038] The term “epigenetic change” is used herein to mean phenotypic changes in living cells, organisms, etc., that are not encoded by the primary sequence (i.e., A, T, C, and G) of the DNA of that cell or organism. Epigenetic changes may include, for example, chemical changes of nucleotides and / or histones (i.e., proteins involved in the coiling and packaging of DNA in the nucleus). Exemplary DNA nucleotide modifications include the common epigenetic marker 5-methylcytidine (5mC) and its oxidation products 5-hydroxymethylcytidine (5hmC), 5-formylcytidine (5fC), and 5-carboxymethylcytidine (5caC). While 5mC is well known for its role in gene silencing, there is growing evidence suggesting metabolic functions of the oxidation intermediates 5hmC, 5fC, and 5caC in the demethylation pathway of 5mC. Further metabolically relevant DNA modifications include chemically modified nucleotides associated with oxidation, alkylation, dimerization, crosslinking, and other DNA damage. While such DNA modifications are important for understanding toxicity, their distribution across the genome when damage occurs is not well understood. DNA modifications may play further regulatory roles, such as being involved in the dynamics of G-quadruplicates in promoters and other regions of the genome.

[0039] As used herein, “epitranscriptome modification” refers to the chemical modification of RNA that occurs during or after transcription. More than 170 different RNA modifications are known, including chemical changes to nucleic acid bases, ribose, and phosphodiester backbones. RNA modifications are found in all RNA types, including mRNA, tRNA, rRNA, lncRNA, and miRNA, and can alter the phenotype of a cell by changing the structure and dynamics of RNA, or by altering the molecular recognition of RNA by other biomolecules such as proteins. Natural chemical RNA modifications of the epitranscriptome control a wide range of functions in RNA metabolism, including RNA processing, splicing, polyadenylation, editing, structure, stability, localization, translation initiation, and gene expression. The epitranscriptome differs depending on cell type, metabolic state, and health status, and plays a crucial (but poorly understood) role in the differentiation of cellular phenotypes and functions, helping to explain dramatic phenotypic differences between cells of the same organism with identical primary genetic sequences. Epitranscriptome changes correlate with disease. For example, mRNA and ncRNA modifications are known to regulate spatiotemporal changes in gene expression during the differentiation process of cancer stem cells, thereby playing an organized role in disease progression. Furthermore, RNA modification is strongly suspected to be an important mechanism by which RNA viruses (e.g., Coronaviridae and Flaviviridae) betray their hosts and evade the innate immune system.

[0040] The term “genome” refers to all the DNA contained in a cell or a population of cells, or a selection of specific types of DNA molecules (e.g., coding DNA, non-coding DNA, mitochondrial DNA, or chloroplast DNA). The term “transcriptome” refers to all the RNA molecules produced in a single cell or a population of cells, or a selection of specific types of RNA molecules that make up the complete transcriptome (e.g., mRNA vs. ncRNA, or specific mRNA within the mRNA transcriptome). In some embodiments, the transcriptome includes several different types of RNA, such as coding RNA (i.e., RNA that is translated into proteins, e.g., mRNA) and non-coding RNA. An unspecified list of various types of RNA molecules found in the transcriptome includes those that may contain modified nucleosides: 7SK RNA, signal recognition particle RNA, antisense RNA, CRISPR RNA, guide RNA, long non-coding RNA, microRNA, messenger RNA, piwi-interacting RNA, repeat-associated siRNA, retrotransposon, ribonuclease MRP, ribonuclease P, ribosomal RNA, small Cajal body-specific RNA, small interference RNA, smY RNA, micronuclear RNA, and transacting siRNA.

[0041] As used herein, “non-classical features” of nucleic acids mean features of nucleic acids distinct from their primary sequence. For example, non-classical features may be chemical modifications to DNA or RNA bases, or to the DNA or RNA backbone. In some embodiments, non-classical features may be structural sequences such as hairpins or loops. In some embodiments, non-classical features may be nucleic acid damage, such as DNA or RNA damage. Other exemplary non-classical structures include, but are not limited to, Z-DNA structures, G-quadrilaterals, i-motifs, bulges, debasement sites, triple helices, tridirectional bonds, cruciform structures, quadruple loops, ribose zippers, and pseudoknots. Nucleic acids, including DNA and RNA, contain many non-classical features. The frequency of these modifications varies greatly depending on the RNA and the type of feature, but clusters of modifications may occur. In some embodiments, non-classical features may result from DNA and / or RNA damage. As used herein, the terms “non-classical features” and “modification” can be used interchangeably as understood in context by those skilled in the art.

[0042] As used herein, the term "target nucleic acid" means a nucleic acid containing one or more non-classical features. The nucleic acid binding molecules described herein can bind to a target nucleic acid when the binding domain of the molecule recognizes a non-classical feature.

[0043] As used herein, the term “substrate” is used to mean any solid support. For example, substrates are beads, chips, plates, slides, dishes, three-dimensional matrices, etc. As described herein, the nucleic acid binding molecules described herein may be bound to one or more substrates, and substrates may be bound to one or more nucleic acid binding molecules. Substrates can be formed from a variety of materials. In some embodiments, substrates are resins, membranes, fibers, polymers. In some embodiments, substrates include Sepharose, agarose, cellulose, polystyrene, polymethacrylate, and / or polyacrylamide. In some embodiments, substrates include polymers such as synthetic polymers. An unlimited list of synthetic polymers includes poly(ethylene) glycol, polyisocyanopeptide polymers, polylactic acid-coglycolic acid, poly(ε-caprolactone) (PCL), polylactic acid, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), chitosan, and cellulose.

[0044] As used herein, the term “barcode” means a synthetically produced nucleic acid. A unique barcode may be assigned to a specific nucleic acid modification so that those modifications can be specifically identified in the methods described herein. Thus, a barcode is “unique” to non-classical modifications when it is specifically used to identify the modification in one or more of the methods described herein. Barcodes can be produced using methods known in the art, such as solid-phase oligonucleotide synthesis. In some embodiments, the barcode may be a DNA barcode (i.e., it may contain a DNA sequence). In some embodiments, the barcode may contain a synthetic DNA structure such as a peptide nucleic acid (PNA) or a lock nucleic acid (LNA). In some embodiments, the synthetic DNA structure may contain one or more modified bases. In some embodiments, the barcode may be an RNA barcode (i.e., it may contain an RNA sequence). The barcode may be of any length, for example, in the range of about 4 to about 150 nucleotides. In some embodiments, the barcode is about 4 to about 20 nucleotides long, for example, about 4 nucleotides, about 5 nucleotides, about 6 nucleotides, about 7 nucleotides, about 8 nucleotides, about 9 nucleotides, about 10 nucleotides, about 11 nucleotides, about 12 nucleotides, about 13 nucleotides, about 14 nucleotides, about 15 nucleotides, about 16 nucleotides, about 17 nucleotides, about 18 nucleotides, about 19 nucleotides, or about 20 nucleotides. Typically, the barcode may contain a reasonably designed sequence that is not present in the genome of any known organism. However, in some embodiments, the barcode may contain a known sequence. For example, the barcode sequence may contain a signature associated with a pathogen or other biological substance. In some embodiments, the barcode may contain a sequence configured to facilitate a sequencing reaction. The terms “barcode” and “adapter” may be used interchangeably herein. As understood in the Art, an adapter, in some embodiments, consists of a barcode.In some embodiments, the adapter may include a barcode and one or more additional elements, as described below and shown in Figures 2A-2G.

[0045] The term "amplification," when used in relation to nucleic acids, means generating copies of those nucleic acids. Nucleic acids can be amplified, for example, using polymerase chain reaction (PCR). Alternative methods of nucleic acid amplification include helicase-dependent amplification (HAD), recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), nucleic acid sequence-based amplification (NASBA), autologous persistent sequence replication (3SR), and rolling circle amplification (RCA).

[0046] As used herein, the terms “intracomplex adapter transfer” or “intracomplex barcode transfer” mean that an adapter and / or barcode is transferred to a target nucleic acid (e.g., DNA or RNA) while a nucleic acid-binding molecule is bound to it. Therefore, as used herein, the term “complex” means the complex formed between a target nucleic acid and its homologous nucleic acid-binding protein.

[0047] As used herein, the terms “crosstalk,” “barcode crosstalk,” and similar terms refer to the out-of-target transfer of nucleic acid barcodes. For example, barcode crosstalk can occur when a barcode on a nucleic acid binding molecule is transferred to a nucleic acid that is not bound to the binding domain of the nucleic acid binding molecule.

[0048] The term “DNA address” refers to a DNA or RNA sequence and / or its complement used as a programmable binding element that facilitates a specific binding event. For example, a deaminase can bind to a DNA or RNA sequence (i.e., the first DNA address) that binds to a target DNA or RNA sequence (e.g., the second DNA address), and guide the deaminase there. The binding of the first DNA address and the second DNA address is shown, for example, in Figure 14B (e.g., address 1 and address 1').

[0049] Nucleic acid damage, such as "DNA damage" or "RNA damage," is a chemical modification of nucleic acids that can occur as a result of endogenous processes and / or exogenous drugs. For example, DNA damage can be caused by oxidative damage (e.g., 8-oxoguanine), reactions with electrophiles and alkylating agents found in charred meat and cigarette smoke (benzo[a]pyrene adducts and alkylated nucleic acid bases), ultraviolet damage (cyclobutanepyrimidine dimers and 6-4 pyrimidine-pyrimidine photoproducts), and metal complex formation (mercury complexes and platinum crosslinks). DNA damage resulting from endogenous processes is frequent. DNA damage is usually repaired by various repair enzymes or bypassed by damage bypass polymerases during genetic code replication. Mutations that result in unnatural cell proliferation and growth drive cancer development. While mutations are readily detectable by standard DNA sequencing, the damage itself cannot be detected by standard DNA sequencing workflows. Damage is not uniformly distributed throughout the genome, and the effectiveness of repair depends on the DNA locus and cellular state. Furthermore, the most common cancer chemotherapy drugs (such as cisplatin and gemcitabine) induce DNA damage, and therefore, mapping DNA damage across the entire human genome offers great potential for understanding the pathogenesis of aging and cancer, and for improving the effectiveness and reducing the toxicity of cancer chemotherapies.

[0050] Nucleic acid binding molecule and method for producing the same Provided herein are nucleic acid binding molecules, each comprising a binding domain and an adapter, which are described in more detail below.

[0051] adapter As used herein, the term “adapter” means any short nucleic acid sequence that can be bound to the end of a DNA or RNA molecule and confers some function to it. For example, in some embodiments, an adapter can facilitate the sequencing and / or identification of a DNA or RNA molecule.

[0052] In some embodiments, the adapter contains 5'-phosphate. In some embodiments, the adapter contains 3'-phosphate. In some embodiments, the adapter contains both 5'-phosphate and 3'-phosphate. In some embodiments, the adapter is single-stranded. In some embodiments, the adapter is double-stranded. In some embodiments, the double-stranded adapter may include a single-stranded adapter hybridized to a complementary oligonucleotide.

[0053] In some embodiments, the adapter is cleavable. For example, the adapter may include one or more cleavage sites. The cleavage sites may include, for example, one or more uracil bases, a sequence recognized by an enzyme (e.g., a restriction enzyme or other nuclease), or a synthetic chemical moiety.

[0054] In some embodiments, the adapter includes a universal forward primer (UFP). In some embodiments, the adapter includes a universal reverse primer (URP). In some embodiments, the adapter includes both a UFP and a URP. In some embodiments, the adapter consists of either a UFP or a URP. UFP and URP sequences are DNA sequences that do not exist in nature and can selectively amplify only the sequences introduced into the target nucleic acid (or a copy thereof). During sequencing, the UFP and / or URP are annealed to the DNA target, providing an initiation site for the extension of a new DNA molecule (i.e., a copy thereof). A list of exemplary UFPs and URPs can be found at the worldwide web address lslabs.com / resources / universal-primer-list. In some embodiments, the universal primer sequences used in the adapter (and transferred to the target nucleic acid) are compatible with established DNA sequencing platforms and can be used to introduce surface adapters such as Illumina P5 and P7 in downstream PCR reactions.

[0055] In some embodiments, the adapter may include a barcode, such as a modified coded barcode (MBC). An MBC is a short, unique nucleic acid sequence. Each MBC is used in relation to a specific epigenetic or epitransscriptome modification, and is useful for its identification and / or analysis. For example, an MBC may be used in an adapter bound to a binding domain specific to a particular non-classical feature. In some embodiments, the adapter may consist of a barcode. In some embodiments, the adapter may consist of MBCs.

[0056] In some embodiments, the adapter may include a unique molecular identifier (UMI). The UMI is 4 [UMIの長さ] It consists of short random sequences with 1 unique variants. For example, a 10-base-length UMI is 1,048,576(4 10 UMI can encode unique molecules. UMI is used for absolute quantification of sequencing reads to correct for PCR amplification bias and errors. For example, an RNA sample may contain 100 copies of transcript A and 100 copies of transcript B. Since transcript B amplifies more efficiently, after PCR amplification, 1M copies of transcript A and 2M copies of transcript B may be detected. When UMI is used for transcript A, 10,000 copies of 100UMI variants will be detected, and for transcript B, 20,000 copies of 100 UMI variants will be detected. By counting the number of UMI variants instead of the number of reads, the absolute number of molecules can be determined.

[0057] Typically, UMI length is chosen to avoid UMI collisions. A UMI collision is defined as the observation of two reads that have the same sequence and the same UMI but originate from two different genomic molecules. UMI collisions are a function of the number of UMIs used, the number of unique alleles, and the frequency of each allele in the population. The ideal UMI length also depends on the error rate and sequencing depth of the sequencing platform. Sequencer platforms with high error rates require longer UMIs because UMI errors can cause accidental UMI collisions. For evaluation sequences where the sequencing depth of the selected locus is deeper than whole-genome sequencing, longer UMIs are also used because many alleles from different genomic molecules share the same sequence. Excessively long UMIs are avoided because they require more sequencing cycles, resulting in shorter reads of the actual target sequence. Long UMIs can also cause mispriming in PCR reactions, leading to sequencing disruptions. UMIs typically range from approximately 3 to 25 nucleotides in length. In some embodiments, UMI is about 3 to about 20 nucleotides long, for example, about 3 nucleotides, about 4 nucleotides, about 5 nucleotides, about 6 nucleotides, about 7 nucleotides, about 8 nucleotides, about 9 nucleotides, about 10 nucleotides, about 11 nucleotides, about 12 nucleotides, about 13 nucleotides, about 14 nucleotides, about 15 nucleotides, about 16 nucleotides, about 17 nucleotides, about 18 nucleotides, about 19 nucleotides, or about 20 nucleotides. In some embodiments, UMI may be 8 nucleotides long. In some embodiments, UMI may be 10 nucleotides long.

[0058] Figures 2A-2G show the structures of exemplary nucleic acid adapters, with the legend describing each element used. These adapters are labeled Type A, Type B, Type C, Type D, Type E, Type F, and Type G for easy reference.

[0059] The adapter shown in Figure 2A (Type A) represents a minimal adapter that may contain either a UFP sequence or a URP sequence. Type A adapters do not contain sequences that can be used for the identification or analysis of non-classical nucleic acid features; instead, they are used for library construction. In some embodiments, Type A adapters are bound to nucleic acid molecules that do not contain non-classical features. In some embodiments, Type A adapters are bound to nucleic acid molecules containing non-classical features after a barcoded adapter has been introduced to the other end of the target nucleic acid. For example, a Type A adapter can be used to cap and prepare nucleic acids for PCR amplification after one or more barcodes have been added.

[0060] The adapters shown in Figures 2B-2G each contain a MBC specific to one of the non-classical DNA / RNA features (e.g., modified bases). As shown in Figure 2B, type B adapters can be used in library preparation workflows involving cDNA cyclization. These contain cleavage sites (CLS). Cleavage of type B adapters may be performed before PCR amplification. As shown in Figure 2C, type C adapters lack a CLS and contain only one universal primer region. Type C adapters can be used, for example, for barcode introduction by ligation reactions. These may be combined with second-strand synthesis methods such as template-switching oligonucleotides or other adapter ligation using Smart-Seq technology. As shown in Figure 2D, type D adapters are specifically designed for encoding by primer extension. Type D adapters have one 3' end spacer (SP) or two spacer regions at both ends (e.g., SP1, SP2). The reaction is initiated by ligating a short spacer region (SP) to the 3' end of the target nucleic acid and ligating a type D adapter with complementary spacers. The spacers may be universal across all nucleic acid binding molecules and cycles, specific to each type of nucleic acid binding molecule, or specific to each cycle of the barcoding. In some embodiments, the adapter includes one, two, three, or four spacers. In some embodiments, the adapter includes one spacer. In some embodiments, the adapter includes two spacers. In some embodiments, the spacers are 3-nucleotide, 4-nucleotide, 5-nucleotide, 6-nucleotide, 7-nucleotide, 8-nucleotide, 9-nucleotide, 10-nucleotide, 11-nucleotide, 12-nucleotide, 13-nucleotide, 14-nucleotide, 15-nucleotide, 16-nucleotide, 17-nucleotide, 18-nucleotide, 19-nucleotide, or 20-nucleotide long. In some embodiments, the spacers are 6-nucleotide long. In some embodiments, the spacers are 7-nucleotide long. In some embodiments, the spacers are 8-nucleotide long.In some embodiments, the spacer includes Sequence ID No. 19. The Type D adapter can be used, for example, for a single barcode transcription by a primer extension reaction, or for multiple consecutive barcode transcriptions. Multiple cycles of barcoding can be used to examine only one or a subset of non-classical features in each cycle. For example, a nucleic acid binding molecule specific to m5C can be used in the first encoding cycle. A nucleic acid binding molecule specific to m6A can be used in the second encoding cycle. A nucleic acid binding molecule specific to inosine, etc., can be used in the third encoding cycle. In another embodiment, the first cycle may try m5C and m6A, and the second cycle may try inosine. In another embodiment, the first encoding cycle may try all non-classical features, and the second encoding cycle may try all non-classical features a second time. As shown in Figure 2E, the Type E adapter, when positioned via the nucleic acid binding molecule containing the adapter, takes the form of a hairpin with random feet that bind to the target nucleic acid near the modification site. The legs can be random sequences or target regions. Furthermore, they may contain modified bases to increase the melting temperature of the nucleic acid double helix and to prevent strand substitution by reverse transcriptase and DNA polymerase. In some embodiments, the stem region of the hairpin anneals stably and is as short as possible to minimize redundant sequencing content. Similar to spacers, the stem is universal to all nucleic acid binding molecules or is diverse. In some embodiments, the loop region is cleavable. Type E adapters can be used, for example, for internal priming or long-read construction. As shown in Figure 2F, type F is an improvement on type E adapters and consists of cleaved loops. The overall structure of type F adapters is Y-shaped, L-shaped, or a combination thereof. As shown in Figure 2G, type G adapters are derived from type D adapters by including DNA addresses. DNA addresses can be included in any adapter architecture.

[0061] In some embodiments, the adapter includes a UFP, URP, or UFP and URP. In some embodiments, the adapter includes a UFP and / or URP, and also includes an MBC. In some embodiments, the adapter includes a UFP and / or URP, MBC, and UMI. In some embodiments, the adapter includes a UFP and / or URP, MBC, UMI, and CLS. In some embodiments, the adapter includes a UFP and / or URP, MBC, UMI, CLS, and SP. In some embodiments, the adapter includes a UFP, CLS, URP, UMI, and MBC. In some embodiments, the adapter includes a UFP, UMI, and MBC. In some embodiments, the adapter includes a URP, UMI, and MBC. In some embodiments, the adapter includes a first SP, MBC, UMI, and a second SP.

[0062] In some embodiments, the adapter has a hairpin shape. In some embodiments, the adapter containing the MBC has a hairpin shape, and the hairpin consists of a stem region 4 to 20 base pairs long and two random or targeted legs, each leg being approximately 4 to 10 base pairs long.

[0063] In some embodiments, the adapter has an L-shape, a Y-shape, or a combination thereof. In some embodiments, the adapter having an L-shape or Y-shape includes a UFP, MBC, and URP. In some embodiments, the adapter having an L-shape or Y-shape includes a UFP, MBC, and URP, and the adapter includes a stem region having a length of about 4 to about 20 base pairs, and further includes random or targeted legs, each leg having a length of about 4 to about 10 base pairs.

[0064] In some embodiments, the adapters described herein may include one or more linkers, such as linkers that assist in linking the binding domain to the adapter. Examples of linkers include polyethylene glycol, hydrocarbons, peptides, DNA, or RNA. Linker lengths vary. Longer linkers can be used when the non-classical features of the DNA or RNA are located far from the 5' or 3' end of the nucleic acid sequence. Shorter linkers are used when the non-classical features of the DNA or RNA are located relatively close to the 5' or 3' end of the nucleic acid sequence.

[0065] In some embodiments, the adapter, or the linker sequence contained therein, is cleavable. For example, the adapter may contain one or more cleavage sites. The adapter may be chemically, photochemically, or enzymatically cleavable. The cleavage sites may include, for example, one or more uracil bases, sequences recognized by enzymes (e.g., restriction enzymes or other nucleases), or synthetic chemical moieties, such as disulfide, carbonate ester, hydrazone, cis-aconityl, or (β-glucuronide).

[0066] As will be described in more detail below, the adapter can be fused to a single-stranded or double-stranded target nucleic acid (e.g., DNA or RNA) using a barcode transfer reaction.

[0067] In some embodiments, primer elongation involves adding a 3' poly-rA tail to the RNA target. In some embodiments, primer elongation involves adding a 3' poly-rA tail to the RNA target, as shown in Figure 23A. The 3' poly-rA tail is added by polyadenylation using any known poly(A) polymerase (e.g., E. coli poly(A) polymerase). In some embodiments, the RNA target is incubated with poly(A) polymerase and a competing poly-dT oligonucleotide. Co-treatment with poly(A) polymerase and a competing poly-dT oligonucleotide controls the length of the added 3' poly-rA tail. Typically, polyadenylation results in an average 3' poly-rA tail length of approximately 150 bases. In some embodiments, the length of the 3' poly-rA tail is approximately 5 nucleotides, 10 nucleotides, 15 nucleotides, 20 nucleotides, 25 nucleotides, 30 nucleotides, 35 nucleotides, 40 nucleotides, 45 nucleotides, 50 nucleotides, 55 nucleotides, or 60 nucleotides.

[0068] In some embodiments, primer extension involves attaching a 3' poly-U tail, a 3' poly-G tail, a 3' poly-A tail, or a 3' poly-G tail to an RNA target. The homopolymer tail is attached using a known poly(U) polymerase (e.g., fission yeast; Schizosaccharomyces pombe Cid1). In some embodiments, the RNA target is incubated with poly(U) polymerase, GTP, and a competing poly-dC oligonucleotide. Co-treatment with poly(U) polymerase and a competing poly-dC oligonucleotide controls the length of the attached 3' poly-G tail. In some embodiments, the length of the 3' poly-G tail is approximately 5 nucleotides, approximately 10 nucleotides, approximately 15 nucleotides, approximately 20 nucleotides, approximately 25 nucleotides, approximately 30 nucleotides, approximately 35 nucleotides, approximately 40 nucleotides, approximately 45 nucleotides, approximately 50 nucleotides, approximately 55 nucleotides, or approximately 60 nucleotides.

[0069] In some embodiments, the adapter includes sequence number 56. In some embodiments, the adapter includes sequence number 57. In some embodiments, the adapter includes sequence number 6. In some embodiments, the adapter including a spacer includes sequence number 25. In some embodiments, the adapter including a spacer includes sequence number 26. In some embodiments, the adapter including a spacer includes sequence number 27. In some embodiments, the adapter including a spacer includes sequence number 38. In some embodiments, the biotin adapter includes sequence number 33. In some embodiments, the DBCO-labeled adapter includes sequence number 22. In some embodiments, the annular (clicked) adapter includes sequence number 39.

[0070] Joint domain As used herein, the term “binding domain” means a nucleic acid, polypeptide, etc., that binds to a non-classical feature of a target nucleic acid, such as a modified nucleoside. The term “binding domain” may be used interchangeably with terms such as “binding agent,” “recognition element,” and “antibody,” as can be understood from the context to those skilled in the art. In some embodiments, the binding domain binds to a non-classical feature of the target nucleic acid. In some embodiments, the binding domain does not bind to any nucleic acid features adjacent to the non-classical feature. In some embodiments, the binding domain binds to both (i) a non-classical feature of the target nucleic acid and (ii) one or more nucleic acid features adjacent to the non-classical feature (e.g., nucleic acid bases, sugars, phosphates, or combinations thereof). In some embodiments, the binding domain may bind to a conserved sequence motif. For example, m 6 A often appears in the following motif: GG(m 6 A)CT. Therefore, the binding domain is m 6 When binding to A, it may also bind to one or more adjacent nucleic acids (e.g., GG or CT). As another example, the binding domain can bind to all or part of the anticodon loop of tRNA. In some embodiments, the binding domain binds to tRNA, where it binds to modifications and known sequences on the tRNA.

[0071] The nucleic acid binding molecules described herein include one or more binding domains, which specifically bind to non-classical features of DNA or RNA. The binding domains described herein are proteins, nucleic acids, or fragments or derivatives thereof that can recognize and bind to non-classical features of the target nucleic acid. For example, in some embodiments, the binding domain includes an antibody, an aptamer, a leader protein, a writer protein, an eraser protein, an artificial polymer scaffold, an artificial protein scaffold, or a selective covalent capture reagent, or fragments or derivatives thereof. In some embodiments, the binding domain includes an IgG antibody, an antigen-binding fragment (Fab), a single-chain variable fragment (scFv), or a heavy or light chain single domain (V H and V L ). In some embodiments, the binding domain includes a heavy-chain antibody (hcAb) or the V H H domain (nanobody). In some embodiments, the binding domain includes artificial protein scaffolds such as adnectin, affibody, affilin, anticalin, atrimer, avimer, bicyclic peptide, centyrin, cis-nut, darpin, finomer, knotted domain, ovobody or pronectin.

[0072] IgG antibody is the main isotype of immunoglobulins. IgG contains two identical heavy chains and two identical light chains, and is stabilized by covalent disulfide bonds among them. IgG recognizes antigens via the variable N-terminal domains of the heavy chain (V H ) and the light chain (V L ) and six complementarity-determining regions (CDRs). Antibodies that bind to some modified DNA and RNA bases are commercially available; for example, several companies such as Active Motif and Sigma sell antibodies specific for hm 5 C. Eurogentec (Belgium) sells monoclonal antibodies that bind to m 5 C.Megabase Research Products (USA) 5We sell rabbit polyclonal serum that binds to C6-methyladenosine and 7-methylguanosine. Abcam (USA) sells recombinant antibodies against RNA modifications m6A, ac4C, m1A, m2,2G, m4C, m2A, m6,6A, and m8A.

[0073] Antibodies that bind to modified bases can also be developed according to methods known to those skilled in the art. In some embodiments, the antibody is a monoclonal antibody, a polyclonal antibody, or a functional fragment or variant thereof. As used herein, the term “antibody” refers to any specific binding substance having a binding domain with the required specificity. Thus, this term covers antibody fragments, derivatives, functional equivalents, and antibody homologs, including any polypeptide containing an immunoglobulin-binding domain, whether natural or synthetic, monoclonal or polyclonal. Chimeric molecules consisting of a fusion of an immunoglobulin-binding domain, or an equivalent thereof, with other polypeptides are also included.

[0074] In some embodiments, the binding domain may include a nanobody. The nanobody is a single variable domain (V) of a heavy chain antibody, as produced by camels and some cartilaginous fish. H Includes H) V HThe H domain consists of three enlarged CDRs compared to those of IgG antibodies, providing an antigen-interacting surface of similar size to IgG (i.e., approximately 800 Ų). Nanobodies bind to antigens with similar affinity to IgG antibodies, but with several advantages: smaller size (15 kDa), less susceptible to reducing environments due to fewer disulfide bonds, higher solubility, and no post-translational glycosylation. Because nanobodies can be produced in bacterial expression systems, their affinity and specificity can be matured by phages and other display technologies. Other advantages include improved thermal stability and solubility, and an easier approach to site-specific labeling. Due to their small size, nanobodies can form convex paratopes, making them suitable for binding to hard-to-access antigens. Exemplary methods for producing nanobodies include immunizing each animal (e.g., camels) with the target antigen, further evolving existing naive libraries, or a combination of these.

[0075] In some embodiments, the binding domain comprises a leader protein, writer protein, or eraser protein. A “leader protein” is a protein that selectively recognizes and binds to specific chemical modifications on DNA or RNA. A “writer protein” is a protein that adds specific chemical modifications to DNA or RNA. An “eraser protein” is an enzyme that removes specific chemical modifications from DNA or RNA. In some embodiments, the binding domain comprises a fragment or derivative of a leader protein, writer protein, or eraser protein. In some embodiments, the binding domain comprises an engineered form of a leader, writer, or eraser protein, such as a form that retains nucleic acid binding but lacks enzymatic activity. Exemplary leader proteins, writer proteins, and eraser proteins that may be used in the binding domains described herein are shown in Tables 1 and 2. Other leader proteins, writer proteins, and eraser proteins are listed at the following World Wide Web address:rnawre.bio2db.com.

[0076] [Table 1] [Table 2-1] [Table 2-2] [Table 2-3] Legend: W: Writer, E: Eraser, R: Leader, TS: Tumor suppressor, Onc: Oncogene. RNA modification: m1A: 1-methyladenosine, ms2i6A: 2-methylthio-N6-isopentenyladenosine, i6A: N6-isopentenyladenosine, m6A: N6-methyladenosine, m3C: 3-methylcytosine, m5C: 5-methylcytosine, ac4C: N4-acetylcytosine, m7Gpp(pN): 7-methylguanosine cap, m7G: 7-methylguanosine internal, m2,2G: N2,N2-dimethylguanosine, m2G: N2-methylguanosine, Q: keuosin, yW et al: Wibtosine and derivatives, m5U: 5-methyluridine, ncm5U: 5-carbamoyl-methyluridine, mcm5U: 5-methoxycarbonyl-methyluridine, mcm5s2U: 5-methoxycarbonylmethyl-2-thiouridine, D. dihydrouridine, Ψ: pseudouridine, Nm: 2'-O-methylnucleotide, m(pN): 5'-phosphate monomethylation, A-to-I: adenosine deamination, C-to-U: cytosine deamination.RNA modifying enzymes: ADAR1-3: Adenosine deaminase RNA-specific 1-3, ALKBH1 / 3 / 5 / 8: AlkB homologs 1 / 3 / 5 / 8, APOBEC1 / 3G: Apolipoprotein B mRNA editing catalytic subunit 1 / 3G, BCDIN3D: BCDIN3 domain-containing RNA methyltransferase, BUD23: RNA methyltransferase and ribosomal maturation factor, CDK5RAP1: CDK5 regulatory subunit-related protein 1, CMTR1 / 2: Cap methyltransferase 1 / 2, CTU1 / 2: Cytoplasmic thiouridyse subunit 1 / 2, DKC1: Diskelin pseudouridine synthase 1, DNMT2: tRNA Aspartate methyltransferase 1, DUS2: Dihydrouridine synthase 2, ELP3: Elongator acetyltransferase complex subunit 3, FTO: FTO α-ketoglutarate-dependent dioxygenase, HENMT1: HEN methyltransferase 1, METTL1 / 2 / 3 / 6 / 8 / 14 / 16: Methyltransferase-like -1 / 2 / 3 / 6 / 8 / 16, NAT10: N-acetyltransferase 10, NSUN1-5: NOP2 / Sun RNA methyltransferase 1-5, NUDT16: Nudix hydrolase 16, RNMT: RNA guanosine-7 methyltransferase, TGT: Queuine TRNA-ribosyltransferase catalytic subunit 1, TRIT1: tRNA isopentenyltransferase 1, TRMT1 / 2A / 2B1 / 5 / 6 / 10C / 11 / 61A / 61B / 112: tRNA methyltransferase subunit, TYW2: tRNA-YW synthesis protein 2 homolog.

[0077] In some embodiments, the binding domain comprises a leader protein. In some embodiments, the binding domain comprises a leader protein selected from NUDT and a secondary YTHDC. NUDT is a U8 snoRNA decapping enzyme (see, for example, Uniprot accession number Q96DE0). YTHDC2 is a 3'-5' RNA helicase (see, for example, Uniprot accession number Q9H6S0). In some embodiments, the binding domain comprises a fragment or derivative of NUDT16 or YTHDC2.

[0078] In some embodiments, the binding domain comprises a writer protein. In some embodiments, the binding domain comprises a writer protein selected from DNTM1, DNTM3 A / B, NAT10, METTL3, METTL8, METTL15, TRM, BMT, DUS2, PUS, and NSUN2. DNMT1 and DNTM3 A / B are DNA(cytosine-5) methyltransferases. NAT10 is an RNA cytidine acetyltransferase (see, for example, Uniprot accession number Q9H0A0). METTL3 is an N6-adenosine-methyltransferase catalytic subunit (see, for example, Uniprot accession number Q86U44). NSUN2 is an RNA cytosine C(5)-methyltransferase (see, for example, Uniprot accession number Q08J23). In some embodiments, the binding domain comprises a writer protein which is a fragment or derivative of NAT10, METTL3, or NSUN2.

[0079] In some embodiments, the binding domain comprises an eraser protein. In some embodiments, the binding domain comprises an engineered eraser protein selected from FTO, ALKBH3, and ALKBH5. FTO is an α-ketoglutarate-dependent dioxygenase (see, for example, Uniprot accession number Q9C0B1). ALKBH3 is an α-ketoglutarate-dependent dioxygenase alkB homolog 3 (see, for example, Uniprot accession number Q96Q83). ALKBH5 is an RNA demethylase (see, for example, Uniprot accession number Q6P6C2). In some embodiments, the binding domain comprises a writer protein which is a fragment or derivative of FTO, ALKBH3, or ALKBH5.

[0080] The binding domain may be selected and / or manipulated to bind to non-classical features of DNA or RNA. For example, non-classical features may be modified bases, DNA damage, modified backbone, or structural elements. In some embodiments, the binding domain may bind to two or more non-classical elements. In some embodiments, the binding domain binds to a variant family having the same binding motif. For example, in some embodiments, the binding domain binds to 5-methylcytidine (5mC) and its oxidation products, 5-hydroxymethylcytidine (5hmC) and 5-formylcytidine (5fC).

[0081] In some embodiments, the binding domain binds to a modified base and / or nucleoside. In some embodiments, the binding domain contacts at least one, at least two, or at least three modified nucleosides. In some embodiments, the binding domain contacts at least one modified nucleoside. In some embodiments, the binding domain contacts at least one modified nucleoside and one or more adjacent nucleotides. Exemplary modified nucleosides that may occur in humans and other organisms are shown in Table 3A. Modified nucleosides known to be expressed in humans are shown in Table 3B. Other modified bases and nucleosides are listed at the worldwide web address genesilico.pl / modomics / modifications.

[0082] [Table 3A] *As those skilled in the art will understand, modified bases / nucleosides that are generally found in RNA may also be found in DNA, and modified bases / nucleosides that are generally found in DNA may also be found in RNA. [Table 3B-1] [Table 3B-2]

[0083] In some embodiments, the binding domain binds to one or more of the following modified nucleosides: 3-methylcytidine (m3C), 5-methylcytidine (m5C), N 4 - Acetylcytidine (ac4C), pseudouridine (Ψ), 1-methyladenosine (m1A), N 6- Methyladenosine (m6A), Inosine (I), 7-Methylguanosine (m7G), Dihydrouridine (D), 3-Methyluridine (m3U), 5-Methyluridine (m5U), 1-Methylguanosine (m1G), N 2 -Methylguanosine (m2G), 5-methyldeoxycytidine (m5dC), N 4 -Methyldeoxycytidine, 5-hydroxymethylcytidine (5-hmC), 5-hydroxymethyldeoxycytidine (5hmdC), 5-carboxydeoxycytidine (5cadC), 5-formylcytidine (5fC), 5-formyldeoxycytidine (5fdC), 6-methyldeoxyadenosine, N 7 -Methylguanosine (m7G), 2,7,2'-methylguanosine, or ribose methylation (Nm).

[0084] In some aspects, the non-classical features are: 3-methylcytidine (m3C), 5-methylcytidine (m5C), N 4 - Acetylcytidine (ac4C), pseudouridine (Ψ), 1-methyladenosine (m1A), N 6 - Methyladenosine (m6A), Inosine (I), 7-Methylguanosine (m7G), Dihydrouridine (D), 3-Methyluridine (m3U), 5-Methyluridine (m5U), 1-Methylguanosine (m1G), N 2 -Methylguanosine (m2G), 5-methyldeoxycytidine (m5dC), N 4 -Methyldeoxycytidine, 5-hydroxymethylcytidine (5-hmC), 5-hydroxymethyldeoxycytidine (5hmdC), 5-carboxydeoxycytidine (5cadC), 5-formylcytidine (5fC), 5-formyldeoxycytidine (5fdC), 6-methyldeoxyadenosine, N 7 -Methylguanosine (m7G), 2,7,2'-methylguanosine, or ribose methylation (Nm).

[0085] In some embodiments, the binding domain binds to nucleic acid damage resulting from naturally occurring oxidative or UV-induced damage, or from large adduct formation or base alkylation caused by exogenous agents. In some embodiments, the nucleic acid damage is caused by 8-oxoguanine (8-oxoG), one or more debase sites, cis-platin crosslinks, benzo(a)pyridinediol epoxide (BPDE) adducts, cyclobutenepyrimidine dimers (CPD), pyrimidine-pyrimidone (6-4) photoproducts (6-4PP), 6-O-methylguanine (O 6 6-O-methylguanine (O) is either 8-oxoguanine (8-oxoG), one or more debase sites, cis-platin crosslinks, benzo(a)pyridiol epoxide (BPDE) adducts, cyclobutenpyrimidine dimers (CPD), pyrimidine-pyrimidone (6-4) photoproducts (6-4PP), or 6-O-methylguanine (O) 6 -MedG), or O6-(carboxymethyl)-2'-deoxyguanosine (O6-CMdG).

[0086] In some embodiments, the binding domain binds to a structural element, which may be, for example, a hairpin or a loop. Other exemplary structural elements include, but are not limited to, the Z-DNA structure, G-quadriplex, i-motif, bulge, triple-helix, tridirectional binding, cruciform structure, quadruple-helix loop, ribose zipper, and pseudoknot.

[0087] Nucleic acid binding molecule and method for producing the same The present invention provides a nucleic acid binding molecule comprising a binding domain and an adapter. An exemplary structure of the nucleic acid binding molecule described herein is shown in Figure 1D. The binding domain specifically binds to non-classical features of DNA or RNA. The adapter contains a nucleic acid barcode sequence specific to the non-classical feature to which the binding domain specifically binds.

[0088] In some embodiments, the nucleic acid binding molecules described herein may further include one or more additional features. For example, in some embodiments, the nucleic acid binding molecule comprising a binding domain and an adapter may further include an enzyme or a catalytic fragment thereof. In some embodiments, the nucleic acid binding molecule comprising a binding domain and an adapter may further include an enzyme (or a fragment thereof) that lacks catalytic activity. In some embodiments, the enzyme is a DNA N-glycosylase or an RNA N-glycosylase, or a catalytic fragment or variant thereof. These enzymes create a debase site that terminates reverse transcription.

[0089] In some embodiments, the nucleic acid binding molecule may include a base editing enzyme. In some embodiments, the enzyme is DNA methylase, RNA methylase, or pseudouridine synthase. The base editing enzyme may be, for example, a cytidine deaminase of the APOBEC family, an adenosine deaminase of the ADAR family, or a catalytic fragment or variant thereof. In some embodiments, the base editing enzyme is APOBEC1. In some embodiments, the base editing enzyme is APOBEC3A. In some embodiments, the cytidine deaminase includes a maltose-binding domain to increase the solubility of the deaminase. In some embodiments, the cytidine deaminase includes a spycatcher peptide to increase the solubility of the deaminase. In some embodiments, the cytidine deaminase includes a maltose-binding domain and a spycatcher peptide to increase the solubility of the deaminase. In some embodiments, the nucleic acid binding molecule may include a transposase. The transposase may be, for example, DDE transposase, tyrosine (Y) transposase, serine (S) transposase, Y2 transposase, or Y1 transposase. In some embodiments, the transposase is Tn5 transposase, or a fragment or derivative thereof. In some embodiments, the transposase is Sleeping Beauty transposase, or a fragment or derivative thereof. In some embodiments, the nucleic acid binding molecule may include an integrase such as HIV integrase.

[0090] The nucleic acid-binding molecules described herein may bind specifically to RNA or specifically to DNA. In some embodiments, the nucleic acid-binding molecules can bind to both RNA and DNA. In some embodiments, the nucleic acid-binding molecules can bind specifically to double-stranded nucleic acids having one or more non-classical features, such as the modified nucleoside shown in Figure 1A. In some embodiments, the nucleic acid-binding molecules can bind specifically to single-stranded nucleic acids having one or more non-classical features, such as the modified nucleoside shown in Figure 1B or the structural features shown in Figure 1C.

[0091] In some embodiments, the nucleic acid-binding molecule binds to a non-classical feature of the target nucleic acid, thereby positioning the DNA adapter close to the 5' or 3' end of the target nucleic acid. For example, Figure 1E illustrates the binding of a nucleic acid-binding molecule to a modified nucleoside on a double-stranded target nucleic acid, thereby positioning the double-stranded barcode close to the 3' end of the target nucleic acid. Figure 1F illustrates the binding of a nucleic acid-binding molecule to a modified nucleoside on a single-stranded target nucleic acid, thereby positioning the single-stranded barcode close to the 3' end of the target nucleic acid. Figure 1G shows how the nucleic acid-binding molecule binds to a structural feature of the target nucleic acid, positioning the barcode close to its 3' end.

[0092] Nucleic acid binding molecules can be prepared using standard molecular biological and / or chemical techniques. For example, in some embodiments, the binding domain is bound to an adapter, forming a binding domain-adapter conjugate. In some embodiments, the DNA adapter includes a linker, and the binding domain is bound to the adapter via the linker. The coupling process may be covalent or non-covalent in some embodiments.

[0093] Adapters (e.g., adapters containing linkers) can be attached to the binding domain in several different ways. In some embodiments, adapters can be covalently attached to the binding domain by random tagging. For example, NHS-activated residues on an adapter may react with one or more amine groups of protein lysine residues exposed on the surface of the binding domain. Similarly, maleimide-activated adapters may react with native or artificial cysteine ​​residues of the binding domain. As will be understood by those skilled in the art, the number of adapters attached to the binding domain can vary depending on the number of reactive lysine or cysteine ​​residues, respectively, and the selection of reaction conditions.

[0094] Site-specific coupling methods can also be used. Site-specific coupling avoids affecting the function of the binding domain and enables reproducible material production. Site-specific internal tagging of the binding domain can be achieved by genetically incorporating non-natural amino acids using cell lines with manipulated aminoacyl-tRNA synthetase / tRNA pairs. The incorporated non-natural amino acids exhibit sites capable of undergoing bioorthogonal reactions. Commonly used amino acids are those with sites capable of undergoing copper-catalyzed azido-alkyne cycloaddition (CuAAC), photoactivated 1,3-dipolar cycloaddition, strain-enhanced azido-alkyne cycloaddition (SPAAC), or reverse electron-required Diels-Alder cycloaddition (IEDDA). Exemplary and versatile methods for C-terminal or N-terminal tagging of the binding domain include the use of protein tags or peptide tags. Protein tags such as SNAP-tag, Halo-tag, Spy-tag, Snoop-tag, Isopeptag, Dog-tag, Sdy-tag, and Clip-tag are small proteins or peptides that can be expressed as protein-tag fusion proteins by cloning the binding domain into a gene that expresses the binding domain. Such protein tags can autocatalyze covalent bond formation with specific peptides or substrates. For example, Spycatcher is a 113-residue protein that recognizes SpyTag, a 13-residue peptide that can readily bind to any DNA sequence. In some embodiments, Spycatcher includes SEQ ID NO: 12. In some embodiments, SpyTag includes SEQ ID NO: 10. Depending on the molecular weight of the binding domain, smaller peptide tags may be preferred. Peptide tags are typically 10-12 amino acid long and act in enzyme-mediated coupling reactions. In some embodiments, the peptide for tagging to the C-terminus includes SEQ ID NO: 11 (LCxPxR, where x is any amino acid).Examples of enzyme-mediated reactions for binding domains and adapters include, but are not limited to, (a) the use of biotin ligase for AP-peptide label binding and biotin-DNA linking (e.g., biotin linker), (b) the use of lipoic acid ligase for LAP-peptide label binding domain and lipoic acid-DNA linking (e.g., lipoic acid linker), (c) the use of tubulin-tyrosine ligase for Tub-tag label binding domain and tyrosine-modified DNA linking (e.g., tyrosine-modified linker), and (d) the use of saltase-A that reacts with LPxTG peptide and glycine-modified DNA (e.g., glycine-modified linker). Furthermore, a group of metal ion recognition tags and small molecule binding motifs can also be used. Another method of peptide tagging is to redirect endogenous cellular mechanisms to introduce aldehydes into recombinant proteins. This method utilizes formylglycinase (FGE), an enzyme that cotranslatively converts cysteine ​​to formylglycine (FGly) within a conserved 13-residue consensus sequence. The resulting aldehyde tag can be easily modified with a reactive amine that binds to DNA.

[0095] In some embodiments, the adapter is bound to the binding domain via a bioorthogonal chemical reaction. In some embodiments, the binding domain contains a DNA oligonucleotide that facilitates barcode binding. DNA oligonucleotides modified with amino, azide, biotin, and alkyne are readily available commercially. Alkyne and azide oligonucleotides can be bound to non-native amino acids in copper-catalyzed azide-alkyne cycloaddition reactions or strain-promoted azide-alkyne cycloaddition reactions. Amino oligonucleotides react with formylglycine and are introduced into the binding domain within the conserved sequence 13aa by formylglycine-producing enzyme (FGE).

[0096] When the nucleic acid binding molecules described herein bind to a target nucleic acid, a complex is formed. In some embodiments, the nucleic acid binding molecules of the complex may be covalently bound to the target nucleic acid. For example, the nucleic acid binding molecules may be chemically and / or photochemically bound to the target nucleic acid.

[0097] Adapter / Barcode Transfer Response The nucleic acid-binding molecules described herein can be used to transfer an adapter to a target nucleic acid, such as an adapter containing a barcode. Therefore, in some embodiments, the nucleic acid-binding molecules described herein can be used to transfer a barcode to a target nucleic acid. The barcode may be an MBC, i.e., a barcode specific to a non-classical function that is specifically bound by the binding domain of the nucleic acid-binding molecule. The target nucleic acid into which the adapter has been introduced is referred herein to as the “labeled target nucleic acid,” the “labeled target,” or a similar term. The target nucleic acid to which the barcode has been transcribed is referred herein to as the “barcoded target nucleic acid,” the “barcoded target,” or a similar term. The reaction in which the adapter is transferred to the target nucleic acid is referred herein to as the “adapter transfer reaction.” Similarly, the reaction in which the barcode is transferred to the target nucleic acid is referred herein to as the “barcode transfer reaction.”

[0098] The purpose of adapter / barcode transfer is to covalently bond an adapter / barcode to a target nucleic acid molecule. For example, in some embodiments, a barcode is transferred to a target nucleic acid by covalently bonding the barcode to the 5' or 3' end of the target nucleic acid. In some embodiments, a barcode is transferred to a target nucleic acid by covalently bonding the barcode or its complement to the 5' or 3' end of the target nucleic acid. The labeled / barcoded nucleic acid molecule may be sequenced in a downstream process in some embodiments. In some embodiments, a copy of the labeled target nucleic acid can be sequenced. Figures 3A-3E show examples of adapter / barcode transfer reactions.

[0099] The enzymes used for adapter transfer differ depending on the target nucleic acid, whether DNA or RNA, and vary depending on the adapter structure. Adapter / barcode introduction into target DNA can be performed using one or more enzymes such as T4 DNA ligase, CircLigase, Klenow fragment, or Bsu DNA polymerase. Adapter / barcode introduction into target RNA can be performed using, for example, T4 RNA ligase, T4 RNA ligase 2, or RtcB ligase. For example, Figure 3A shows ligation between a single-stranded DNA adapter (e.g., one containing a barcode, or an adapter containing a barcode) and a single-stranded target nucleic acid. In some embodiments where the target nucleic acid is RNA, the adapter contains a 5' phosphate group and is catalyzed by T4 RNA ligase. Alternatively, the adapter can be 5'-preadenylated and transferred by T4 RNA ligase 2 to eliminate the need for ATP and limit the reaction to a single turnover. Alternatively, an unphosphorylated adapter may be used and transferred to 3'-phosphorylated RNA using RtcB ligase. In some embodiments where the target nucleic acid is DNA, the adapter / barcode can be transferred in a reaction catalyzed by CircLigase.

[0100] Splint ligation can also be used to introduce adapters / barcodes into target nucleic acids. Splint ligation involves linking two nucleic acids using crosslinking DNA or RNA oligonucleotides. For example, sprint ligation of two RNAs (e.g., target RNA and adapter / barcode) can be performed using T4 ligase and a complementary bridging RNA oligonucleotide. For example, the sprint nucleic acid construct shown in Figure 3B can be created using sprint ligation. SplintR ligase is used to ligate the 3' end of the RNA to the 5' pDNA. When the target molecule is DNA, sprint DNA ligation can be performed using enzymes such as T4 DNA ligase, T3 DNA ligase, T7 DNA ligase, or E. coli DNA ligase.

[0101] Sprint extension and primer extension are other methods that can be used to introduce adapters / barcodes into target nucleic acids. A “sprint” is a sequence that spans a ligation junction. When primers are used, they generally do not span a ligation junction. Figure 3C shows adapter transfer by sprint extension, where the adapter sequence is used as a sprint to create a copy of the target nucleic acid molecule's sequence. When the target nucleic acid molecule is RNA, this reaction is catalyzed by reverse transcriptases such as Avian Myeloblastosis Virus (AMV) reverse transcriptase and Moroni mouse leukemia virus (M-MuLV, MMLV), with the 3' end of the DNA adapter being completely or partially matched. Therefore, the 3' end of the sprint may contain random bases or synthetic universal bases that promiscuously form base pairs. When the target molecule is DNA, the primer can be extended by any suitable DNA polymerase, regardless of whether it has 3'→5' exonuclease activity or not.

[0102] In some embodiments, template extension may be used to transfer the adapter / barcode to the target nucleic acid. Figure 3D shows direct adapter transfer by primer extension, where the adapter is copied to the target nucleic acid by polymerase using a bound copy of the adapter as a template. In some embodiments, the polymerase operates at a temperature that allows for a short spacer sequence and lacks 3'-to-5' exonuclease activity and 3' tailing activity. For DNA adapter / barcode, this reaction is catalyzed by DNA polymerase, e.g., Klenow fragment, T7, T4, or Bsu DNA polymerase. Figure 3D can be performed as part of a multicycle encoding process or as a single cycle. In some embodiments, the resulting barcoded nucleic acid is capped with a universal primer as a final step. The universal primer serves as the reverse transcription start site. In some embodiments, the reverse transcription primer includes SEQ ID NO: 8.

[0103] Furthermore, double-strand ligation can also be used to transfer adapter / barcodes to target nucleic acids. For example, Figure 3E shows double-strand ligation for adapter / barcode transfer. In some embodiments, the target nucleic acid molecule may be double-stranded DNA or an RNA / DNA hybrid, and may have either blunt or sticky ends. Ligation of blunt and sticky ends of double-stranded DNA is catalyzed by T4, T3, T7, or E. coli ligases.

[0104] In some embodiments, chemical ligation may be used to introduce an adapter / barcode into a target nucleic acid.

[0105] Method for facilitating adapter / barcode transfer within a complex through spatial separation Intracomplex transfer of adapters / barcodes can be facilitated by spatially separating the molecules involved in the reaction. Specifically, transfer can be facilitated by separating the complex containing the nucleic acid-binding molecule, the target nucleic acid, and / or the nucleic acid-binding molecule bound to the target nucleic acid, so that the nucleic acid-binding molecule can only interact with the target nucleic acid to which it is bound.

[0106] Barcode transfer can be performed in several different environments where spatial separation is possible. Spatial separation can be achieved, for example, by highly diluting the complex containing nucleic acid-binding molecules bound to the target nucleic acid in a solution. The solution must be sufficiently diluted so that the complex containing the nucleic acid-binding molecules bound to the target nucleic acid present therein can be spatially separated. Such spatial separation facilitates barcode transfer within the complex and substantially prevents barcode transfer between nucleic acid-binding molecule complexes. In some embodiments, the concentration of the complex in the diluted solution is less than 10 nM, less than 1 nM, less than 0.1 nM, less than 0.01 nM, or less than 0.001 nM.

[0107] In some embodiments, spatial separation can be achieved by surface immobilization. For example, the nucleic acid binding molecules described herein can be immobilized by binding to a substrate. Each substrate may contain only one type of nucleic acid binding molecule (Figure 5A), or it may contain at least two, at least three, at least four, at least five, or more types of nucleic acid binding molecules (Figure 5B). Each “type” of nucleic acid binding molecule binds to different non-classical features and / or constitutes a different barcode. In some embodiments, the first nucleic acid binding molecule is spatially separated from the second nucleic acid binding molecule on the surface of the substrate. Surface binding ability and form can be adjusted to allow for absolute or relative quantification of target molecules and modifications.

[0108] Exemplary substrates to which nucleic acid-binding molecules can be bound include, for example, beads, chips, plates, slides, dishes, or three-dimensional matrices. In some embodiments, the substrate is a resin, membrane, fiber, or polymer. In some embodiments, the substrate is a bead, such as one containing Sepharose, agarose, cellulose, polystyrene, polymethacrylate, and / or polyacrylamide. In some embodiments, the support is a magnetic bead. In some embodiments, the support is a polymer, such as a synthetic polymer. An unspecified list of synthetic polymers includes polystyrene, poly(ethylene) glycol, polyisocyanopeptide polymer, polylactic acid-coglycolic acid, poly(ε-caprolactone) (PCL), polylactic acid, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), chitosan, cellulose, and the like.

[0109] Nucleic acid-binding molecules can be directly bound to the substrate surface. For example, a molecule can be directly bound to the substrate by one or more covalent or non-covalent bonds. In embodiments where the substrate is a 3D matrix or other 3D structure, the nucleic acid-binding molecule may be bound to multiple surfaces of the substrate.

[0110] In some embodiments, the nucleic acid binding molecule may be indirectly bound to the surface of the substrate. For example, the nucleic acid binding molecule may be indirectly bound to the substrate surface via a capture molecule, or the capture molecule may be directly bound to the substrate. The capture molecule may be a nucleic acid, protein, sugar, chemical linker, etc., that can bind to or link to both the substrate and the nucleic acid binding molecule and / or the target nucleic acid. In some embodiments, the capture molecule binds to the nucleic acid binding molecule. In some embodiments, the capture molecule binds to the binding domain or adapter (e.g., the linker of the adapter) of the nucleic acid binding molecule. In some embodiments, the capture molecule binds to the target nucleic acid. In some embodiments, the capture molecule binds to the sequence or structural features of the target nucleic acid (Figure 5C). For example, in some embodiments, the capture molecule can bind to the poly(A) tail or a specific DNA or RNA sequence of the target nucleic acid.

[0111] In some embodiments, target nucleic acids can be directly bound to the surface of a substrate via reactive chemical groups. For example, nucleic acid targets are modified with azide groups to perform alkyne-decorated beads and Cu-catalyzed click chemistry. Other examples include trans-cyclooctene (TCO) / methyl-tetrazine and DBCO / azide.

[0112] In some embodiments, the first nucleic acid-binding molecule is separated from the second nucleic acid-binding molecule on the substrate surface so that each nucleic acid-binding molecule can interact with only one target nucleic acid. In some embodiments, the first nucleic acid-binding molecule is at least 50 nm away from the second nucleic acid-binding molecule. For example, the first and second nucleic acid-binding molecules may be separated by about 50 nm to about 500 nm, for example, about 50 nm to about 100 nm, about 100 nm to about 150 nm, about 150 nm to about 200 nm, about 200 nm to about 250 nm, about 250 nm to about 300 nm, about 300 nm to about 350 nm, about 350 nm to about 400 nm, about 400 nm to about 450 nm, or about 450 nm to about 500 nm. In some embodiments, the first and second nucleic acid-binding molecules may be separated by about 500 nm or more.

[0113] Generally, the purpose of binding nucleic acid-binding molecules (or target nucleic acids) to a substrate is to ensure intracomplex transfer of the adapter and / or barcode. Substrates containing two or more spatially separated nucleic acid-binding molecules can be prepared using methods known to those skilled in the art. Figures 4A-4D provide unspecified examples of methods for binding nucleic acid-binding molecules or target nucleic acids to a substrate and immobilizing them on the substrate. These examples are described in detail below. Figures 5A-5C show unspecified examples of methods for immobilizing nucleic acid-binding molecules or target nucleic acids on beads.

[0114] Binding of nucleic acid binding molecules to substrates Figure 4A shows nucleic acid-binding molecules directly or indirectly bound to a substrate. In some embodiments, multiple nucleic acid-binding molecules can be immobilized on a substrate using site-directed chemistry. For example, in some embodiments, the binding domain of a nucleic acid-binding molecule may include a site for immobilization on the substrate and a site for tethering a DNA adapter. Binding of the binding domain to the substrate surface is facilitated by fusing an autocatalytic protein tag (e.g., spycatcher, saltase A, SNAP tag, Halo tag, CLIP tag) to the end of the binding domain. These protein tags on the binding domain can be reacted covalently with a congenerally reactive site on the substrate surface. For example, a spycatcher protein can be artificially incorporated into the binding domain. The spy tag forms a covalent bond with the spy tag protein (13aa peptide). When the spy tag is bound to the substrate surface, the reaction between the binding domain bound to the spycatcher and the spy tag plays a role in covalently binding the binding domain to the substrate. Similarly, the binding domain can be fused with a saltase A tag and reacted with pentaglysin bound to the substrate surface. As another example, the binding domain can be fused with a SNAP tag and reacted with O6-benzylguanine bound to the substrate surface. In some embodiments, the binding domain can be fused with a CLIP tag and used to react with O2-benzylcytosine bound to the substrate surface. In some embodiments, the binding domain can be fused with a Halo tag which can be used to react with alkyl halides present on the substrate surface.

[0115] In some embodiments, the binding molecule may include a biotin moiety. Such a binding molecule can be immobilized on the substrate surface by a biotin-binding capture molecule (e.g., streptavidin).

[0116] Figures 17A-B show the nanobody size (Figure 17A) and the molecular structure including three complementarity-determining regions (CDRs) (Figure 17B). Figure 17B shows a DNA adapter site-specifically bound to the N-terminus via thiol-maleimide chemistry. The deaminase spycatcher fusion protein is site-specifically bound to the C-terminal spytag peptide. Surface immobilization of the nucleic acid binding molecule is achieved by the reaction of an aminooxy functionalized surface with an internal 13aa peptide that is co-translationally converted to formylglycine by formylglycine-generating enzyme (FGE). Figure 17C shows an example of (i) forming a nucleic acid binding molecule by barcode labeling of an antibody-containing binding domain, and (ii) site-specific immobilization of the nucleic acid binding molecule on a substrate surface. In this example, the DNA barcode is site-specifically bound to the C-terminal domain of the antibody light chain via an internal 13 amino acid peptide that is co-translationally converted to formylglycine by formylglycine-generating enzyme (FGE) to form a nucleic acid binding molecule. Surface immobilization of nucleic acid-binding molecules is achieved by the reaction of spy tags and spy catchers. The spy tag is a short 13aa peptide, which is created on the C-terminus of the antibody heavy chain. Spy catcher proteins are presented on the substrate surface at an appropriate density. The C-terminus of the spy tag and the N-terminus of the spy catcher spontaneously react to form an isopeptide bond.

[0117] Binding of target nucleic acid to substrate Figure 4B shows a nucleic acid binding molecule indirectly bound to a substrate via a capture molecule. In this example, the capture molecule contains a nucleic acid sequence that binds to the poly(A) tail of the target nucleic acid, but other unique nucleotide sequences on the target nucleic acid may also be used. Figure 4C shows a target nucleic acid indirectly bound to a substrate via a capture molecule, where the capture molecule is a hybridization probe that binds to the target nucleic acid (i.e., is specific to the primary sequence or secondary structure of the target nucleic acid). Figure 4D shows a target nucleic acid directly bound to a substrate via covalent bonding.

[0118] Therefore, in some embodiments, the substrate may be decorated with oligonucleotide capture molecules that hybridize to the features of the target nucleic acid. For example, mRNA can be captured by hybridization to a capture molecule containing polydT oligonucleotides or gene-specific sequences. In some embodiments, the capture molecule is present at a low surface density to physically separate the nucleic acid binding molecule. For example, low surface density is generally used in the substrate binding schemes shown in Figures 4B, 4C, and 4D. The target nucleic acid can hybridize to the capture molecule before or after it binds to the nucleic acid binding molecule. Barcode transfer from the nucleic acid binding molecule to the target nucleic acid may occur in some embodiments in a surface-bound state (i.e., when the target nucleic acid is bound to the substrate).

[0119] Beads for target nucleic acid capture by hybridization can be prepared by directly attaching 5'-amino-modified oligonucleotides to surface-activated beads. Surface-activated beads may present epoxy, tosyl, carboxylic acid, or amine groups for covalent bonding. Carboxylate beads typically require reaction with carbodiimide to facilitate peptide bond formation, while amine beads typically require a bifunctional NHS linker. In some embodiments, the bead surface is passivated to prevent nonspecific binding. Passivation can be achieved in some embodiments by co-implanting polyethylene glycol (PEG) molecules having the same linking chemistry. For example, 5'-amino-modified oligonucleotides and amino-terminated polyethylene glycol (PEG) are used such that, on average, most substrate sites are occupied by PEG molecules that spatially separate the oligonucleotides. By varying the ratio of oligonucleotides to PEG molecules, the surface density of the captured molecules can be adjusted.

[0120] In some embodiments, the beads are Sepharose beads made of mTet (tetrazine) and carboxy-PEG. Lowering the ratio of mTet to carboxy-PEG reduces crosslinking between target nucleic acids. In some embodiments, the mTet:carboxy-PEG ratio is 1:500, 1:600, 1:700, 1:800, 1:900, 1:1000, 1:1100, 1:1200, 1:1300, 1:1400, 1:500, 1:1000, 1:2000, 1:3000, 1:4000, 1:5000, 1:6000, 1:7000, 1:8000, 1:9000, or 1:10000. In some embodiments, the mTet:carboxy-PEG ratio is 1:1000.

[0121] Binding domain - enzyme conjugate The present invention also provides conjugates comprising a binding domain bound to an enzyme or a fragment thereof. The enzyme or fragment thereof may be catalytically active or catalytically inactive. In some embodiments, the enzyme or fragment thereof may be covalently or noncovalently bound to the binding domain. For example, the enzyme or fragment may be synthetically bound to the binding domain or genetically fused to the binding domain. In some embodiments, the binding domain and the enzyme (or fragment) may be expressed as a single transcript (e.g., as a fusion protein). In some embodiments, the binding domain is bound to the enzyme (or fragment) via a linker.

[0122] In some embodiments, the enzyme may be a nucleic acid base editing enzyme (also referred to herein as a base editing enzyme). The base editing enzyme may be, for example, an adenosine deaminase, a cytosine deaminase, a glycosylase, a methylase, a demethylase, a dioxygenase, or other enzymes that modify one or more nucleic acid bases of DNA or RNA.

[0123] In some embodiments, the enzyme may be a transposase. In some embodiments, the enzyme is a Tn5 transposase. Transposases are present in both prokaryotes and eukaryotes and catalyze the movement of defined DNA elements (transposons) to other parts of the genome via a 'cut and paste' mechanism. Transposases are widely used in many biomedical applications. For example, a highly active Tn5 transposase derived from E. coli can bind to a double-stranded synthetic 19bp mosaic end (ME) recognition sequence, which can be attached to any sequencing adapter. In some embodiments, the ME-adapter includes CTGTCTCTTATACACATCT;SEQ ID NO: 58. In some embodiments, the ME-adapter includes AGATGTGTATAAGAGACAG;SEQ ID NO: 59. In some embodiments, the ME-adapter includes TTTGTGAUGCGATGAACTCAGAGTGCTTNNNNNNNNNNNNAGATGTGTATAAGAGACAG;SEQ ID NO: 60, where N is a barcode. In some embodiments, mosaic ends containing SEQ ID NO: 58 are hybridized to ME-adapters containing SEQ ID NO: 60. Each transposase molecule simultaneously attaches two ME-tagged adapters. Tn5 transposases have been used in in vitro tagmentation reactions (fragmenting target sequences and simultaneously tagging them with sequencing adapters) using double-stranded DNA or RNA / DNA heteroduplexes as substrates. A major advantage of tagmentation is that it reduces the amount of nucleic acid used and greatly simplifies the assay workflow. Tagmentation is commonly performed using picograms of DNA or RNA and has been successful in single-cell approaches.

[0124] In some embodiments, the binding domain-enzyme conjugate includes a binding domain that specifically binds to RNA modifications, DNA modifications, or both RNA and DNA modifications, and guides the transposase to the target nucleic acid. The transposase bound to the modification-specific binding domain inserts a specific barcode into the RNA / DNA duplex and adds universal primer sites and reverse primer sites. Tagmentation is magnesium ion-dependent, and tagmentation can be induced by the addition of magnesium ions. The length of the tagged duplex varies depending on the reaction conditions and can be optimized to a short length of 30 base pairs. Therefore, targeted tagmentation can detect DNA or RNA modifications with a base resolution of up to 30 base pairs.

[0125] In some embodiments, the transposase may not be directly tethered or fused to the binding domain that recognizes DNA / RNA modifications. In some embodiments, the transposase may be tethered or fused to a peptide or protein domain that covalently or noncovalently binds to a structural element of the binding domain that recognizes DNA / RNA modifications. In some embodiments, the binding domain, e.g., an antibody, is genetically fused to a spytag peptide, while the transposase is genetically fused to a spycatcher protein. The spytag and spycatcher spontaneously form covalent bonds, targeting the transposase to the modification site. In some embodiments, the transposase is genetically fused to protein A, G, or L. In some embodiments, the transposase is genetically fused to protein G. In some embodiments, the transposase is genetically fused to protein L. Proteins A, G, or L bind to a specific region of an IgG antibody, directing the transposase activity to the DNA or RNA modification binding antibody.

[0126] In some embodiments, a transposase can bind to an ME-tagged adapter covalently bonded to its binding domain. The adapter exists as a single strand with an ME tag, and hybridization of the ME complement triggers in-situ addition of the transposase. The binding domain can present two or more ME adapter molecules, allowing for the addition of two adapters to the transposase. In some embodiments, the ME-adapter molecules have the same sequence. In some embodiments, the ME-adapter molecules have different sequences. In some embodiments, the ME-adapter contains a barcode specific to DNA or RNA modification.

[0127] Cytosine deaminases catalyze the hydrolytic deamination of cytosine to uracil, mutating CG base pairs to TA base pairs. The APOBEC (apolipoprotein B mRNA editing catalytic polypeptide-like) family of cytosine deaminases has diverse and important functions in human health and disease. While all APOBEC enzymes bind to single-stranded DNA and RNA, only some enzymes deamidate RNA bases. APOBEC1 and APOBEC3A, in particular, modify DNA and RNA. The E. coli cytosine deaminase CodA catalyzes the conversion of 5-fluorocytosine (5Fc) to 5-fluorouracil (5FU). This activity allows for the formation of cytotoxic chemotherapeutic agents from non-cytotoxic precursors. APOBEC enzymes are designed to process double-stranded DNA.

[0128] RNA-acting adenosine deaminases (ADARs) catalyze the hydrolytic deamination of adenosine to inosine. Since inosine acts like guanine in cellular mechanisms, this is equivalent to mutating AT base pairs to GC base pairs. Two enzymes are involved in human adenosine deamination: ADAR1 and ADAR2. ADAR proteins have a modular structure containing a double-stranded RNA-binding domain and a C-terminal deaminase domain. While double-stranded RNA is required for ADAR activity, recent reports have demonstrated ADAR activity on the DNA strand of RNA / DNA heteroduplexes. Recently, ADAR2 has been designed to perform not only adenosine to inosine conversion but also cytosine to uracil conversion.

[0129] In some embodiments, the binding domain-enzyme conjugate includes a binding domain that specifically binds to RNA and / or DNA modifications and directs cytosine and adenosine deaminases to the target nucleic acid. At the target site, the deaminase enzyme introduces a single-point location that indicates the location of non-classical features of the DNA / RNA. Base editing is another method for localizing modifications and is an alternative to generating cleaved cDNA by photocrosslinking proteins and nucleic acids for this purpose. In some embodiments, cytosine-to-uracil editing may be used to introduce the cleavage site.

[0130] In some embodiments, the base editing enzyme may not be directly tethered or fused to the binding domain that recognizes DNA / RNA modifications. Instead, the base editing enzyme may be tethered or fused to a peptide or protein domain that covalently or noncovalently binds to a structural element of the binding domain that recognizes DNA / RNA modifications, as shown in Figures 6A–6C. For example, the binding domain that recognizes RNA / DNA modifications may be a primary antibody, and the deaminase enzyme may be tethered or fused to a secondary antibody (Figure 6A). In some embodiments, the binding domain, e.g., a nanobody, represents a DNA adapter containing a DNA address, a linker, and a barcode. The deaminase is labeled with a sequence complementary to the DNA address, and DNA hybridization targets the enzyme to the modification site (Figure 6B). In some embodiments, the binding domain, e.g., a nanobody, is gene-fused to a spytag peptide, while the deaminase is gene-fused to a spycatcher protein. The spytag and spycatcher spontaneously form covalent bonds, guiding the deaminase to the modification site (Figure 6C). In some embodiments, the deaminase is fused to protein G bound to the primary antibody (Figure 6D). In some embodiments, the enzyme is a base-editing enzyme fused to protein A (UniProt accession numbers P38507 & P02976), protein G (UniProtion accession numbers Q54181 & P19909), or protein L (UniProtion accession number Q51918). In some embodiments, the enzyme is a base-editing enzyme fused to protein A. In some embodiments, the enzyme is a base-editing enzyme fused to protein G. In some embodiments, the enzyme is a base-editing enzyme fused to protein L.

[0131] In some embodiments, the conjugate comprises (i) a nucleic acid binding molecule and a peptide tag, and (ii) an enzyme or fragment thereof fused to a protein capable of covalent reactions with the peptide tag. In some embodiments, the conjugate comprises (i) an enzyme or fragment thereof containing a peptide tag, and (ii) a nucleic acid binding molecule fused to a protein capable of covalent reactions with the peptide tag. In some embodiments, the conjugate comprises (i) a nucleic acid binding molecule and a protein tag, and (ii) an enzyme or fragment thereof fused to a peptide tag capable of covalent reactions with the protein tag. In some embodiments, the conjugate comprises (i) a nucleic acid binding molecule and (ii) an enzyme or fragment thereof fused to a protein capable of high affinity binding to a specific region of the binding domain. In some embodiments, the peptide tag is a spy tag. In some embodiments, the enzyme is a deaminase. In some embodiments, the protein capable of covalently reacting with the peptide tag is a spycatcher protein.

[0132] In some embodiments, the conjugate comprises (i) a nucleic acid binding molecule and a peptide tag, and (ii) an enzyme or fragment fused to a protein tag capable of covalently reacting with the peptide tag. In some embodiments, the conjugate comprises (i) an enzyme or fragment containing a peptide tag, and (ii) a nucleic acid binding molecule fused to a protein tag capable of covalently reacting with the peptide tag. In some embodiments, the conjugate comprises (i) a nucleic acid binding molecule and a protein tag, and (ii) an enzyme or fragment fused to a peptide tag capable of covalently reacting with the protein tag. In some embodiments, the conjugate comprises (i) a nucleic acid binding molecule and (ii) an enzyme or fragment fused to a protein tag capable of binding with high affinity to a specific region of the binding domain. In some embodiments, the peptide tag is a spy tag. In some embodiments, the enzyme is a deaminase. In some embodiments, the protein capable of covalently reacting with the peptide tag is a spycatcher protein.

[0133] In some embodiments, the conjugate is covalent. In some embodiments, the conjugate is non-covalent.

[0134] Nucleic acid analysis methods including localization of non-classical features by targeted nucleic acid modification or editing. The nucleic acid-binding molecules described herein, which are capable of intracomplex barcode transfer as described above, can be used in various methods for analyzing nucleic acids, particularly for recognizing non-classical features on target nucleic acids. Accordingly, the present invention provides methods for analyzing non-classical features on target nucleic acids, including multiple profiling methods for RNA and DNA modifications across transcriptomes and genomes. In these methods, the binding domain of the nucleic acid-binding molecule recognizes the non-classical features of RNA or DNA. Subsequently, an adapter or a part of it (e.g., a barcode) is transferred from the nucleic acid-binding molecule to the target nucleic acid (i.e., a labeled / barcoded target nucleic acid is generated). Since the barcode is specific to the particular non-classical feature bound by the target nucleic acid, this step serves to write information from the recognition event into the nucleic acid sequence of the target nucleic acid. The barcoded target nucleic acid is converted into a sequencing library and read by DNA / RNA sequencing. This step reveals the sequence of the barcode, which correlates with the non-classical features of the target nucleic acid. Base sequencing can also confirm the localization of the non-classical features in the target nucleic acid. The high-throughput profiling methods described herein enable the parallel identification of the nature and location of multiple or all DNA / RNA modifications.

[0135] The methods described herein include the following series of steps. As will be understood by those skilled in the art, in some embodiments various steps may be omitted and / or performed in a different order.

[0136] Collision between nucleic acid binding molecules and target nucleic acids In some embodiments, the methods described herein include the step of contacting one or more nucleic acid-binding molecules with one or more target nucleic acids. The target nucleic acids include DNA, RNA, or a combination of DNA and RNA. The target nucleic acids can be isolated, for example, from the cells or tissues of an organism. In some embodiments, the target nucleic acids may be fragmented.

[0137] Contact between nucleic acid-binding molecules and target nucleic acids can occur in solution. For example, a composition containing one or more target nucleic acids can be brought into contact with a composition containing one or more nucleic acid-binding molecules. In some embodiments, the contact occurs in a dilute solution, and only one nucleic acid-binding molecule can interact with each target nucleic acid.

[0138] In some embodiments, contact occurs on the substrate. For example, one or more target nucleic acids can be bound to the substrate, and one or more nucleic acid binding molecules can be brought into contact with the target nucleic acids bound to the substrate. In some embodiments, one or more nucleic acid binding molecules may be bound to the substrate, and one or more target nucleic acids may be brought into contact with the nucleic acid binding molecules bound to the substrate. A substrate containing nucleic acid binding molecules and a method for producing the same are described above and shown in Figures 4A-4D and 5A-5C.

[0139] The target nucleic acid may be contacted with only one type of nucleic acid-binding protein (i.e., to detect one non-classical feature), or in some embodiments, the target nucleic acid may be contacted with two or more types of nucleic acid-binding molecules to detect multiple non-classical features. For example, the target nucleic acid may be contacted with at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or more different types of nucleic acid-binding molecules. In some embodiments, the target nucleic acid may be contacted with 1-5, 5-10, 10-25, 25-50, 50-100, 100-150, 150-175, 175-200, or more different types of nucleic acid-binding molecules. When using multiple types of nucleic acid binding molecules, contact may occur simultaneously (i.e., the target nucleic acid may be brought into contact with multiple nucleic acid binding molecules that recognize different non-classical features at the same time) or sequentially (i.e., the target nucleic acid may be brought into contact with a first nucleic acid binding molecule that recognizes a first non-classical feature, and then with a second nucleic acid binding molecule that recognizes a second non-classical feature).

[0140] In some embodiments, the target nucleic acid is contacted with a first pool of nucleic acid binding molecules, and then with a second pool of nucleic acid binding molecules. In some embodiments, the pools may contain different types of nucleic acid binding molecules (i.e., recognizing different types of non-classical features). In some embodiments, each pool may contain 1-5, 5-10, 10-25, 25-50, 50-100, 100-150, 150-175, 175-200, or more different types of nucleic acid binding molecules.

[0141] Barcode Transfer Each nucleic acid binding molecule specifically binds to a non-classical feature of the target nucleic acid, bringing the nucleic acid adapter close to either the 3' or 5' end of the target nucleic acid. The adapter (e.g., containing a barcode, or an adapter containing a barcode) can then be transferred to the target nucleic acid. In some embodiments, the transcription is carried out in an environment that substantially prevents off-target generation of the barcoded nucleic acid. Such an environment may be one in which the target nucleic acids cannot interact with each other (i.e., only one nucleic acid binding molecule can interact with each target nucleic acid). This can be achieved, for example, by carrying out the barcode transcription reaction in a dilute solution, or by immobilizing either the target nucleic acid or the nucleic acid binding molecule on a substrate and achieving their spatial separation. In some embodiments, the transfer is carried out by copying the target nucleic acid to produce a labeled / barcoded copy of the target nucleic acid. For example, if the barcode is transcribed to or close to the target nucleic acid, a polymerase chain reaction (PCR) can be used to produce a barcoded copy of the target nucleic acid.

[0142] The barcode transfer reaction and spatial separation are as described above and are shown in Figures 3A-3E.

[0143] Modification of target nucleic acid (or its copy) In some embodiments, the method may include a step of modifying a barcoded target nucleic acid or barcoded copy. This modification may occur after the nucleic acid binding molecule has bound to a non-classical feature, and in some embodiments, after the barcode has been transferred to the target nucleic acid (or a barcoded copy of the target nucleic acid has been generated).

[0144] Modifications are made so that the location of non-classical features is identifiable based on the primary nucleic acid sequence of the barcoded target nucleic acid or its barcoded copy, and therefore detectable in downstream sequencing steps. Many different types of modifications are performed for this purpose. For example, in some embodiments, modifications can prevent polymerase bypass during copying of the target nucleic acid (or its barcoded copy).

[0145] In some embodiments, the modification is achieved in part by chemically modifying the binding domain of the nucleic acid-binding molecule. In some embodiments, this can induce cleavage during the copying of the target nucleic acid while the binding domain is bound.

[0146] In some embodiments, the modification involves photochemically linking a nucleic acid-binding molecule (or a fragment thereof, such as a binding domain) to a target nucleic acid (or a barcoded copy thereof). Methods for photochemically linking nucleic acids and proteins are known to those skilled in the art. For example, photochemical linking can be induced by exposing a complex containing the nucleic acid-binding molecule and the target nucleic acid to ultraviolet (UV) light.

[0147] In some embodiments, modification involves editing bases at or near the site where a nucleic acid-binding molecule binds to a target nucleic acid. For example, base editing can be performed using cytosine deaminase or adenosine deaminase. The base-editing molecule may, if required, bind to the nucleic acid-binding molecule or a portion thereof, or to a binder that recognizes the nucleic acid-binding molecule, such as a secondary antibody that binds to a primary antibody-DNA adapter conjugate (Figure 6A-6C). Adenosine deaminase converts adenosine (A) to inosine (I), and the amplification enzyme base-pairs with cytosine (C), introducing a mutation from thymine (T) to cytosine (C). Cytosine deaminase converts cytosine (C) near the modification site to uracil (U), introducing a mutation from guanine (G) to adenosine (A). Another method for localizing non-classical features is NEB. (登録商標) Company USER (商標)This involves cleaving uracil (U) by a mixed enzyme of uracil deglycosylase and endonuclease VIII, which generates cleaved reads.

[0148] Amplification and sequencing After a target nucleic acid (or its barcoded copy) is modified, it can be amplified and sequenced. This process reveals the barcode sequence, which correlates with the non-classical features to which nucleic acid-binding molecules in the target nucleic acid originally bound. Sequencing also reveals the length of the cleavage fragments, allowing for the localization of non-classical features in the target nucleic acid. Sequencing may also reveal mutations near non-classical features, from which their location can be informatively derived. Mutations may be the result of base editing by deaminase enzymes, or they may be the result of an increased base insertion error rate in the enzyme used to copy the nucleic acid target (DNA polymerase if the target is DNA, or reverse transcriptase if the target is RNA). Non-classical features may naturally increase the enzymatic bypass error rate, or their effect may be amplified by chemical modification.

[0149] Accordingly, in certain embodiments, the methods described herein may include a step of sequencing a barcoded target nucleic acid or a copy thereof. The sequencing step can be carried out using any suitable method known in the art. For example, sequencing can be carried out using next-generation sequencing (NGS), massively parallel sequencing, or deep sequencing. There are many NGS platforms that can be used in the methods of the present invention. For example, Illumina (登録商標) (Solexa (登録商標) The sequencing of DNA works by identifying DNA bases as each base emits a fluorescent signal and adding them to the nucleic acid chain. (登録商標)454 sequencing is based on pyrosequencing, a technique that uses fluorescence to detect the release of pyrophosphate after nucleotides have been incorporated into a new strand of DNA by polymerase. Ion Torrent (proton / PGM sequencing) measures the direct release of protons (H+) from the incorporation of individual nucleotides by DNA polymerase.

[0150] In some embodiments, sequencing is not essential for detecting target nucleic acids. For example, target nucleic acids can be detected using PCR. For example, PCR can be used to detect whether a target nucleic acid (e.g., a barcode) is present. In some embodiments, target nucleic acids are detected using fluorescent probes (e.g., fluorescently labeled hybridization probes). In some embodiments, target nucleic acids are detected using microarrays or other nucleic acid arrays. Methods for analyzing sequencing results or data obtained from any of the methods for detecting target nucleic acids described herein are known to those skilled in the art. For example, standard bioinformatics techniques are used to analyze sequencing results.

[0151] In some embodiments, sequencing is not required to detect the addition of barcodes by reactions mediated by nucleic acid-binding molecules. For example, the presence of DNA / RNA modifications can be confirmed by detecting the associated barcodes using nucleic acid electrophoresis, fluorescence hybridization probes, PCR, or other nucleic acid amplification methods that can be induced by the barcode.

[0152] Exemplary methods for identifying, quantifying, or localizing non-classical features on target nucleic acids. In some embodiments, the methods described herein can be used not only to identify modifications (i.e., non-classical features) on target nucleic acids, but also to quantify the modifications and to localize the modifications on target nucleic acids with a resolution of approximately one base (see, for example, Figure 8). In some embodiments, the method enables localization of modifications with a resolution of 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases.

[0153] In some embodiments, an RNA sample containing modified and unmodified RNA transcripts is provided, as shown in the dual-workstream approach outlined in Figure 7. In this figure, unmodified RNA transcripts are labeled “Transcript A,” and Type 1 and Type 2 RNA modifications represent any type of modification. Each transcript in the RNA sample may or may not contain non-classical features.

[0154] Next, the RNA transcript is brought into contact with the beads, and the beads are directly or indirectly bound to nucleic acid-binding molecules specific to non-classical features (i.e., type 1 and / or type 2 RNA modifications in Figure 7). Modified RNA molecules bind to the beads, while unmodified RNA remains in the supernatant. To quantify the level of RNA modification, both fractions (substrate-bound fraction and supernatant fraction) can be processed and converted into sequencing libraries. Unmodified RNA molecules are capped at both ends with adapters containing UFP and URP, while modified RNA molecules receive a barcode indicating their modification (i.e., transcribed from the nucleic acid-binding molecule bound to them).

[0155] As shown in Figure 7, a normalized probe (control) can be spiked into both workstreams (surface-bound, supernatant) to enable relative quantification. Furthermore, absolute quantification can be achieved by counting the unique molecular identifiers that may be present in the adapter of the nucleic acid-binding molecule. Many RNA modifications occur at low copy numbers. Therefore, the split workflow has the advantage of combining modified and unmodified fractions in a ratio that provides optimal sensitivity for low-copy-number transcripts at a given sequencing depth. This split workflow allows for the measurement of the stoichiometry and abundance of RNA modifications. "Stoichiometry" is a relative number, calculated by dividing the copy number of a particular locus containing the non-classical feature by the total copy number of that locus. "Abundance" is the absolute number of occurrences of the non-classical feature of the nucleic acid at a given locus.

[0156] In some embodiments, a method for analyzing multiple target nucleic acids may include RNA profiling by barcode transfer via ligation and localization of non-classical features by cDNA cleavage (see, e.g., Figure 8). In some embodiments, the method includes depleting or enriching an RNA sample by physically or chemically fragmenting the RNA using conditions that preserve RNA modifications (see Figure 8, step A). ​​One or more nucleic acid binding molecules can then be added to the RNA sample. The binding domain of the nucleic acid binding molecule recognizes the RNA modification and juxtaposes the adapter (e.g., an adapter containing a DNA barcode) with the end of the RNA target (see Figure 8, step B). In some embodiments, the binding domains of the target RNA and the nucleic acid binding molecule may be crosslinked (e.g., photocrosslinked) to generate a mark (i.e., modification) that prevents reverse transcriptase from copying beyond the recognition element. In some embodiments, a stop point can be created without crosslinking by selecting and manipulating a recognition element that presents additional reactive groups that disrupt polymerase-RNA interactions and / or can participate for the same purpose (see Figure 8, step D). Subsequently, a single-strand adapter ligation is used to provide primer binding sites for reverse transcription, and cDNA can be synthesized by primer extension (see Figure 8, step F). The cDNA is synthesized such that the ends of the transcript indicate the sites of RNA modifications. The resolution at which the modifications are localized depends on the nature of the cleavage mechanism.

[0157] cDNA molecules may be cyclized. For example, a cDNA molecule with a type B adapter can be cyclized by Circligase (see Figure 8, step H). Cleavage of the cyclized cDNA yields strand-specific linear cDNA fragments, which can be easily converted into a sequencing library using PCR amplification (see Figure 8, step I). Primers can be used to introduce adapter pieces useful for downstream processes such as sequencing.

[0158] Figure 9 shows a method for analyzing DNA modifications by barcoding and enzymatic base editing (e.g., uracil addition) to create cleavage sites. Since DNA is double-stranded and base editing by deaminase enzymes requires single-stranded nucleic acids, the first step is to separate the DNA strands. This can be done by ligating a Y-shaped adapter to the ends of the DNA fragment according to a standard protocol (i.e., end repair, A-tailing, adapter ligation). In some embodiments, one arm of the Y-shaped adapter contains a 5' azide group as a chemical handle. After denaturing the double-stranded DNA with 95% formamide, it can be bound to beads such as magnetic beads. For example, alkyne groups (100 nm) exposed on the surface. 2 Magnetic beads having an alkyne group density of 1 per bead can be added. The addition of Cu(I) induces covalent bonding of nucleic acids to the beads. Complementary DNA strands are randomly attached to the bead surface and are spatially separated from each other, so hybridization is not possible under physiological buffer conditions. Single-stranded DNA bound to the beads can come into contact with a nucleic acid binding molecule and a barcode indicating DNA modification. The barcode can then be transferred to the single-stranded target nucleic acid by ligation. Next, a binding domain-enzyme conjugate containing, for example, an antibody specific to the binding domain of the nucleic acid binding molecule (e.g., an anti-mouse antibody) and a base editing enzyme (e.g., cytosine deaminase) is added. When the binding domain-enzyme conjugate comes into contact with the binding domain of the nucleic acid binding molecule, the enzyme (cytosine deaminase) edits the bases of the single-stranded target nucleic acid (e.g., changing cytosine (C) near the modification site to uracil (U)). Deaminase is inactivated, and the DNA strand is cleaved by the addition of USER (a mixture of uracil deglycosylase and endonuclease VIII). Primer extension by DNA polymerase generates cleavage reads indicating the locations of DNA modifications. The reads are converted into a library and can be sequenced using standard methods.

[0159] In some embodiments, a method for analyzing multiple target nucleic acids can be used to detect / quantify one DNA or RNA modification per reaction. In some embodiments, the method for analyzing multiple target nucleic acids can be adapted to detect multiple DNA or RNA modifications by sample splitting, as shown in Figure 10. For example, a binding domain conjugated to a base editing enzyme such as adenine deaminase can be introduced into each reaction. Adenine deaminase converts adenine (A) to inosine (I), inducing a T→C mutation and indicating an RNA modification site. In the splitting scheme shown in Figure 10, a binding domain without a tether adapter is used. Each partition contains only one binding domain-deaminase conjugate, and after immunoprecipitation, a type C adapter is added to each partition and ligated to the enriched target. Type C barcoding allows the split reactions to be pooled before RNA Seq library preparation.

[0160] In some embodiments, multiple modification profiling and base editing can be combined. Figure 11 shows a method of RNA profiling using barcode ligation and base editing with adenosine deaminase. The process is similar to the workflow shown in Figure 9, except that the binding domain-enzyme conjugate contains adenosine deaminase. Adenosine (A) is converted to inosine (I) to indicate the modification site, the first strand is synthesized by reverse transcription, and then the second strand cDNA is synthesized in a manner that preserves the strand information. By incorporating only uracil into the second strand, the second strand can be removed by USER cleavage. Strand RNA library preparation is advantageous when performing base editing because only the edited strand is amplified.

[0161] The methods described herein may also be used to analyze DNA or RNA containing two or more modifications (i.e., non-classical features). For example, as shown in Figure 12, a two-cycle profiling can be employed to add a reverse adapter and a forward adapter to the 5' and 3' ends of a target RNA, respectively. The first step is to ligate the phosphorylated 5' end of the target RNA fragment with a reverse adapter having a free 3'OH. ​​The adapter is bound to the nucleic acid binding molecule via its 5' end, with the 3' end free. The nucleic acid binding molecule closest to the 5' end is likely to be more favorable than the recognition element closer to the 3' end. The barcode is transferred from the nucleic acid binding molecule, with the remainder of the nucleic acid binding molecule remaining chemically bound to the 5' end. Subsequently, nucleic acid binding molecules with different adapter structures can be added and bound to a forward adapter with a free 5' end. The adapter is bound to the nucleic acid binding molecule via its 3' end, with the 5' end being a free phosphorylated end. Depending on the conditions used to remove the nucleic acid binding molecule used in the first cycle, its binding domain may re-bind, blocking access to already encoded sites and reducing the likelihood of double profiling. Barcode transfer from the nucleic acid binding molecule in the second cycle can be achieved by extending the sprint oligo (e.g., by reverse transcriptase). This method yields a cDNA fragment with forward and reverse primers that can be amplified by PCR, ready for sequencing.

[0162] Figure 13 provides an exemplary reaction scheme for profiling any number of RNA modifications (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more RNA modifications). In the first step, a single-stranded spacer is ligated to the target nucleic acid. Next, a nucleic acid binding molecule with a type D adapter is added. If a matching RNA modification is present, the binding domain of the nucleic acid binding molecule binds and the spacer region of the type D adapter anneals. The barcode and spacer are copied by a DNA polymerase such as Klenow fragment, Bsu polymerase, T4 and T7 polymerase, or Bst polymerase. Next, the nucleic acid binding molecule is removed and the target nucleic acid is brought into contact with a second nucleic acid binding molecule (i.e., a nucleic acid binding molecule with different binding specificity) to add another barcode to the 3' end. In the final cycle, the 3' end is capped with a universal primer (such as UFP or URP) and used as a reverse transcriptase primer.

[0163] Figure 14B illustrates how to address situations where multiple copies of the same type of modification exist along the target RNA strand in each cycle of modification analysis, and where deaminase is targeted to the binding domain via hybridization of complementary DNA addresses. The presence of one or more identical modifications is indicated by barcode transcription by a type G adapter derived from a type D adapter, as described in Figure 13. The binding domain-type G adapter conjugate used in this method contains address 1, which is the DNA address. Following the binding of this binding domain, barcode introduction by primer extension is initiated. To mark the location of each modification, a conjugate containing cytidine deaminase and the complementary DNA address (address 1') is added and binds to address 1 on the binding domain-type D adapter conjugate. The deaminase can edit all modification sites in cycle 1. In cycle 2, a different binding domain-type D adapter conjugate containing address 2, specific to the other RNA modification, is introduced. Primer extension is initiated, followed by the addition of the appropriate cytidine deaminase and address 2', and editing is permitted to mark the position of the second modification type.

[0164] Figures 15A-15D illustrate a barcoding method using tagmentation. This method utilizes a dimeric nucleic acid-binding molecule containing a binding domain bound to a transposase. The transposase molecule is attached to a double-stranded DNA adapter that indicates a specific RNA modification. The transposase binds to the double-stranded DNA adapter and ligates it to the 5' end of the double-stranded DNA substrate, thereby cleaving and inserting the adapter. The 3' end is not tagged, and the resulting gap can be filled by a polymerase reaction. In some embodiments, the transposase can use a DNA / RNA heteroduplex as the substrate. The tagmentation reaction typically produces fragments of 200-300 nt in length, which can be optimized by sample input. In some embodiments, the nucleic acid-binding molecule-transposase conjugate is added to unfragmented total RNA or enriched / deleted RNA. Upon recognizing the modified RNA base, the transposase inserts a specific barcode into the RNA / DNA duplex, adding universal primer sites and reverse primer sites. Library preparation is completed by filling the gaps using an appropriate polymerase. Tagmentation is performed by framing RNA modification sites with specific barcodes, and positional information is obtained by constructing transposase linkers of a length that optimizes positional resolution.

[0165] Figure 16 shows a profiling method for multiple modifications combined with long-read construction using a type E adapter. The type E adapter contains barcodes and short random feet that hybridize near the modifications. With appropriate linker and foot design, they are sequenced on the RNA and represent the order and type of RNA modifications. Gaps are filled with reverse transcriptase and joined by ligation. Strand information is preserved by using a smart-Seq approach for template switching. Smart-Seq takes advantage of the reverse transcriptase property of tailing blunt ends with short polyC sequences. The polyC tails are primed with short LNA-GGG primers to initiate second strand synthesis.

[0166] In some embodiments, a method for analyzing multiple target nucleic acids includes: (i) contacting a target nucleic acid with a nucleic acid binding molecule described herein; (ii) generating a barcoded target nucleic acid by (a) transcribing a nucleic acid barcode onto the target nucleic acid in an environment that substantially prevents off-target generation of the barcoded nucleic acid, or (b) generating a barcoded copy of the target nucleic acid; (iii) modifying the barcoded target nucleic acid or its barcoded copy so that the locations of non-classical features can be identified based on the primary nucleic acid sequence of the barcoded target nucleic acid or its barcoded copy; and (vi) sequencing the barcoded target nucleic acid. In some embodiments, steps (i) to (iii) are repeated at least once (e.g., at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, or more times). In some embodiments, a different nucleic acid binding molecule is used each time steps (i) to (iii) are repeated. In some embodiments, the same nucleic acid binding molecule is used each time steps (i) to (iii) are repeated. In some embodiments, the method includes amplifying a barcoded target nucleic acid or a copy thereof before sequencing.

[0167] In some embodiments, a method for detecting or quantifying two or more non-classical features in multiple target nucleic acids includes: (i) contacting a target nucleic acid with at least two nucleic acid binding molecules, each nucleic acid binding molecule comprising a binding domain and an adapter; wherein the binding domain of each nucleic acid binding molecule binds to different non-classical features of DNA or RNA; wherein the adapter comprises a nucleic acid barcode sequence specific to the non-classical feature specifically bound by each binding domain; (ii) (a) transferring a nucleic acid barcode to a target nucleic acid to generate a barcoded target nucleic acid in an environment that substantially prevents off-target generation of the barcoded nucleic acid, or (b) generating a barcoded copy of the target nucleic acid; (iii) modifying the barcoded target nucleic acid or its barcoded copy so that the location of the non-classical features can be identified based on the primary nucleic acid sequence of the barcoded target nucleic acid or its barcoded copy; and (vi) sequencing the barcoded target nucleic acid. In some embodiments, the method includes amplifying the barcoded target nucleic acid or its copy before sequencing.

[0168] In some embodiments, a method for detecting non-classical features in a target nucleic acid includes: (i) contacting the target nucleic acid with a nucleic acid binding molecule as described herein; (ii) (a) transcribing a nucleic acid barcode onto the target nucleic acid to produce a barcoded target nucleic acid in an environment that substantially prevents off-target generation of the barcoded nucleic acid, or (b) producing a barcoded copy of the target nucleic acid; and (iii) detecting the presence of a barcode in the target nucleic acid or the copy thereof.

[0169] A method for determining the location of a non-classical feature in a target nucleic acid with single-nucleotide resolution, the method comprising: (i) contacting the target nucleic acid with a nucleic acid binding molecule described herein; (ii) transferring a nucleic acid barcode to the target nucleic acid in an environment that substantially prevents off-target generation of barcoded nucleic acid to generate a barcoded target nucleic acid; and (iii) detecting the presence of a barcode in the target nucleic acid or a copy thereof, wherein the nucleic acid binding molecule comprises one or more binding domains capable of: inducing mutation in the target nucleic acid; or preventing polymerase bypass, thereby causing cleavage during copying of the target nucleic acid. In some embodiments, steps (i) to (iii) are repeated at least once. In some embodiments, a different nucleic acid binding molecule is used each time steps (i) to (iii) are repeated. In some embodiments, the same nucleic acid binding molecule is used each time steps (i) to (iii) are repeated.

[0170] The methods described herein can be used to diagnose diseases, disorders, or conditions. For example, in some embodiments, the methods may be used to diagnose cancer in subjects requiring such diagnosis. In some embodiments, the kits may be used to monitor diseases, disorders, or conditions over time, such as responses to one or more treatments. For example, the kits may be used to monitor changes in the epigenetic and / or epitransscriptome over time in subjects undergoing cancer treatment (i.e., chemotherapy, radiotherapy, etc.). In some embodiments, the methods may be used to analyze cells or tissues from subjects requiring such diagnosis. For example, the methods may be used to detect non-classical features in cells or tissues isolated from blood samples, biopsy samples, autopsy samples, etc.

[0171] In some embodiments, the method may be used to detect and / or monitor epigenetic changes in cells commercially used for the production of one or more products, such as cells used in industrial fermentation. In some embodiments, the method may be used to detect and / or monitor epigenetic changes in plant cells or tissues.

[0172] composition containing nucleic acid binding molecules The present invention also provides compositions comprising one or more nucleic acid-binding molecules as described herein. In some embodiments, the composition comprises one or more nucleic acid-binding molecules. For example, the composition may comprise a first nucleic acid-binding molecule that binds to a first non-classical feature, and a second nucleic acid-binding molecule that binds to a second non-classical feature. In some embodiments, the composition may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 or more different types of nucleic acid-binding molecules.

[0173] Furthermore, this specification provides compositions comprising one or more complexes, each complex comprising a nucleic acid-binding molecule bound to a target nucleic acid.

[0174] In some aspects, the compositions described herein include one or more carriers, excipients, buffers, etc. The compositions may have a pH of about 0.5, about 1.0, about 1.5, about 2.0, about 2.5, about 3.0, about 3.5, about 4.0, about 4.5, about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, about 8.0, about 8.5, about 9.0, about 9.5, about 10.0, about 10.5, about 11.0, about 11.5, about 12.0, about 12.5, about 13.0, about 13.5, or about 14.0. In some aspects, the compositions are pharmaceutical compositions.

[0175] Nucleic acid analysis kit The nucleic acid-binding molecules described herein may be provided in a kit (for example, as components of a kit). For example, a kit may include a nucleic acid-binding molecule, or one or more components thereof, and informational materials. The informational materials may be, for example, explanatory materials, teaching materials, sales materials, or other materials relating to the methods described herein and / or the use of the nucleic acid-binding molecule. The format of the informational materials in a kit is not limited. In some embodiments, the informational materials may include information on the production of the nucleic acid-binding molecule, such as molecular weight, concentration, expiration date, batch or place of production information. In some embodiments, the informational materials may include a list of disorders and / or medical conditions that can be diagnosed or evaluated using the kit.

[0176] In some embodiments, nucleic acid-binding molecules may be provided in a manner suitable for use in the methods described herein (e.g., in an easy-to-use tube, in an appropriate concentration, etc.). In some embodiments, the kit may require some preparation or manipulation of the nucleic acid-binding molecules before use. In some embodiments, nucleic acid-binding molecules are provided in liquid, dry, or lyophilized form. In some embodiments, nucleic acid-binding molecules are provided in aqueous solution. In some embodiments, nucleic acid-binding molecules are provided in a sterile nucleic acid-free solution. In some embodiments, nucleic acid-binding molecules are provided in a composition that is substantially free of nucleic acids other than those that may constitute the molecule itself.

[0177] In some embodiments, the kit may include one or more syringes, tubes, ampoules, foil packages, or blister packs. The kit containers may be airtight, waterproof (i.e., preventing changes due to moisture or evaporation), and / or light-shielding.

[0178] In some embodiments, the kit may be used to carry out one or more of the methods described herein, such as a method for analyzing a population of target nucleic acids. In some embodiments, the kit can be used to diagnose a disease, disorder, or medical condition. For example, in some embodiments, the kit can be used to diagnose cancer. In some embodiments, the kit can be used to monitor a disease, disorder, or condition over time, such as a response to one or more treatments. For example, the kit can be used to monitor changes in the epigenetic and / or epitransscriptome over time in a subject receiving cancer treatment. [Examples]

[0179] Examples The following examples, which are not limited to this, further illustrate aspects of the compositions and methods of the present invention.

[0180] Example 1: Design, selection, and characterization of binding domains The binding domain is designed for use in nucleic acid binding molecules (also called BACs (=binding domain adapter conjugates)) that bind to N6-methyladenosine (m6A), pseudouridine (Ψ), inosine (I), and 5-methylcytosine (m5C). Initially, commercially available antibodies were screened. Antibodies with advantageous properties (such as monoclonal antibodies) were selected.

[0181] Initial antibody characterization was performed by plate ELISA. Biotinylated RNA oligonucleotides (Horizon Discovery) containing m6A (SEQ ID NO: 1), Ψ (SEQ ID NO: 2), I (SEQ ID NO: 3), or m5C (SEQ ID NO: 4), as shown in Table 4, and an unmodified control oligonucleotide (SEQ ID NO: 5) were added to streptavidin-coated 96-well plates (Thermo Fisher, catalog number 15125) at 4°C and washed with phosphate-buffered saline (PBS). In another experiment, the ability of antibodies to bind to double-stranded RNA modifications was evaluated by converting the oligonucleotides to RNA / DNA heteroduplexes by reverse transcription (Protoscript II, NEB catalog number M0368L). Since RNA sequences adopt stable secondary structures, RNA modifications are often presented as double-stranded structures, and antibodies that recognize modifications regardless of base pairing are considered superior. Antibodies were added to plates and incubated at 22°C for 60 minutes. Unbound antibodies were washed, and alkaline phosphatase (AP)-labeled detection antibodies (Thermo Fisher, catalog numbers 31430 and 31460) were added. After washing the unbound detection antibodies, AP substrate was added to the plate (Thermo Fisher, catalog number 34028), and the presence or absence of bound antibodies was determined by absorbance detection at 450 nm.

[0182] [Table 4]

[0183] Antibody binding affinity was evaluated by titrating the amount of antibody used in the assay and fitting the resulting curve to a binding model. Figure 19 shows the binding curves for a subset of antibodies with good binding characteristics to m6A (Thermo Fisher, catalog no. 61755 (Ab01), MA5-33030 (Ab02) (Synaptic Systems catalog no. 345E11 (Ab05)), m5C (Thermo Fisher, catalog no. MA5-24694 (Ab16)), I (Diagenode, catalog no. C15200251 (Ab10)), and Ψ (Diagenode, catalog no. C15200247 (Ab11), MBL, catalog no. D347-3 (Ab19)). All antibodies except the pseudouridine antibody showed good binding affinity to the antigen in single-stranded RNA with a sub-nanomole dissociation constant K D The antibodies bound at (affinity index) and showed specificity of more than 100 times. The pseudouridine antibody had only nanomolar affinity and specificity of about 10 times. Ab02, Ab05, and Ab16 are particularly desirable because they show strong binding to RNA / DNA heteroduplexes. The dissociation constant obtained from this ELISA format is a result of avidity, and because the density of RNA strands on the surface is high, both antibody arms can bind to modified bases. This bidentate binding mode is known to slow the dissociation rate and increase overall affinity. Based on the data presented herein, it is expected that the affinity in a 1:1 complex of one molecule will be low. Ab05, Ab10, Ab16, and Ab19 were selected for further analysis.

[0184] Example 2: Determination of mutation profile and cleavage pattern of binding domain Mutation profiles and cleavage patterns can be characterized for either (1) the antibody identified in Example 1, or (2) its derivative (e.g., an scFv containing the CDR sequence of the antibody in Example 1). Specifically, the binding domain described in Example 1 binds to a nucleic acid target. The binding domain and nucleotide are crosslinked. After adapter-binding of the target nucleotide, cDNA is prepared using reverse transcription, amplified by PCR, and sequenced to evaluate the mutation and cleavage profiles of the target nucleotide.

[0185] First, we evaluate the mutation patterns arising from the reverse transcription of antibody-binding RNA strands using RNA transcribed in vitro. First, AmpliScribe (商標) Using the T7 High Yield Transcription Kit (Lucigen), 500 nucleotides of RNA are transcribed in vitro while varying the ratio of modified and unmodified nucleotide triphosphates (NTPs) (TriLink) to generate RNA containing one or more modifications (m6A, Ψ, and / or m5C). The transcripts are fragmented into 50 to 150 nucleotides using an RNA fragmentation reagent (Thermo) and incubated with each candidate antibody.

[0186] To investigate whether UV crosslinking induces reverse transcription cleavage at the modification site, UV light (e.g., approximately 0.15 J / cm²) was applied to each antibody-RNA complex solution. 2 Irradiation is performed at 254 nm. After crosslinking, the antibody-RNA complex is captured by protein A / G dynabeads (Thermo). Protein A / G binds to the Fc region of the antibody with high affinity. Subsequently, the 3' end of the RNA is dephosphorylated with polynucleotide kinase (NEB), and the DNA adapter is ligated with T4 RNA ligase (NEB). The adapter is preadenylated at the 5' end: 5rApp / AGATCGGAAGAGCGGTTCAG / 3ddC, where 5rApp means 5' preadenylation and 3ddc means 3' dideoxy-C (SEQ ID NO: 6).

[0187] The RNA ligated to the adapter is eluted from the beads, purified, and primed with an oligonucleotide complementary to the ligated adapter (i.e., a reverse transcriptase primer). The reverse transcriptase primer is 5' phosphorylated to allow downstream cyclization and contains a degenerate base-framed 4-letter barcode, a BamHI restriction site (gatc, SEQ ID NO: 7), and forward and reverse primer binding sites: 5'P-NNAACCNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC-3' (SEQ ID NO: 8).

[0188] Reverse transcription is performed to produce cDNA. Reverse transcription is carried out using a panel of reverse transcriptases, including, for example, Superscript III (Thermo), to allow comparison of mutation and cleavage patterns of each enzyme. After size selection of the cDNA using AMPure beads (Agencourt), cyclization is performed at 60°C using CircLigase II (Lucigen), and cleavage is performed with BamHI restriction enzyme. The library is amplified by PCR using an appropriate sequencing adapter and sequenced using a MiSeq instrument (Illumina). Reads are aligned to a reference RNA sequence, and mutation and cleavage patterns are evaluated.

[0189] Example 3: Preparation of nucleic acid binding molecules by random labeling of binding domains Nucleic acid-binding molecules were prepared by conjugating DNA oligonucleotides to the antibody described in Example 1 using amine-reactive chemistry. Amino-modified DNA oligonucleotides were randomly conjugated to the antibody using an Oligonucleotide Conjugation Kit (Vector Labs, catalog number S-9011-1). The first step involved modifying the amino-terminal DNA oligonucleotide with a 4FB crosslinking agent and modifying the lysine residues of the antibody with a HyNic reagent. Simply mixing the activated oligonucleotide and antibody resulted in the formation of a covalent bond between them.

[0190] The stoichiometry of the label was evaluated by SDS gel electrophoresis, and its function was confirmed by plate ELISA as described in Example 1. Figure 20A shows how the efficiency of oligonucleotide labeling of Ab01 changed in response to HyNic concentrations (i.e., 0, 10, 25, and 50-fold molar excess). With a 10-fold molar excess of HyNic, antibody conjugates with 0, 1, or 2 oligonucleotides were present, while with a 50-fold molar excess of HyNic, the number of oligonucleotides ranged from 1 to 7.

[0191] For use in barcoding assays, a HyNic concentration that minimizes the amount of unlabeled antibody while avoiding labeling of functionally important lysine residues is preferred. In practice, the optimal HyNic ratio varied depending on the IgG isotype and paratope sequence (Figure 20B). Ab05 showed up to 8 oligonucleotides per antibody, Ab10 up to 5, Ab16 up to 3, and Ab19 up to 1. The adapter used for all labeling reactions in Figure 20B was the same, designed for primer extension-based barcoding (Type 2D adapter), and included a PEG linker (iSp18) for binding to the binding domain, a blocked 3' end (3SpC3), and a 5' amine (5AmMC6) ( / 5AmMC6 / T / iSp18 / TATAAGAGACAGACACAGGCCACTCAGTCTAT / 3SpC3 / ; SEQ ID NO: 9). The adapter for general use in primer extension-based barcoding and sequencing has the following structure:

number

[0192] To confirm the antibody binding activity after labeling with oligonucleotides, the ELISA experiment described in Example 1 was performed. Comparing the binding curves of the same antibody before and after labeling, Ab05, Ab16, and Ab10 all lost their activity, but Ab05 remained active. D More than 15 times the amount was lost, resulting in the worst hit (Figures 21A-21C). However, these experiments demonstrate detectable binding of antibodies as binding domains used for identifying nucleotide modifications.

[0193] Example 4: Preparation of nucleic acid binding molecules using site-specific labeling of antibody glycosylation domains To avoid inhibition of binding activity, Ab05 was site-specifically labeled using the SiteClick Antibody Azide Modification Kit (Thermo Fisher, catalog number S20026). SiteClick labeling uses an enzyme to specifically bind the azide portion to the heavy chain of the IgG antibody, ensuring that the antigen-binding domain remains unchanged for binding to the antigen target. This site selectivity was achieved by targeting the glycosylation domain, which is essentially present in all IgG antibodies regardless of isotype and host species. Galactosidase, using β-1,4-galactosyltransferase, catalyzes the hydrolysis of the β-1,4-linked D-galactopyranosyl residue and subsequent azide-galactopyranosyl binding. Once azide-modified, the DBCO (dibenzocyclooctyl) labeled adapter (e.g., DBCO / 5AmMC6 / T / iSp18 / TATAAGA GAC AGACAGGCCACTCAGTCTAT / 3SpC3 / ; SEQ ID NO: 22) bound to the Fc region, yielding antibodies showing one or two adapters, but also several unlabeled antibodies (Figure 21D). ELISA assays confirmed that the binding affinity of the site-specific labeled antibody remained unchanged (Figure 21E).

[0194] Example 5: Preparation of nucleic acid binding molecules and immobilization onto beads using site-specific labeling by genetic engineering. When nucleic acid-binding molecules are used in bead-based assays, the molecules are immobilized on the surface in an orientation that maintains their binding activity. To reproducibly prepare nucleic acid-binding molecules for such assays, site-specific labeling of the binding domain (e.g., an antibody or its fragment) is used. The following method is applicable to any protein-binding domain and is not limited to antibodies.

[0195] First, the antibody is designed as follows: The Spytag peptide (AHIVMVDAYKPTK, SEQ ID NO: 10) is fused to the C-terminus of the antibody heavy chain. The C-terminus of the antibody light chain is modified with a short peptide of the form LCxPxR (where x can be any amino acid) (SEQ ID NO: 11). This peptide is a substrate for formylglycine-producing enzyme (FGE). Thus, the antibody is expressed and purified containing the two peptide fusion tags (Figure 17C).

[0196] A bacterial expression system expressing FGE is selected. This enzyme co-translates formylglycine. The aldehyde group of formylglycine is a reactive chemical handle, used to convert the amino group to an oxime or hydrazone before binding amino DNA.

[0197] To immobilize nucleic acid-binding molecules onto beads, the beads are decorated with a spycatcher protein. The N-terminus of the spycatcher rapidly and completely reacts with the C-terminal spy tag indicated by the binding domain of the nucleic acid-binding molecule, forming a covalent isopeptide bond. The natural spycatcher is a 139-amino acid protein and does not contain cysteine: msyyhhhhhh dydipttenl yfqgamvdtl sglsseqgqs gdmtieedsa thikfskrde dgkelagatm elrdssgkti stwisdgqvk dfylypgkyt fvetaapdgy evataitftv neqgqvtvng katkgdahi (SEQ ID NO: 12). A single cysteine ​​mutation has been introduced at the C-terminus to enable surface coupling by maleimide chemistry (see Example 9).

[0198] Example 6: Immobilization of nucleic acid-binding molecules onto protein G beads and target precipitation of nucleic acids Figure 5A shows the simplest assay configuration for multiple detection of nucleic acid modifications. Each bead contains only one type of nucleic acid-binding molecule, representing a "bead type." Several types of beads are combined and mixed with nucleic acid targets to simultaneously examine multiple nucleic acid modifications. Since all nucleic acid-binding molecules in the bead types immunoprecipitate the same target, strict control of their surface density is not necessary. Targets that bind to a nucleic acid-binding domain but are barcoded by adjacent nucleic acid-binding molecules are correctly identified.

[0199] A universal method for immobilizing IgG antibodies is to use commercially available Protein G beads. Protein G is an immunoglobulin-binding protein expressed in Group C and Group G Streptococcus. It is a 65kDa (G148 Protein G) and 58kDa (C40 Protein G) cell surface protein that binds to the Fab and Fc regions of most IgG isotypes. In this example, we describe the immobilization of randomly adapter-labeled nucleic acid-binding molecules onto Protein G beads and the specific precipitation of modified RNA sequences.

[0200] Unlabeled antibodies against m6A (Ab05), m5C (Ab16), and I (Ab10) were added to magnetic protein G dynabeads (Thermo Fisher, catalog number 10009D). 50 μL of dynabeads were washed and PBST (0.1% tween) was used to wash them. (登録商標)The beads were incubated with 200 μL of antibody (0.05 μg / μL) in PBS (containing surfactant). After antibody conjugation at 22°C for 20 minutes, the beads were washed with 200 μL of PBST. The loaded beads were exposed to a mixture of synthetic RNA targets at 22°C for 1 hour. Each target showed a single modification (m6A (SEQ ID NO: 13), m5C (SEQ ID NO: 18), I (inosine) (SEQ ID NO: 16), or no modification) as shown in Table 5. The targets were 5' modified with fluorescein (FAM) to enable ratiometric detection on the gel. After washing with PBST, the immunoprecipitated RNA was recovered at 70°C for 2 minutes using 2x TBU sample loading buffer (Thermo Fisher, catalog no. LC6876). The targets were quantified on a 15% TBU gel (Thermo Fisher, catalog no. EC62755BOX) (Figure 22). All antibodies showed a clear preference for the same type of target, albeit with varying levels of specificity. The latter was equivalent to or greater than 10 times for most antibody-target combinations, which was lower than the values ​​predicted by ELISA (Example 1). This finding is attributed to the lack of avidity in the inverted format, where antibodies were immobilized instead of RNA targets, and to differences in stringency in the washing procedure.

[0201] [Table 5]

[0202] Example 7: Barcoding of a random RNA sequence pool by primer extension Primer extension-based barcoding requires the presence of a rationally designed sequence (spacer, SP; see Figures 2D and 3D) at the 3' end of the target RNA. Adapters for primer extension-based barcoding contain a sequence complementary to the spacer. Hybridization of the adapter with the target spacer creates a concave 3' end that can be extended by DNA polymerase or reverse transcriptase, and the barcoding sequence is copied to the target RNA. The following example provides a method for tagging a random pool of RNA sequences with a spacer using a tailing or ligation reaction (Figure 23A).

[0203] The initial method involved adding a 3' polyrA tail to the RNA target. (rN) 30 ) were polyadenylated using E. coli poly(A) polymerase (NEB, catalog number M0276 L) in the presence of 1 mM ATP. 30 random b RNA molecules (5'-FAM-(rN) 30 The number of A atoms added to the pool of (SEQ ID NO: 23) shows a broad Gaussian distribution with an average of around 150b. A-tail sizing was achieved by adding an excess of a competing poly(dT) oligonucleotide of the desired length to the reaction. The competitor bound to the A-tail, shifted the position of the polymerase, and terminated the reaction. Figure 23B shows poly(dT) 20 The generation of 20b spacers by adding oligonucleotides to the tailing reaction is shown. Figure 23C shows the generation of 10, 20, and 30b spacers by adding poly(dT) oligonucleotides of corresponding lengths to the tailing reaction, and the effect of temperature was investigated. The 20b and 30b poly(dT) competitors yielded the desired spacer lengths, but the 10b competitor could not control the spacer length. This is likely because the 10b A / T double helix is ​​not stable at the reaction temperatures tested. Shorter homopolymer tails can be created using poly(U) polymerase in the presence of a 10b competitor oligonucleotide complementary to GTP or CTP. This approach can be extended to any spacer length that allows the competitor to hybridize to the homopolymer tail at a given reaction temperature.

[0204] Messenger RNA (mRNA) has a 3'-A-tail, which is widely used to selectively hybridize mRNA molecules to immobilized polydT probes. Aside from providing a spacer binding method, this method allows for the A-tailing of any RNA population, which can then be immobilized on beads by the hybridization described in Figure 4B.

[0205] The second method involved enzymatic ligation. Spacers containing any of the base sequences were introduced by 3' ligation catalyzed by T4 RNA ligase I (NEB, catalog number M0204L). This reaction requires the 3' end of dephosphorylated RNA and a 5'-phosphorylated DNA spacer. Figure 23D shows the ligation of 5'-phosphorylated DNA sequences of sizes 10b, 20b, 30b, and 50b (sequence numbers 28-31, respectively, see Table 6) with a 30b degenerate RNA library (sequence number 23). The size range was selected to provide useful information for spacer introduction (typical spacer size is approximately 10b) and barcoding by ligation as described in Figure 3A (typical adapter sizes are 25b or larger). The standard conditions for ligating spacers or adapters were the same: the reaction was incubated at room temperature for 1 hour using an optimized ligation buffer (500 nM RNA target, 2.5 μM 5' phosphorylated DNA, 50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM DTT, 0.5 mM ATP, 20% PEG-8000, and 0.5 units / μL T4 RNA ligase I). The ligation products were analyzed by denaturing gel electrophoresis. Gel quantification showed that the reaction proceeded fastest with medium-length DNA sequences (20b and 30b) and slower with very short sequences (10b) and long sequences (50b) (Figure 23D). Therefore, typical spacer ligation was performed overnight to maximize conversion, and adapters for barcoding using the same ligation reaction were designed not to exceed 50b.

[0206] Nucleic acid-binding molecules that act as adapters for primer-extended barcoding contact target RNA specifically via non-classical features and non-specifically via spacers. Compared to barcoding by ligation, the binding mode changes from monovalent to divalent, adding a designed avidity. This presents an opportunity to increase binding affinity, but also carries the risk of decreasing binding specificity. To avoid negatively impacting specificity, the spacer interaction must be weak enough that it cannot be maintained without the non-classical features. Therefore, the spacer should be as short as possible, but long enough to allow polymerase binding and, in particular, effectively compete with the intramolecular secondary structure formed by the RNA.

[0207] The effect of spacer length on primer extension in the absence of nucleic acid binding molecules (also known as the synthesis of complementary free adapters) is shown in Figure 23E using a 50b RNA sequence (SEQ ID NO: 13) with a common structural complexity. The 50b DNA target (SEQ ID NO: 15) and 18b RNA target (SEQ ID NO: 24) shown in Table 6 were tested in parallel to determine the differences that could arise from structural complexity. All targets exhibited a 3' DNA spacer of the sequence ACTGAGTG (SEQ ID NO: 19). Adapters applied in 1-fold or 5-fold excess in solution to the target contained complementary 8b, 10b, or 12b spacers (SEQ ID NOs: 25-27 and 38 shown in Table 5). A typical primer extension reaction includes 10 mM Tris pH 7.9, 2 mM MgCl2, 100 μM dNTPs, 0.1% Tween-20, 1 μM target, 1 μM or 5 μM adapter, 0.25 units / μL of Klenow fragment (3'→5' exo), and 6% DMSO if necessary. Standard reaction conditions were primer extension at 22°C for 5 minutes. The results showed that long RNAs were less elongable than DNA and short RNAs, regardless of spacer length. Under conditions that destabilize intramolecular secondary structures, such as high temperature (37°C for 5 minutes), the presence of DMSO, and high adapter concentrations (5-fold excess of the target), long spacers were advantageous (Figure 23F). This finding suggests that spacer access is hindered by the RNA secondary structure, and even 12b spacers cannot easily penetrate stable RNA secondary structures unless their structure is destabilized by additional means. Example 8 below demonstrates that primer extension is facilitated when a nucleic acid binding molecule is involved. Here, antigen recognition by the binding domain fixes the adapter very close to the RNA target, leading to a localized high concentration of the adapter, which in turn accelerates the enzymatic reaction ("proximity effect").

[0208] [Table 6]

[0209] Example 8: Barcode Transfer to Immunoprecipitated RNA This example is an extension of Example 6, where a random adapter-labeled antibody was added to Protein G beads instead of an unlabeled antibody to induce barcode transfer to immunoprecipitated nucleic acid targets by primer extension or ligation.

[0210] To Protein G beads, an m6A nucleic acid binding molecule (Ab05 with 8b or 12b spacer primer extension adapter), an m5C nucleic acid binding molecule (Ab16 with 8b spacer primer extension adapter), or an I nucleic acid binding molecule (Ab05 and Ab10 with 8b or 12b spacer primer extension adapter) was added individually.

[0211] Each bead was incubated with a mixture of two RNA targets or DNA targets. The Ab05 and Ab16 beads were incubated with the m6A and m5C RNA targets (SEQ ID NO: 13 and 14) shown in Table 7. The Ab10 beads were incubated with the m5C and I DNA targets (SEQ ID NO: 15 and 16). The RNA strands were bound to the beads and washed with phosphate buffered saline (PBS) to remove unbound nucleic acids. Then, the beads were suspended in a primer extension buffer containing Klenow fragment.

[0212] The resulting product (i.e., the target RNA extended by the barcode) was visualized on a 15% TBU gel, and the length and amount of the product were analyzed (Figure 24A). Ab16 using the 8b spacer primer extension adapter correctly barcoded the m5C RNA target. No background barcode of the m6A target was detected, demonstrating the specificity of the reaction. Ab05 with a 12b spacer correctly barcoded the m6A RNA target, but the 8b spacer version could not precipitate any target. Since unlabeled Ab05 easily precipitated the m6A target, it was suggested that the additional stabilization of the 12b spacer weakened the binding affinity of the label to the extent required for binding. Ab10 also showed the same phenomenon. The 12b spacer version precipitated the target, but the 8b spacer version did not. However, Ab10 completely lost its specificity, and the spacer interaction exceeded the selectivity of the antibody. Figure 24B shows that the activity of Ab05 and the specificity of Ab10 were restored using an 8b spacer, and the binding domain impairment could be avoided by selectively labeling the antibody site. In summary, the primer extension reaction functions efficiently in an antibody-mediated format, but random labeling can weaken the binding affinity (e.g., Ab05) or adversely affect the specificity (e.g., Ab10) in the presence of a 12b spacer. The primer extension in Example 7 suggests that a 12b spacer may be necessary for RNA extension, but this dataset clearly shows that the proximity effect accelerates the reaction and that a 12b spacer may be too long and lead to a lack of specificity. Therefore, future nucleic acid binding molecules can be labeled with an 8b spacer adapter as shown in Figure 24B.

[0213] No stabilizing spacer interaction was observed with barcode ligation by primer ligation. Figure 24C shows the barcoding of an m6A-labeled RNA target (SEQ ID NO: 17) by Ab01 labeled with a circular adapter (SEQ ID NO: 39). The adapter sequences for barcode ligation by ligation and analysis by sequence had the following structure:

Number

[0214] [Table 7]

[0215] Example 9: Preparation of beads containing nucleic acid binding molecules spaced one molecule apart While the standard method for CHIP-Seq involves the precipitation of nucleic acid targets using antibodies immobilized on protein A / G dynabeads, the beads used in this embodiment are customized to offer several advantages: (i) improved surface passivation avoids false positives (the passivated surface avoids nonspecific binding to the beads, so binding of modified nucleic acids is substantially via interaction with nucleic acid binding molecules); (ii) the density of nucleic acid binding molecules on the bead surface is adjustable to provide adequate spatial separation between molecules on the surface necessary for barcoding, for example, Figure 5B; (iii) the beads can be designed to facilitate the capture and / or co-implantation of recognition elements other than the antibody Fc region; (iv) the nucleic acid binding molecules are covalently bound and do not co-elute during the workflow process; and (v) multiple types of nucleic acid binding molecules can be present on the surface, which is relevant to several applications.

[0216] The carboxylated dynabeads (Thermo) are surface-coated with a binary mixture of amino-PEG4-alcohol (Broadpharm, BP-20589) and Mal(maleimide)-PEG2-amine (Broadpharm, BP-23313). Mal(maleimide)-PEG2-amine is used to bind cysteine-modified spycatchers, while the amino-PEG-alcohol creates voids around nucleic acid binding molecules, passivating the bead surface against nonspecific binding. The ratio of amino-PEG4-alcohol to Mal-PEG2-amine (i.e., passivation molecule:activating molecule) is approximately 100 nm. 2 Each molecule is designed to have one spycatcher molecule immobilized. This ensures that the nucleic acid-binding molecule is spatially isolated and sequestered from other molecules when it binds to the target RNA, thus guaranteeing intramolecular barcode transfer.

[0217] After washing the DynaBeads with 25 mM MES pH 5 (2-(N-morpholino)ethanesulfonic acid), 50 μL of fresh EDC (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride) and 50 μL of NHS (N-hydroxysuccinimide) in 25 mM MES pH 5 are added to a 100 μL suspension of beads. The mixture is allowed to react at room temperature for 30 minutes. The supernatant is then removed and the beads are washed again. After the EDC / NHS step, the DynaBeads are coated with a binary mixture of amino-PEG4-alcohol and MAL-PEG2-amine. The maleimide group is covalently bonded to the spycatcher in the next step. The spycatcher is dissolved in 20 mM Tris pH 7, and the cysteine ​​group is reduced with TCEP (tris(2-carboxyethyl)phosphine). The maleimide-activated beads and spycatcher protein are mixed and allowed to react at room temperature for 2 hours. After washing the beads, the spytag DNA conjugate and spycatcher protein are reacted, and the number of spycatcher proteins per bead is calculated by quantifying the conjugate by qPCR. The spycatcher-decorated beads are reacted with the spytag-binder-barcode conjugate described in Example 4.

[0218] Example 10: Preparation of passivation beads with adjustable capture probe density In the targeted nucleic acid modification analysis shown in Figure 4C, the target nucleic acid sequence is captured on beads, and then non-classical features are encoded. Separation is achieved by precisely controlling the surface density of the encoding complex, preventing crosslinking between adjacent molecules. The following describes the preparation of beads with various capture probe densities.

[0219] Porous NHS-activated Sepharose beads (Cytiva, catalog number 17071601) were washed with 100% isopropanol and 1 mM HCl. To passivate and chemically functionalize the beads, they were incubated at room temperature for 16 hours in 0.25 M sodium bicarbonate buffer pH 8, 0.5 M NaCl, 40 mM COOH-PEG4-amine (passivation molecule; Broadpharm, catalog number BP-20423), and a variable amount of mTet(tetrazine)-PEG4-amine (functionalization molecule; Broadpharm, catalog number BP-22435). Beads with mTet-PEG:carboxy-PEG ratios of 1:1,000, 1:10,000, and 1:100,000 were prepared using 40 μM, 400 μM, and 4,000 μM mTet-PEG. 100% carboxy-PEG beads were prepared and the background was measured. The 3' amine of the DNA capture probe (CATCTGACGCTGCCGACGATTTTTT / 3AmMO / ; SEQ ID NO: 20) was activated with NHS-PEG-TCO (trans-cyclooctene) (Broadpharm, catalog number BP-22418), and then tested in 1x PBST (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, 0.1% Tween). (登録商標) The mTet / TCO pair was immobilized on beads by reacting it with mTet in a surfactant at 22°C for 16 hours. Under physiological conditions, the mTet / TCO pair was 800M -1 s -1 This is a well-studied reverse-demand Diels-Alder cycloaddition reaction that occurs at the above rate and forms a dihydropyridazine bond.

[0220] An amplifiable tracer oligonucleotide (TCGTCGGCAGCGTCAGATGATTGTGTTAGGCTAGTAAGTAGATGGATTAGACCGTCGAGTGAGTAGAGTACGTAGTGCA, SEQ ID NO: 21) was hybridized to a capture probe on beads, and the capture probe density was determined by qPCR. The threshold cycle (Ct) value was converted to the number of DNA molecules per bead based on a calibration curve (Figure 25). For every tenfold increase in mTet-PEG, tenfold more tracer oligonucleotides could be captured, which was consistent with theoretical predictions. The mTet concentration that provided a distance to prevent neighbor-to-neighbor interactions for encoding complexes was experimentally determined (see Example 12). Background was low, and the number of DNA strands detected in mTet-free beads corresponded to 0.1% of the molecules detected in the highest density beads.

[0221] Example 11: Proximity barcoding in solution using a model nucleic acid binding domain and ligation The dissociation constants of streptavidin and biotin are approximately 10 -14 The affinity is on the order of mol / L, one of the strongest affinity interactions known in nature, orders of magnitude stronger than the typical affinity of antibodies to modified RNA bases. A simple nucleic acid binding molecule was designed containing streptavidin as the binding domain and a biotinylated ligation adapter. The aim of this method is to transfer the barcode of a nucleic acid binding molecule only to the target RNA to which the molecule is bound, using a binding domain with extremely high affinity and specificity. Such a model system is useful for process control and for exploring the upper limit of barcoding when the affinity of the nucleic acid binding molecule is near-infinite.

[0222] Streptavidin and biotin adapter (SEQ ID NO: 33) were mixed in low ionic strength buffer (10 mM Tris pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20) in ratios of 1:1, 1:2, 1:3, and 1:4, and the resulting complexes were analyzed by electrophoresis using a natural 8% TBE gel (Figure 26A). Three of the four biotin-binding pockets of streptavidin were filled as the concentration of the biotin adapter increased. The 1:2 ratio is optimal for encoding because there is no unlabeled streptavidin present, and there are binding pockets available for binding to biotinylated RNA targets.

[0223] To demonstrate proximity encoding in solution, streptavidin nucleic acid-binding molecules were mixed with an equimolar mixture of m6A-modified RNA (off-target; SEQ ID NO: 32) and biotin RNA (on-target; SEQ ID NO: 40). The RNA strands were dye-labeled and sized differently to distinguish on-target and off-target encoding by gel electrophoresis. Ligation was performed at 22°C for 1 hour using 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM DTT, 0.5 mM ATP, 400 nM 1:2 streptavidin-biotin-adapter conjugate, and 100 nM of each RNA target. The PEG-8000 concentration during the ligation reaction was varied from 0 to 25% to adjust the mean intermolecular spacing by molecular crowding. After ligation, streptavidin was detached from the adapter by cleaving it with a single uracil molecule using a USER (NEB, catalog number M5505L) to facilitate gel analysis. Molecular crowding reduced the available volume for biomolecules, effectively increasing the concentration. This result was consistent with the theory that specific barcoding is predicted at low PEG concentrations with large intermolecular spacings, while high PEG concentrations cause molecular condensation and induce crosslinking (Figure 26B). The crosslinking observed in this example occurred when the streptavidin conjugate barcoded another nearby but unbound m6A RNA, even though it was bound to the correct biotin-RNA. This example demonstrates that on-target barcoding is possible in solution.

[0224] [Table 8]

[0225] Example 12: Barcode transfer by sequence-specific capture of RNA on a single molecular bead and barcoding using a model nucleic acid binding domain. In this example, the same model-binding domain derived from streptavidin and the same experimental design as described in Example 11 are used. However, the ligation reaction was carried out on immobilized beads prepared as described in Example 10. Two types of beads were used: Sepharose beads with an mTet:carboxy-PEG ratio of 1:100, or Sepharose beads with an mTet:carboxy-PEG ratio of 1:1000.

[0226] Each reaction involved 2,000 1:100 mTET / carboxy beads or 20,000 1:1,000 mTET / carboxy beads decorated with capture DNA (SEQ ID NO: 20). The beads were incubated with a mixture of biotin (SEQ ID NO: 31) and m6A RNA (SEQ ID NO: 32) (1.5 μM) in 80 μL of 5XSSC buffer containing 0.1% Tween20 at 37°C for 1 hour. Both RNA targets showed 21b regions complementary to the capture probe on the beads. After hybridization was complete, the beads were washed twice with 200 μL of high-salt PBST (PBS containing 0.1% Tween20 and 360 mM NaCl) and once with 100 μL of PBT (PBS containing 0.1% Tween20 and 360 mM NaCl) to remove unbound targets. The beads were incubated with streptavidin-adapter conjugates in high-salt PBST for 20 minutes. The excess conjugate was washed as described for the RNA target. Ligation and analysis were performed in the same manner as in Example 11. Figure 26B shows specific barcoding of the biotin target using 1:1,000 mTET / carboxy beads and crosslinking using 1:100 mTET / carboxy beads. In this example, crosslinking resulted from greater adhesion to the RNA target surface at higher 1:100 mTET / carboxy beads densities.

[0227] Example 13: Barcode transfer in solution using primer extension measured by ligation and PCR The purpose of the following method is to exclusively transfer the barcode of a nucleic acid-binding protein (i.e., the nucleic acid-binding proteins described in Examples 3 and 4) to the target RNA to which the molecule is bound.

[0228] Mix and bind target RNAs having m6A and m5C modifications (Figures 18A and 18B) and their cognate nucleic acid-binding molecules. The barcode transfer reaction is carried out in solution, and the barcode transfer mechanism is either ligation or primer extension. In the case of barcode transfer by ligation, the barcode is bound to the binding domain of the nucleic acid-binding molecule (i.e., antibody) via the 5' end, and the 3' end of the barcode is pre-adenylated. Ligation is initiated by the addition of T4 RNA ligase II. In barcode transfer by primer extension, a short spacer sequence is added to the 3' end of the target RNA, and the barcode contains a region complementary to the spacer. Spacer extension is carried out at 37 °C for 5 minutes using a DNA polymerase such as the Klenow fragment and dNTP (deoxyribonucleotide triphosphate).

[0229] Barcode transfer efficiency and off-target barcodes are measured by PCR using a model oligonucleotide system. The pairing of correct and incorrect barcodes is determined based on the length of the PCR product, as described in Figures 18A and 18B. Specifically, after completion of the barcode transfer reaction, the reaction product is PCR amplified, and the size of the product is visualized by gel electrophoresis. Bands of unexpected size indicate the occurrence of off-target barcode transfer. This reaction scheme is used to optimize the structure of the adapter, the choice of enzyme, and the reaction conditions for maximum barcode transfer efficiency and minimum off-target activity.

[0230] Example 14: Barcode Transfer by Sequence-Specific Capture of RNA Barcode transfer can also be performed when binding the target RNA itself to the surface of the beads (Figure 4C). The target RNA is captured on the bead surface by nucleic acid hybridization (i.e., the capture of the target RNA on the bead surface is not altered by the recognition of modifications to the target RNA by nucleic acid binding molecules). Target capture by nucleic acid hybridization enables selective enrichment of the desired genomic or transcriptome region.

[0231] Instead of cysteine-modified spycatchers, thiolated DNA oligonucleotides are immobilized, and the sequence of these thiolated DNA oligonucleotides is complementary to the region of the target RNA. These capture oligonucleotides are placed 100 nm on the bead surface to ensure the specificity of the intramolecular barcode transfer reaction. 2 They are present in amounts of less than one molecule per molecule. The m6A and m5C model oligonucleotides (Figures 18A and 18B) are captured in the hybridization buffer. After washing, a pool of nucleic acid binding molecules that can bind to m6A and m5C is added. Next, the barcode transcription reaction is performed by ligation or primer extension as described in Examples 6 and 7. The barcode transfer efficiency and specificity are measured by PCR.

[0232] Example 15: Preparation of binding domain-cytosine deaminase conjugate and measurement of base editing Cytosine deaminase catalyzes the hydrolytic deamination (C-to-U mutation) of cytosine to uracil. This enzyme is used in gene editing and is targeted to a target gene region by fusing to a catalytically inactive Cas9-guide RNA complex. In this example, cytosine deaminase was targeted to RNA modification by a binding domain (e.g., antibody binding). The objective was to design a binding domain-deaminase conjugate that restricts deaminase activity to a few-base window adjacent to the RNA modification.

[0233] Most cytosine deaminases act on single-stranded DNA. APOBEC1 and APOBEC3A are the only enzymes known to possess RNA editing activity, and rat APOBEC1 (Uniprot accession number P38483) has been successfully used for targeted RNA editing via a catalytically inactive Cas9-guide RNA complex. Human YTHDF2 (Uniprot accession number Q9Y5A9) is a naturally occurring m6A leader protein, and its sequence is K D It binds to m6A with a dissociation constant in the range of 150-1200 nM. Two approaches were used to obtain the m6A target-binding domain-deaminase conjugate. One approach involved directly fusing APOBEC1 to YTHDF2 (Meyer, K. Nature Methods 16, 1275-1280 (2019)). The other approach involved fusing a spy tag to APOBEC1 and a spycatcher to YTHDF2, and then reacting them to form a covalent conjugate as part of the assay workflow.

[0234] First, three fusion constructs were expressed in E. coli cells: (1) APOBEC1-YTH-His (Figure 27 and SEQ ID NO: 34) containing rat APOBEC1 (aa1-229) and the YTHDF2 binding domain (aa385-579); (2) APOBEC1-Spytag-His (Figure 27 and SEQ ID NO: 35) containing the same APOBEC1 and Spytag 002; (3) Spycatcher-YTH-His (Figure 27 and SEQ ID NO: 36) containing the same YTHDF2 fragment and Spycatcher 002 provided in Table 6; and (4) MBD-TEV-APOBEC1-Spycatcher-His containing a maltose binding domain (MBD), a TEV protease cleavage site (TEV), and the above APOBEC1 and Spycatcher. Spytag 002 and Spycatcher 002 represent the latest version of the Spy system, which exhibits the fastest reaction rate among covalent peptide tags reported to date. The gene was codon-optimized, synthesized, cloned into a pET-30a vector in a frame with a C-terminal his-tag, and expressed in BL21 cells. Figure 28 shows similar induction after 16 hours at 15°C and 4 hours at 37°C. However, only spycatcher-YTH-His was present in the soluble fraction, and APOBEC-containing proteins were mostly insoluble. To address the solubility of APOBEC, MBD-TEV-APOBEC1-spycatcher-His was constructed. This protein has maltose-binding domains (MBDs), known for their excellent solubility, and spycatchers at both ends of APOBEC. A TEV cleavage site was introduced to allow removal of the MBDs. This construct produced soluble proteins, particularly after 16 hours of expression at 15°C (Figure 28). To disrupt electrostatic interactions with nucleic acids, cells were lysed in a high-salt buffer and nuclease (50 mM) was applied. The samples were treated with Tris, 500 mM NaCl, 1 mM TCEP, pH 8.0, and nuclease (Thermo Fisher, catalog number 88700). Binding to both MBD and Ni columns was moderate, indicating that neither affinity tag was adequately accessible.The eluted fractions were pooled and subjected to size exclusion purification (Superdex 200 column) (Figures 29A and 29B). Although the first deaminase conjugate developed was insoluble, these data demonstrate the possibility of creating a soluble protein tag-deaminase conjugate for applications that restrict deaminase activity in proximity to the target nucleotide modification.

[0235] [Table 9-1] [Table 9-2]

[0236] Example 16: RNA profiling by barcoding, cDNA cleavage, and cyclization In this embodiment, modifications on the target RNA are identified by recognition by a nucleic acid-binding molecule and subsequent transcription of a barcode to the RNA target. The site of the modification is revealed by cleavage of the cDNA during reverse transcription (Figure 8). This is induced by crosslinking of the binding domain of the nucleic acid-binding molecule or by a binding domain that has been manipulated accordingly.

[0237] Total Human Reference RNA (manufactured by Thermo) depletes riboRNA and magnesium (Mg 2+ By incubation with ions at 95°C, the RNA is fragmented into pieces averaging 100–150 nucleotides in size. The 3' end of the RNA is dephosphorylated using T4 polynucleotide kinase (NEB) and shrimp alkaline phosphatase (NEB). RNA samples are spiked at known concentrations with control RNA oligonucleotides containing N6-methyladenosine (m6A), pseudouridine (Ψ), and 5-methylcytosine (m5C), as well as unmodified similar oligonucleotides, as positive controls.

[0238] Beads displaying nucleic acid-binding molecules that recognize RNA modifications m6A or m5C are prepared using the methods described in Examples 4 and 5. Each bead type displays a single nucleic acid-binding molecule. The adapter design is shown in Figure 2B. The beads are mixed and incubated with the RNA sample in binding buffer, then heated to 0.15 J cm. -2 Crosslinking is performed using UV light at 254 nm. The supernatant contains unmodified RNA, but the modified RNA is bound to the beads.

[0239] To measure the abundance and stoichiometry of RNA modifications, the unmodified and modified RNA fractions are converted into RNA-Seq libraries using a split workflow (see Figure 7). Barcoding of the unmodified RNA fraction is performed as follows: a type B adapter (Figure 2B) is added to the supernatant, and ligation to the 3' end of the RNA is performed using T4 RNA ligase. The adapter is not bound to a nucleic acid binding molecule, and all unmodified RNA strands receive the same adapter and barcoding. If necessary, the RNA is fused in ethanol-containing RLT buffer (Qiagen) with Dynabeads. (商標) MyOne (商標)The RNA is purified during the assay process by physical adsorption to physiological saline (Thermo Fisher). In the case of modified RNA, the barcode is transferred from the bead-immobilized nucleic acid binding molecule to the RNA molecule. The RNA molecule remains bound to the bead via the nucleic acid binding molecule. After this step, all protocol steps are identical for both unmodified and modified RNA. A universal primer is added and extended by Superscript III (Thermo), and the cDNA is cleaved at the modification site. Intramolecular ligation is initiated by incubation with CircLigase II (Lucigen) at 60°C to form a circular cDNA. After cleaving the adapter between the UFP and URP regions with restriction enzymes (Figure 2B), the cDNA is converted into a library by PCR using a sequencing adapter. The modified and unmodified fractions are combined before sequencing and sequenced at 20 million reads. The types, number, and positions of m6A, Ψ, and m5C are provided as follows. A control oligonucleotide is used as a control to account for inefficiencies during parallel library preparation.

[0240] Example 17: Target capture and strand RNA library preparation with barcoding and base editing modification profiling In this example, specific RNA sequences are enriched by hybridization, and strand information is preserved during library preparation. Beads with single-molecule interstitial capture probes are prepared as described in Example 10. Each bead type displays a capture probe for a specific RNA locus, and the bead types are pooled to correspond to any number of RNA loci.

[0241] Fragmented RNA was incubated with a bead pool in hybridization buffer (5× citrate saline (SSC), 40% formamide, 0.1% Tween-20 detergent) at 37°C for 16 hours. The RNA strands bound to the capture probe regardless of their modification status. A pool of nucleic acid binding molecules was added for each of the 10 modifications. The nucleic acid binding molecules contained modification-specific IgG antibodies with a spy tag (SEQ ID NO: 10) genetically engineered into the C-terminus of the light chain. For modification site labeling, a deaminase-spycatcher fusion protein was added, which rapidly reacted with the spy tag to label the modification site with a C-to-U mutation. After removing the protein conjugate, the unmodified portion of the RNA was barcoded in a second ligation step using a free adapter. For a given locus, the modification stoichiometry was equivalent to the number of modified barcodes divided by the total number of barcodes. Subsequently, the first-strand cDNA was synthesized using a standard method, and the second strand was synthesized in the presence of dUTP. The resulting library is treated with USER enzyme (NEB) to remove the second strand, thereby preserving the strand information. Subsequently, DNA sequencing is performed to identify the locations of RNA modifications at all sites in the RNA sample.

[0242] Example 18: Profiling of DNA modifications by strand separation, barcoding, and base editing In this embodiment, covalent immobilization of adapter-bound DNA to beads is used to enforce the retention of strand separation and enable base editing by single-strand-specific cytosine deaminase for marking the precise locations of non-classical features (Figure 9).

[0243] DNA samples are fragmented using shear force or other common methods known to those skilled in the art. After DNA strand end repair and A-tailing, Y-shaped adapters are ligated to both ends. These adapters are characterized by 3'-azide modifications, a widely used modification of synthetic oligonucleotides. Under conditions suitable for denaturing (separating) double-stranded DNA (e.g., in a polar organic solvent such as ethanol or acetonitrile, or in a 95% aqueous solution of formamide), single-stranded DNA is covalently bonded to a substrate at an interval of one molecule using a click reaction. This click reaction may be a Cu(I)-catalyzed azide-DNA azide-alkyne cycloaddition reaction between low-density surface-bound alkynes, a strain-accelerated azide-alkyne cycloaddition reaction, or other variations of this Huis Ten chemistry.

[0244] After immobilization, denaturation conditions are removed (e.g., by solvent exchange or solvent evaporation), and a buffer solution is introduced along with the nucleic acid binding molecules linked to the barcode. Subsequently, barcode transfer is performed by sprint DNA ligation catalyzed by T4 DNA ligase, as determined by the specific recognition of non-classical features.

[0245] After barcode transfer is complete, a secondary antibody conjugated to cytosine deaminase is introduced, and C-to-U base editing is performed adjacent to the non-classical feature sites. Following base editing, the DNA strand is cleaved from the substrate using USER cleavage. Next, a primer is introduced and bound to an adapter, and DNA polymerase is used for cDNA synthesis, cleaved at the uracil site. Library preparation and DNA sequencing identify the locations of non-classical features at all sites in the DNA sample.

[0246] Example 19: DNA library preparation with 2 cycles of RNA modification profiling and base editing In this embodiment, multiple modifications and their occurrence are detected on the same RNA target strand. This is achieved through two rounds: modification recognition by nucleic acid-binding molecules and subsequent barcode transcription by primer extension (shown in Figures 14A and 14B). After each primer extension, the presence of multiple modifications of the same type is recorded by base editing.

[0247] To distinguish between editing cycles, the first cycle involves adenosine deaminase-mediated base editing (A-to-I mutation), and the second cyRNA is chemically fragmented to an average size of 200-300 bp. A short 8-base spacer is ligated to the 3' end of the RNA to enable barcode introduction by primer extension. This spacer functions as a hybridization site for the incoming barcode and universal primer. The ligated RNA fragments are immunoprecipitated using a single type of bead and bound for approximately 2 hours. After washing the beads, barcode transfer is performed by incubation at 37°C for approximately 5 minutes using Klenow fragments and dNTPs. During this step, the type of bead to which the DNA target is bound is marked.

[0248] The modification site is encoded by introducing a mutation from A to I near the modification site. For this purpose, a secondary antibody-adenosine deaminase conjugate is added and the reaction is carried out.

[0249] Once editing is complete, the RNA is eluted and immunoprecipitated using a second bead type. Barcode transfer and base editing are repeated, but this time base editing is performed with cytosine deaminase that has been modified to introduce a C-to-U mutation. The barcodes transcribed in the second cycle contain universal primer caps to enable amplification of the DNA target. A library for sequencing is prepared by adapter PCR using a DNA polymerase that allows uracil modification.

[0250] Example 20: Design of APOBEC-spycatcher fusion protein for in vitro translation and functional testing In this example, a cell-free in vitro translation system is used to express a deaminase enzyme designed for targeted deamination. The solubility and protein folding problems observed with APOBEC1 expression in E. coli are thought to be due to cytotoxicity, as APOBEC's DNA editing activity damages the host cell genome. In vitro translation systems are often used for toxic proteins that are difficult to express. Figure 30 shows the amino acid sequences of APOBEC1 and APOBEC3A(E109A) fused to a spycatcher via an XTEN linker (SEQ ID NOs. 42 and 43, respectively). In contrast to the genes used in Example 15, the his tag for affinity purification and the unnecessary GS linker were omitted to minimize structural damage to the enzyme. For the APOBEC1 fusion protein, the gene was PCR amplified from a plasmid expressing SEQ ID NO. 37 using a primer with a T7 promoter region. The APOBEC3A enzyme was constructed from the same plasmid by cloning the APOBEC3A(E109A) sequence (IDT) into a gblock. Both enzymes were processed using PURExpress. (登録商標) Protein expression was performed using an in vitro protein synthesis kit (New England Biolabs) with spycatcher fusion. 500 ng of each PCR-amplified gene was used as input, and the reaction was constructed according to the manufacturer's protocol. Protein expression was performed at 37°C for 5 hours.

[0251] Enzyme activity was measured by adding unpurified cell-free extracts containing the enzyme of interest to FAM-labeled DNA oligonucleotides. Cytidine deaminase activity converted C to U, which was then cleaved by the USER enzyme (NEB). Figure 31 shows the cleavage products observed as the concentration of the cell-free extract decreased after incubation at 37°C for 30 minutes. The most concentrated reaction contained 1.25 μL of cell-free extract in 10 μL of reaction mixture (100 nM FAM-DNA, 10 mM bis-tris-propane-HCl pH 7, 10 mM MgCl2, 100 μg / mL BSA). The cell-free extracts were further diluted to 1:2, 1:4, 1:8, and 1:16. APOBEC1A showed weak deamination activity, which was enhanced in the presence of the spycatcher protein. By comparison, APOBEC3A was at least 10-fold more active than APOBEC1A, but was mildly inhibited upon addition of the spycatcher fusion.

[0252] These results confirm that catalytically active APOBEC1 and APOBEC3A fusion enzymes can be expressed in an in vitro translation system.

[0253] Example 21: Targeted deamination using APOBEC-spycatcher fusion protein This example demonstrates that the APOBEC-spycatcher fusion protein can target specific sites on the DNA strand via spycatcher-spytag interactions. The covalent spycatcher / spytag reaction restricts deaminase activity to the region near the attachment site.

[0254] Figure 32 describes the poisoned primer assay (PPA) used to measure the size of the deaminase activity window. DNA or RNA templates containing multiple Cs at regular intervals were hybridized with FAM-labeled primers. Primer extension was performed in the presence of dCTP, dTTP, dGTP, and ddATP, along with DNA polymerase (Klenow fragment for DNA templates) or reverse transcriptase (M-MLV for RNA templates), after treating the DNA template with deaminase. The presence of C-to-U editing promoted ddATP uptake and caused primer termination. The size distribution of the extension products was analyzed by denaturing gel electrophoresis to identify the base editing sites.

[0255] First, the PPA assay was tested using commercially available APOBEC3A (New England Biolabs). Figure 33 shows that APOBEC3A was highly active on DNA templates (U and C templates are SEQ ID NOs. 44 and 45, respectively) but weakly active on RNA (U and C templates are SEQ ID NOs. 46 and 47, respectively). Therefore, this enzyme is a suitable candidate for marking the locations of non-classical features in DNA.

[0256] To test the ability of deaminases to target non-classical features as shown in Figure 6C, a simplified model system was used (Figure 34). Instead of using a spytag label-binding domain, the spytag peptide was directly bound to the DNA strand (e.g., SEQ ID NO: 50) at the thymine position. The spytag peptide bound distally, 26b away from the first C (SEQ ID NO: 48) at the thymine, or proximal, 2b away from the first C (SEQ ID NO: 49) at the thymine.

[0257] Figure 35 shows the results of a targeted deamination assay performed using the APOBEC3A fusion protein. A 100 nM DNA template (with and without spytags) was incubated with 7.6 μL of cell-free extract containing APOBEC3A and APOBEC3A-spycatchers in a total reaction volume of 42 μL in deamination buffer (10 mM bis-tris-propane-HCl pH 7, 10 mM MgCl2, 100 μg / mL BSA). 8 μL time points were collected at 1, 3, 8, and 15 minutes, and the deaminase was immediately inactivated by heat at 95°C. 1 μL of Klenow DNA polymerase mix was added to the reaction mixture to obtain final concentrations of 10 μM dTTP, 10 μM dCTP, 10 μM dGTP, 200 μM ddATP, and 0.2 units / μL of Klenow DNA polymerase exo(-). The PPA reaction was allowed to proceed at 37°C for 10 minutes and analyzed by denatured gel electrophoresis. The editing site was identified using a FAM-labeled primer (SEQ ID NO: 51).

[0258] Figure 35 shows the clear difference in gel banding patterns observed between APOBEC3A fused with a spycatcher and APOBEC3A without a spycatcher. In the absence of both the spycatcher and spytag, each of the seven Cs is equally edited, as indicated by edited (stopped) bands of varying sizes. In the presence of both, only the primer +2 and +7 bands accumulate over time, indicating a narrower reach of the enzyme. This accumulation of failed products was more pronounced when the spytag was proximal.

[0259] This embodiment represents the first example of forcing site-directed deamination by tethering APOBEC3A to the reaction site via a spy tag / spy catcher.

[0260] Example 22: Two-plex targeted tagging of DNA / RNA heteroduplexes In this embodiment, RNA modification-specific barcoding is facilitated by targeted tagmentation. This is achieved by conjugating a tagmentable mosaic end (ME) adapter to an RNA-specific antibody. After the antibody is conjugated to the RNA modification, an active transposome is assembled in situ by loading a Tn5 transposase onto the antibody-conjugated ME adapter. This allows the transposase to target the modification site, enabling site-specific tagmentation and insertion of a barcoded adapter adjacent to the modification site.

[0261] An m6A-specific antibody is modified with two barcoded i5-ME sequences (i5-ME-BC1), and an m5C-specific antibody is conjugated to the other two i5-ME sequences (i5-ME-BC2) using cytoclic chemistry (Example 4). Modified control RNA templates are prepared by in vitro transcription of plasmid DNA with T7 RNA polymerase. A 2000 bp PCR amplicon of the PhiX genome (NEB, catalog number N3023S) is transcribed in the presence of m6A triphosphate, and a 2000 bp PCR amplicon of M13mp18 single-stranded DNA (NEB, catalog number N4040S) is transcribed in the presence of m5C triphosphate. Both sequences are captured on magnetic beads via a sequence-specific hybridization probe (Figure 36, step A). ​​The captured RNA is reverse transcribed using the capture probe as a primer for SuperScript II reverse transcriptionase (Figure 36, step B). A pool of individual or different barcoded i5-ME-antibody conjugates is added to the immobilized RNA / DNA double helix and incubated until saturation binding is reached (Figure 36, Step C). Next, functional transpososomes are assembled in situ: in the first step, antibody-bound i5-Tn5 monomers are generated by adding free Tn5 and ME' oligos to the surface-bound i5-ME-antibody conjugates (Figure 36, Step D). Tn5 now binds to the double-stranded i5-ME / ME' adapter. In the second step, Tn5 with a pre-attached i7-ME / ME' adapter is added to form an i5- / i7-Tn5 dimer (Figure 36, Step E). After transposome assembly, tagmentation is initiated by adding a MgCl2-containing buffer (Figure 36, Step F), forming products with barcoded adapters as shown in Figures 15A-15D. RNA / DNA fragments are released from the beads via tagmentation, and the size profile of the supernatant is analyzed by capillary electrophoresis before and after PCR. Sequence determination of the obtained reads and alignment with the PhiX or M13 genome confirmed that the M13 reads were correctly assigned m5C-specific barcodes and the PhiX reads were correctly assigned m6A-specific barcodes.Thus, this process allows for the detection of one or more RNA modifications in a single reaction through targeted tagging.

[0262] Various aspects Notwithstanding the attached claims, the following numbered embodiments also constitute part of the present invention. 1.i) Joining domain, and ii) Adapter, A nucleic acid binding molecule comprising the binding domain, wherein the binding domain specifically binds to a non-classical feature of DNA or RNA, and the adapter comprises a nucleic acid barcode sequence specific to the non-classical feature to which the binding domain specifically binds. 2. The nucleic acid binding molecule according to embodiment 1, wherein the binding domain comprises an antibody, nanobody, aptamer, leader protein, writer protein, eraser protein, artificial polymer scaffold, artificial protein scaffold, or selective covalent capture reagent, or a fragment or derivative thereof. 3. The nucleic acid binding molecule according to embodiment 2, wherein the leader protein is NUDT16 or YTHDC2, or a fragment or derivative thereof. 4. The nucleic acid binding molecule according to embodiment 2, wherein the writer protein is DNTM1, DNTM3A / B, NAT10, METTL3, METTL8, METTL14, METTL16, TRM, BMT, DUS2, PUS, or NSUN2, or a fragment or derivative thereof. 5. The nucleic acid binding molecule according to embodiment 2, wherein the eraser protein is FTO, ALKBH3, or ALKBH5, or a fragment or derivative thereof. 6. The nucleic acid binding molecule according to embodiment 2, wherein the binding domain does not have catalytic activity. 7. A nucleic acid binding molecule according to any one of embodiments 1 to 6, wherein the adapter is detachable. 8. A nucleic acid binding molecule according to any one of embodiments 1 to 7, wherein the adapter comprises at least one universal forward primer (UFP) and a universal reverse primer (URP). 9. A nucleic acid binding molecule according to any one of embodiments 1 to 8, wherein the adapter includes a unique molecular identifier (UMI). 10. A nucleic acid binding molecule according to any one of embodiments 1 to 9, wherein the non-classical feature is a modified nucleoside. 11. Modified nucleosides include 3-methylcytidine (m3C), 5-methylcytidine (m5C), N4-acetylcytidine (ac4C), pseudouridine (Ψ), 1-methyladenosine (m1A), N6-methyladenosine (m6A), inosine (I), 7-methylguanosine (m7G), dihydrouridine (D), 3-methyluridine (m3U), 5-methyluridine (m5U), 1-methylguanosine (m1G), N2-methylguanosine (m2G), and 5-methyldeoxycy The nucleic acid binding molecule according to embodiment 10, which is thidine (m5dC), N4-methyldeoxycytidine, 5-hydroxymethylcytidine (5-hmC), 5-hydroxymethyldeoxycytidine (5hmdC), 5-carboxydeoxycytidine (5cadC), 5-formylcytidine (5fC), 5-formyldeoxycytidine (5fdC), 6-methyldeoxyadenosine, N7-methylguanosine (m7G), 2,7,2'-methylguanosine, or ribose methylated (Nm). 12. A nucleic acid binding molecule according to any one of embodiments 1 to 9, wherein the non-classical feature is nucleic acid damage. 13. The method according to embodiment 12, wherein the nucleic acid damage is caused by an oxidation process or contact with ultraviolet light. 14. The method according to embodiment 12, wherein nucleic acid damage is caused by large adduct formation or base alkylation due to an exogenous agent. 15. Damage to 8-oxoguanine (8-oxoG), one or more debase sites, cis-platin crosslinks, benzo(a)pyridinediol epoxide (BPDE) adducts, cyclobutenpyrimidine dimers (CPD), pyrimidine-pyrimidone (6-4) photoproducts (6-4PP), 6-O-methylguanine (O 6 The nucleic acid binding molecule according to claim 12, which is O6-(carboxymethyl)-2'-deoxyguanosine (O6-CMdG). 16. A nucleic acid binding molecule according to any one of embodiments 1 to 9, wherein the non-classical features are structural elements. 17. The nucleic acid binding molecule according to embodiment 16, wherein the structural elements are a hairpin, loop, Z-DNA structure, G-quadriplex, i-motif, bulge, triple-strand, trident, cruciform structure, quadruple-strand, ribose zipper, or pseudoknot. 18. A nucleic acid binding molecule according to any one of embodiments 1 to 17, wherein the binding domain is in contact with at least one modified nucleoside. 19. A nucleic acid binding molecule according to any one of embodiments 1 to 18, wherein the binding domain is in contact with a modified nucleoside and one or more nucleotides adjacent thereto. 20. A nucleic acid binding molecule according to any one of embodiments 1 to 19, wherein the adapter includes a linker and the binding domain is bound to the linker. 21. The nucleic acid binding molecule according to any one of embodiments 1 to 20, wherein the nucleic acid binding molecule further comprises an enzyme or a catalytic fragment or derivative thereof. 22. The nucleic acid binding molecule according to embodiment 21, wherein the enzyme is a base editing enzyme. 23. The nucleic acid binding molecule according to embodiment 22, wherein the base editing enzyme is cytosine deaminase or adenosine deaminase. 24. A nucleic acid binding molecule according to embodiment 23, wherein the base editing enzyme is APOBEC1 or APOBEC3A, or a catalytic fragment or derivative thereof. 25. The nucleic acid binding molecule according to embodiment 23, wherein the enzyme is DNA or RNA methylase, or pseudouridine synthase, or a catalytic fragment or derivative thereof. 26. The nucleic acid binding molecule according to embodiment 21, wherein the enzyme is DNA N-glycosylase or RNA N-glycosylase. 27. The nucleic acid binding molecule according to embodiment 21, wherein the enzyme is a transposase or an integrase. 28. The nucleic acid binding molecule according to embodiment 21, wherein the enzyme lacks catalytic activity. 29. A conjugate comprising a binding domain and an enzyme or a fragment thereof, wherein the binding domain binds to a nucleic acid binding molecule according to any one of embodiments 1 to 28. 30. The conjugate according to embodiment 29, wherein the binding domain and the enzyme of its fragment are covalently bonded. 31. The conjugate according to embodiment 29, wherein the binding domain and the enzyme or its fragment are non-covalently bonded. 32. The conjugate according to any one of embodiments 29 to 31, wherein the enzyme is a Tn5 transposase. 33. The conjugate according to embodiment 32, wherein tagmentase is fused with protein A, G, or L. 34.i) a nucleic acid binding molecule according to any one of embodiments 1 to 28, further comprising a peptide tag, and (ii) an enzyme or fragment thereof fused to a protein tag that can covalently react with the peptide tag. 35.i) a nucleic acid binding molecule according to any one of embodiments 1 to 28, further comprising a protein tag, and (ii) an enzyme or fragment thereof fused to a peptide tag that can covalently react with the protein tag. 36. The conjugate according to any one of embodiments 34 to 35, wherein the peptide tag is a Spytag. 37. The conjugate according to any one of embodiments 34 to 36, wherein the enzyme is a deaminase and is fused to a spycatcher protein. 38.i) A conjugate comprising (ii) a nucleic acid binding molecule according to any one of embodiments 1 to 28, and an enzyme or fragment thereof fused to a protein that can bind with high affinity to a specific region of the binding domain. 39. The conjugate according to embodiment 38, wherein the binding domain is an IgG antibody or a fragment thereof. 40. The conjugate according to embodiment 39, wherein the enzyme is a deaminase fused to protein A, G, or L. 41.i) a nucleic acid binding molecule according to any one of embodiments 1 to 28, further comprising a nucleic acid tag, and (ii) an enzyme or fragment thereof fused to a complementary nucleic acid tag that can hybridize to the nucleic acid tag of the nucleic acid binding molecule. 42. A complex comprising a nucleic acid binding molecule according to any one of embodiments 1 to 28, bound to a target nucleic acid. 43. The complex according to embodiment 42, wherein a nucleic acid binding molecule and a target nucleic acid are covalently bonded. 44. A substrate bound to a nucleic acid binding molecule according to any one of embodiments 1 to 28. 45. The substrate according to embodiment 44, wherein the substrate is a bead, a chip, a plate, a slide, a dish, or a three-dimensional matrix. 46. ​​The substrate according to embodiment 45, wherein a nucleic acid binding molecule is bound to the surface of the substrate. 47. The substrate according to embodiment 46, wherein a nucleic acid binding molecule is indirectly bound to the surface of the substrate via a capture molecule, and the capture molecule is directly bound to the substrate. 48. The substrate according to embodiment 47, wherein the capture molecule binds to the nucleic acid binding molecule. 49. The substrate according to embodiment 47, wherein the capture molecule is bound to the target nucleic acid. 50. The substrate according to embodiment 47, wherein the nucleic acid binding molecule binds to a target nucleic acid bound to the capture molecule. 51. A substrate according to any one of embodiments 44 to 50, wherein the nucleic acid binding molecule is spatially separated from the second nucleic acid binding molecule on the surface of the substrate. 52. A polymer bonded to a nucleic acid binding molecule according to any one of embodiments 1 to 28. 53. A method for producing a nucleic acid binding molecule according to any one of embodiments 1 to 28, comprising coupling a binding domain to an adapter to form a binding domain-adapter conjugate. 54. A method for analyzing multiple target nucleic acids, (i) A step of bringing a target nucleic acid into contact with a nucleic acid binding molecule according to any one of embodiments 1 to 28; (ii)(a) generating a barcoded target nucleic acid by transcribing a nucleic acid barcode onto a target nucleic acid in an environment that substantially prevents off-target generation of barcoded nucleic acid, or (b) generating a barcoded copy of the target nucleic acid; (iii) Modifying the barcoded target nucleic acid or its barcoded copy so that the location of non-classical features is identifiable based on the primary nucleic acid sequence of the barcoded target nucleic acid or its barcoded copy; and (iv) Steps to determine the base sequence of a barcode target nucleic acid. Analytical methods, including those mentioned above. 55. The method according to embodiment 54, comprising adding a short nucleic acid sequence to the 3' end of the target nucleic acid prior to step (i) in order to facilitate barcode transcription. 56. The method according to embodiment 54, wherein steps (i) to (iii) are repeated at least once. 57. The method according to embodiment 56, wherein a different nucleic acid binding molecule is used each time steps (i) to (iii) are repeated. 58. The method according to embodiment 56, wherein the same nucleic acid binding molecule is used each time steps (i) to (iii) are repeated. 59. The method according to embodiment 21, wherein a nucleic acid barcode is enzymatically transferred to a target nucleic acid by single-strand ligation, sprint ligation, primer extension, or double-strand ligation. 60. The method according to aspect 59, wherein a nucleic acid barcode is transferred to a target nucleic acid by primer extension, where the primer extension begins by ligation of the nucleic acid having a universal sequence to the 3' end of the target nucleic acid. 61. The method according to embodiment 60, wherein a nucleic acid barcode is transferred to a target RNA by primer elongation, where the primer elongation begins by enzymatically tailing the 3' end of the target nucleic acid using Escherichia coli poly(A) polymerase or Schizosaccharomyces pomby Cid1 poly(U) polymerase, in combination with one ribonucleotide and a competing complementary poly-dT, poly-dA, poly-dG, or poly-dC oligonucleotide. 62. The method according to any one of embodiments 54 to 61, comprising amplifying a barcoded target nucleic acid or a copy thereof before sequencing. 63. The method according to any one of embodiments 54 to 61, wherein the target nucleic acid comprises DNA, RNA, or a mixture thereof. 64. The method according to any one of embodiments 54 to 63, wherein the target nucleic acid includes at least one non-classical feature. 65. The method according to embodiment 64, wherein the non-classical feature is a modified nucleoside. 66. Modified nucleosides include 3-methylcytidine (m3C), 5-methylcytidine (m5C), N4-acetylcytidine (ac4C), pseudouridine (Ψ), 1-methyladenosine (m1A), N 6 - Methyladenosine (m6A), Inosine (I), 7-Methylguanosine (m7G), Dihydrouridine (D), 3-Methyluridine (m3U), 5-Methyluridine (m5U), 1-Methylguanosine (m1G), N 2 -Methylguanosine (m2G), 5-methyldeoxycytidine (m5dC), N 4 -Methyldeoxycytidine, 5-hydroxymethylcytidine (5-hmC), 5-hydroxymethyldeoxycytidine (5hmdC), 5-carboxydeoxycytidine (5cadC), 5-formylcytidine (5fC), 5-formyldeoxycytidine (5fdC), 6-methyldeoxyadenosine, N 7 The method according to embodiment 61, wherein the methylguanosine is m7G, 2,7,2'-methylguanosine, or ribose methylated (Nm). 67. The method according to embodiment 64, wherein the non-classical feature is nucleic acid damage. 68. The method according to embodiment 67, wherein nucleic acid damage is caused by an oxidation process or contact with ultraviolet light. 69. The method according to embodiment 67, wherein nucleic acid damage is caused by large adduct formation or base alkylation due to an exogenous agent. 70. Damage to 8-oxoguanine (8-oxoG), one or more debase sites, cis-platin crosslinks, benzo(a)pyridinediol epoxide (BPDE) adducts, cyclobutenepyrimidine dimers (CPD), pyrimidine-pyrimidone (6-4) photoproducts (6-4PP), 6-O-methylguanine (O 6 The nucleic acid binding molecule according to embodiment 64, which is -MedG, or O6-(carboxymethyl)-2'-deoxyguanosine (O6-CMdG). 71. The method according to aspect 64, wherein the non-classical features are structural elements. 72. The method according to embodiment 71, wherein the structural elements are a hairpin, loop, Z-DNA structure, G-quadruplicate, i-motif, bulge, triple, trident, cruciform structure, tetraloop, ribose zipper, or pseudoknot. 73. The method according to any one of embodiments 54 to 72, wherein a nucleic acid binding molecule is bound to the surface of a substrate and spatially separated from other nucleic acid binding molecules so that each target nucleic acid can come into contact with only one target nucleic acid binding molecule. 74. The method according to any one of embodiments 54 to 73, wherein a nucleic acid barcode is transferred to a target nucleic acid by covalently bonding the barcode or its complement to the 5' or 3' end of the target nucleic acid. 75. The method according to any one of embodiments 54 to 73, wherein a nucleic acid barcode is enzymatically transferred to a target nucleic acid by single-strand ligation, sprint ligation, primer extension, or double-strand ligation. 76. The method according to any one of embodiments 54 to 73, wherein a nucleic acid barcode is transferred to a target nucleic acid by chemical ligation. 77. The method according to any one of embodiments 54 to 76, wherein the modification includes photochemically or chemically linking a nucleic acid binding molecule to a target nucleic acid. 78. The method according to any one of embodiments 54 to 77, wherein the binding domain presents a chemical crosslinking portion in an orientation that promotes a covalent bonding reaction with a nucleic acid target. 79. The method according to any one of embodiments 54 to 77, wherein the modification involves editing a base near or at a site where a nucleic acid-binding molecule binds to a target nucleic acid. 80. A method for detecting and / or quantifying two or more non-classical features in multiple target nucleic acids, (i) A step of contacting a target nucleic acid with at least two nucleic acid binding molecules, each nucleic acid binding molecule comprising a binding domain and an adapter, wherein the binding domain of each nucleic acid binding molecule binds to different non-classical features of DNA or RNA, and the adapter comprises a nucleic acid barcode sequence specific to the non-classical feature to which each binding domain specifically binds; (ii) A step of (a) transferring a nucleic acid barcode to a target nucleic acid in an environment that substantially prevents off-target generation of barcoded nucleic acids to generate a barcoded target nucleic acid, or (b) generating a barcoded copy of the target nucleic acid; (iii) Modifying the barcoded target nucleic acid or its barcoded copy so that the location of non-classical features can be identified based on the primary nucleic acid sequence of the barcoded target nucleic acid or its barcoded copy; and (vi) The process of determining the base sequence of a barcoded target nucleic acid. Methods that include... 81. The method according to embodiment 80, comprising amplifying a barcoded target nucleic acid or a copy thereof before sequencing. 82. The method according to embodiment 80 or 81, wherein the target nucleic acid comprises DNA, RNA, or a mixture thereof. 83. The method according to any one of embodiments 80 to 82, wherein at least one of the non-classical features is a modified nucleoside. 84. Modified nucleosides include 3-methylcytidine (m3C), 5-methylcytidine (m5C), and N 4 - Acetylcytidine (ac4C), pseudouridine (Ψ), 1-methyladenosine (m1A), N 6 - Methyladenosine (m6A), Inosine (I), 7-Methylguanosine (m7G), Dihydrouridine (D), 3-Methyluridine (m3U), 5-Methyluridine (m5U), 1-Methylguanosine (m1G), N 2 -Methylguanosine (m2G), 5-methyldeoxycytidine (m5dC), N 4-Methyldeoxycytidine, 5-hydroxymethylcytidine (5-hmC), 5-hydroxymethyldeoxycytidine (5hmdC), 5-carboxydeoxycytidine (5cadC), 5-formylcytidine (5fC), 5-formyldeoxycytidine (5fdC), 6-methyldeoxyadenosine, N 7 The method according to embodiment 83, wherein the methylguanosine is m7G, 2,7,2'-methylguanosine, or ribose methylated (Nm). 85. The method according to aspect 82, wherein the non-classical feature is nucleic acid damage. 86. The method according to embodiment 85, wherein nucleic acid damage is caused by an oxidation process or contact with ultraviolet light. 87. The method according to embodiment 85, wherein nucleic acid damage is caused by large adduct formation or base alkylation due to an exogenous agent. 88. Damage to 8-oxoguanine (8-oxoG), one or more debase sites, cis-platin crosslinks, benzo(a)pyridinediol epoxide (BPDE) adducts, cyclobutenpyrimidine dimers (CPD), pyrimidine-pyrimidone (6-4) photoproducts (6-4PP), 6-O-methylguanine (O 6 The nucleic acid binding molecule according to embodiment 82, which is -MedG, or O6-(carboxymethyl)-2'-deoxyguanosine (O6-CMdG). 89. The method according to any one of embodiments 80 to 82, wherein at least one of the non-classical features is a structural element. 90. The method according to embodiment 89, wherein the structural elements are hairpins, loops, Z-DNA structures, G-quadruplicates, i-motifs, bulges, triples, tridents, cruciform structures, quadruple loops, ribose zippers, or false bonds. 91. The method according to any one of embodiments 80 to 90, wherein nucleic acid binding molecules are bound to the surface of a substrate and are spatially separated so that each target nucleic acid can contact only one target nucleic acid binding molecule. 92. The method according to any one of embodiments 80 to 91, wherein a nucleic acid barcode is transferred to a target nucleic acid by covalently bonding the barcode or its complement to the 5' or 3' end of the target nucleic acid. 93. The method according to any one of embodiments 80 to 91, wherein a nucleic acid barcode is enzymatically transferred to a target nucleic acid by single-strand ligation, sprint ligation, primer extension, or double-strand ligation. 94. The method according to any one of embodiments 80 to 90, wherein a nucleic acid barcode is transcribed onto a target nucleic acid by chemical ligation. 95. The method according to any one of embodiments 80 to 94, wherein the modification includes photochemically linking a nucleic acid binding molecule to a target nucleic acid. 96. The method according to any one of embodiments 80 to 94, wherein the modification involves editing a base near or at a site where a nucleic acid-binding molecule binds to a target nucleic acid. 97. A method for detecting non-classical features in a target nucleic acid, (i) A step of bringing a target nucleic acid into contact with a nucleic acid binding molecule according to any one of embodiments 1 to 28; (ii)(a) A step of generating a barcoded target nucleic acid by transferring a nucleic acid barcode to a target nucleic acid in an environment that substantially prevents off-target generation of the barcoded target nucleic acid; and (iii) Steps to detect the presence of a barcode in the target nucleic acid or a copy thereof. Methods that include... 98. The method according to embodiment 97, wherein the non-classical feature is a modified nucleoside. 99. Modified nucleosides include 3-methylcytidine (m3C), 5-methylcytidine (m5C), and N 4 - Acetylcytidine (ac4C), pseudouridine (Ψ), 1-methyladenosine (m1A), N 6 - Methyladenosine (m6A), Inosine (I), 7-Methylguanosine (m7G), Dihydrouridine (D), 3-Methyluridine (m3U), 5-Methyluridine (m5U), 1-Methylguanosine (m1G), N 2 -Methylguanosine (m2G), 5-methyldeoxycytidine (m5dC), N 4-Methyldeoxycytidine, 5-hydroxymethylcytidine (5-hmC), 5-hydroxymethyldeoxycytidine (5hmdC), 5-carboxydeoxycytidine (5cadC), 5-formylcytidine (5fC), 5-formyldeoxycytidine (5fdC), 6-methyldeoxyadenosine, N 7 The method according to embodiment 98, wherein the methylguanosine is m7G, 2,7,2'-methylguanosine, or ribose methylated (Nm). 100. The method according to embodiment 97, wherein the non-classical feature is nucleic acid damage. 101. The method according to embodiment 100, wherein nucleic acid damage is caused by an oxidation process or contact with ultraviolet light. 102. The method according to embodiment 100, wherein nucleic acid damage is caused by large adduct formation or base alkylation due to an exogenous agent. 103. Damage to 8-oxoguanine (8-oxoG), one or more debase sites, cis-platin crosslinks, benzo(a)pyrenediol epoxide (BPDE) adducts, cyclobutenpyrimidine dimers (CPD), pyrimidine-pyrimidone (6-4) photoproducts (6-4PP), 6-O-methylguanine (O 6 The method according to embodiment 100, wherein the material is O6-(carboxymethyl)-2'-deoxyguanosine (O6-CMdG). 104. The method according to embodiment 100, wherein the non-classical features are structural elements. 105. The method according to claim 104, wherein the structural element is a hairpin, loop, Z-DNA structure, G-quadruplicate, i-motif, bulge, triple, trident, cruciform structure, quadruplicate, ribose zipper, or false bond. 106. The method according to any one of embodiments 97 to 105, wherein the transfer comprises covalently attaching a barcode or its complement to the 5' or 3' end of a target nucleic acid. 107. The method according to any one of embodiments 97 to 105, wherein a nucleic acid barcode is transferred to a target nucleic acid by single-strand ligation, sprint ligation, sprint extension, template extension, or double-strand ligation. 108. The method according to any one of embodiments 97 to 105, wherein a nucleic acid barcode is transferred to a target nucleic acid by chemical ligation. 109. The method according to any one of embodiments 97 to 108, wherein steps (i) to (iii) are repeated at least once. 110. The method according to any one of embodiments 97 to 109, wherein detecting the presence of a barcode includes modifying a barcoded target nucleic acid or a barcoded copy thereof. 111. The method according to any one of embodiments 97 to 109, wherein detecting the presence of a barcode comprises amplifying a barcoded target nucleic acid or a copy thereof. 112. The method according to any one of embodiments 97 to 109, wherein detecting the presence of a barcode includes sequencing a barcoded target nucleic acid. 113. A method for determining the location of non-classical features in a target nucleic acid with single-nucleotide resolution in the vicinity or with single-nucleotide resolution. (i) A step of bringing a target nucleic acid into contact with a nucleic acid binding molecule according to any one of embodiments 1 to 28; (ii) the step of transferring a nucleic acid barcode to a target nucleic acid in order to generate a barcoded target nucleic acid in an environment that substantially prevents off-target generation of the barcoded target nucleic acid; and (iii) A step of detecting the presence of a barcode in the target nucleic acid or a copy thereof; Here, the nucleic acid binding molecule contains a binding domain capable of one or more of the following: (a) to induce mutations in the target nucleic acid; or (b) A process that prevents polymerase bypass and causes cleavage during copying of the target nucleic acid. Methods that include... 114. The method according to embodiment 113, wherein preventing polymerase bypass includes chemically or photochemically linking a nucleic acid binding molecule to a target nucleic acid. 115. The method according to embodiment 113, comprising chemically modifying the binding domain to induce cleavage during copying of a target nucleic acid in order to prevent polymerase bypass. 116. The method according to any one of embodiments 113 to 115, wherein the non-classical feature is a modified nucleoside. 117. Modified nucleosides include 3-methylcytidine (m3C), 5-methylcytidine (m5C), and N 4 - Acetylcytidine (ac4C), pseudouridine (Ψ), 1-methyladenosine (m1A), N 6 - Methyladenosine (m6A), Inosine (I), 7-Methylguanosine (m7G), Dihydrouridine (D), 3-Methyluridine (m3U), 5-Methyluridine (m5U), 1-Methylguanosine (m1G), N 2 -Methylguanosine (m2G), 5-methyldeoxycytidine (m5dC), N 4 -Methyldeoxycytidine, 5-hydroxymethylcytidine (5-hmC), 5-hydroxymethyldeoxycytidine (5hmdC), 5-carboxydeoxycytidine (5cadC), 5-formylcytidine (5fC), 5-formyldeoxycytidine (5fdC), 6-methyldeoxyadenosine, N 7 The method according to embodiment 116, wherein the methylguanosine is m7G, 2,7,2'-methylguanosine, or ribose methylated (Nm). 118. The method according to any one of embodiments 113 to 115, wherein the non-classical feature is nucleic acid damage. 119. The method according to aspect 118, wherein nucleic acid damage is caused by an oxidative process or contact with ultraviolet light. 120. The method according to embodiment 118, wherein nucleic acid damage is caused by large adduct formation or base alkylation due to an exogenous agent. 121. Damage to 8-oxoguanine (8-oxoG), one or more debase sites, cis-platin crosslinks, benzo(a)pyrenediol epoxide (BPDE) adducts, cyclobutenepyrimidine dimers (CPD), pyrimidine-pyrimidone (6-4) photoproducts (6-4PP), 6-O-methylguanine (O 6 -MedG), or O6-(carboxymethyl)-2'-deoxyguanosine (O6-CMdG), as described in embodiment 118. 122. The method according to any one of embodiments 113 to 115, wherein the non-classical feature is a structural element. 123. The method according to embodiment 122, wherein the structural elements are hairpins, loops, Z-DNA structures, G-quadruplicates, i-motifs, bulges, triples, tridents, cruciform structures, quadruple loops, ribose zippers, or false bonds. 124. The method according to any one of embodiments 113 to 123, wherein the transfer comprises covalently attaching a barcode or its complement to the 5' or 3' end of a target nucleic acid. 125. The method according to any one of embodiments 113 to 123, wherein steps (i) to (iii) are repeated at least once. 126. The method according to embodiment 124, wherein a different nucleic acid binding molecule is used each time steps (i) to (iii) are repeated. 127. The method according to embodiment 124, wherein the same nucleic acid binding molecule is used each time steps (i) to (iii) are repeated. 128. The method according to any one of embodiments 113 to 127, wherein detecting the presence of a barcode includes modifying a barcoded target nucleic acid or a barcoded copy thereof. 129. The method according to any one of embodiments 113 to 127, wherein detecting the presence of a barcode comprises amplifying a barcoded target nucleic acid or a copy thereof. 130. The method according to any one of embodiments 113 to 127, wherein detecting the presence of a barcode includes sequencing a barcoded target nucleic acid. 131. The method according to any one of embodiments 113 to 127, wherein detecting the presence of a barcode includes sequencing an adapter for nucleic acids and nucleic acid-binding molecules. 132. The method according to any one of embodiments 113 to 131, wherein transferring a nucleic acid barcode to a target nucleic acid includes covalently bonding the barcode or its complement to the 5' or 3' end of the target nucleic acid.

Claims

1. i) a binding domain, and ii) an adapter; wherein the binding domain specifically binds to a non-classical feature of DNA or RNA, the adapter comprises a nucleic acid barcode sequence that is unique to the non-classical feature specifically bound by the binding domain, and the binding domain comprises an antibody, a nanobody, an aptamer, a reader protein, a writer protein, an eraser protein, an artificial polymer scaffold, an artificial protein scaffold, or a selective covalent capture reagent, or a fragment or derivative thereof.

2. The nucleic acid binding molecule of claim 1, wherein the reader protein is NUDT16 or YTHDC2, or a fragment or derivative thereof, the writer protein is DNTM1, DNTM3A / B, NAT10, METTL3, METTL8, METTL14, METTL16, TRM, BMT, DUS2, PUS, or NSUN2, or a fragment or derivative thereof, and the eraser protein is FTO, ALKBH3, or ALKBH5, or a fragment or derivative thereof.

3. The nucleic acid binding molecule of claim 1 or 2, wherein the binding domain has no catalytic activity.

4. The nucleic acid binding molecule of any one of claims 1 to 3, wherein the adapter is cleavable, the adapter comprises at least one of a universal forward primer (UFP) and a universal reverse primer (URP), and the adapter comprises a unique molecular identifier (UMI) or a combination thereof.

5. Non-classical features include 3-methylcytidine (m3C), 5-methylcytidine (m5C), N4-acetylcytidine (ac4C), pseudouridine (Ψ), 1-methyladenosine (m1A), N6-methyladenosine (m6A), inosine (I), 7-methylguanosine (m7G), dihydrouridine (D), 3-methyluridine (m3U), 5-methyluridine (m5U), 1-methylguanosine (m1G), N2-methylguanosine (m2G), 5-methyldeoxycytidine (m5dC), N4-methyl 5. The nucleic acid binding molecule of claim 1, wherein the modified nucleoside is selected from 5-methylcytidine, 5-hydroxymethylcytidine (5-hmC), 5-hydroxymethyldeoxycytidine (5hmdC), 5-carboxydeoxycytidine (5cadC), 5-formylcytidine (5fC), 5-formyldeoxycytidine (5fdC), 6-methyldeoxyadenosine, N7-methylguanosine (m7G), 2,7,2'-methylguanosine, or ribose methylation (Nm).

6. 5. The nucleic acid binding molecule of any one of claims 1 to 4, wherein the non-classical characteristic is nucleic acid damage, the nucleic acid damage is due to an oxidative process or exposure to ultraviolet light, the nucleic acid damage is due to bulky adduct formation or base alkylation by an exogenous agent, or the nucleic acid damage is 8-oxoguanine (8-oxoG), one or more abasic sites, cis-platin crosslinks, benzo(a)pyrene diol epoxide (BPDE) adducts, cyclobutene pyrimidine dimers (CPD), pyrimidine-pyrimidone (6-4) photoproducts (6-4PP), 6-O-methylguanine (O 6 -MedG), or O6-(carboxymethyl)-2'-deoxyguanosine (O6-CMdG).

7. 5. The nucleic acid binding molecule of any one of claims 1 to 4, wherein the non-classical feature is a structural element selected from a hairpin, a loop, a Z-DNA structure, a G-quadruplex, a triplex, an i-motif, a bulge, a triplex, a three-pronged bond, a cruciform structure, a quadruplex, a ribose zipper, or a pseudoknot.

8. 8. A nucleic acid binding molecule according to any one of claims 1 to 7, wherein the binding domain is contacted with at least one modified nucleoside.

9. 9. A nucleic acid binding molecule according to any one of claims 1 to 8, wherein the binding domain contacts the modified nucleoside and one or more nucleotides adjacent thereto.

10. The nucleic acid binding molecule of claim 1 , wherein the adaptor comprises a linker and the binding domain is attached to the linker.

11. The nucleic acid binding molecule of claim 1 , further comprising an enzyme or a catalytic fragment or derivative thereof.

12. 12. The nucleic acid binding molecule of claim 11, wherein the enzyme is a base editing enzyme; a DNA or RNA methylase, or a pseudouridine synthetase, or a catalytic fragment or derivative thereof; a DNA N-glycosylase or an RNA N-glycosylase; or a transposase or an integrase.

13. The nucleic acid binding molecule of claim 12, wherein the base editing enzyme is cytosine deaminase or adenosine deaminase.

14. The nucleic acid binding molecule of claim 12, wherein the base editing enzyme is APOBEC1 or APOBEC3A, or a catalytic fragment or derivative thereof.

15. A conjugate comprising a binding domain and an enzyme or a fragment thereof, wherein the binding domain binds to a nucleic acid binding molecule according to any one of claims 1 to 14.

16. 16. The conjugate of claim 15, wherein the binding domain and the enzyme or fragment thereof are covalently linked.

17. 16. The conjugate of claim 15, wherein the binding domain and the enzyme or fragment thereof are non-covalently linked.

18. 18. The conjugate of any one of claims 15 to 17, wherein the enzyme is Tn5 transposase.

19. The conjugate of claim 18, wherein the Tn5 transposase is fused to protein A, G or L.

20. (i) a nucleic acid binding molecule comprising i) a binding domain, and ii) an adapter, further comprising a protein tag, wherein the binding domain specifically binds to a non-classical feature of DNA or RNA, and the adapter comprises a nucleic acid barcode sequence that is unique to the non-classical feature specifically bound by the binding domain; and (ii) an enzyme or a fragment thereof fused to a peptide tag capable of covalently reacting with the protein tag; A conjugate comprising:

21. (i) a nucleic acid binding molecule comprising i) a binding domain, and ii) an adaptor, wherein the binding domain specifically binds to a non-classical feature of DNA or RNA, and the adaptor comprises a nucleic acid barcode sequence that is unique to the non-classical feature specifically bound by the binding domain; and (ii) an enzyme or a fragment thereof fused to a protein capable of binding with high affinity to a specific region of the binding domain; A conjugate comprising:

22. 22. The conjugate of claim 21 , wherein the binding domain is an IgG antibody or a fragment thereof.

23. 22. The conjugate of claim 21 , wherein the enzyme is a deaminase fused to Protein A, G or L.

24. A complex comprising a nucleic acid binding molecule bound to a target nucleic acid, wherein the nucleic acid binding molecule comprises i) a binding domain, and ii) an adaptor, wherein the binding domain specifically binds to a non-classical feature of DNA or RNA, and the adaptor comprises a nucleic acid barcode sequence that is unique to the non-classical feature specifically bound by the binding domain; wherein the nucleic acid binding molecule and the target nucleic acid are covalently linked; Complex.

25. 1. A method for analyzing a plurality of target nucleic acids, comprising: (i) contacting a target nucleic acid with a nucleic acid binding molecule comprising i) a binding domain, and ii) an adaptor, where the binding domain specifically binds to a non-classical feature of DNA or RNA, and the adaptor comprises a nucleic acid barcode sequence that is unique to the non-classical feature specifically bound by the binding domain; (ii) (a) transferring a nucleic acid barcode to a target nucleic acid to generate a barcoded target nucleic acid, or (b) generating a barcoded copy of the target nucleic acid, in an environment that substantially prevents off-target generation of the barcoded nucleic acid; (iii) modifying the barcoded target nucleic acid or a barcoded copy thereof such that the location of the non-classical feature is identifiable based on the primary nucleic acid sequence of the barcoded target nucleic acid or the barcoded copy thereof; and (iv) determining the sequence of the barcoded target nucleic acid , an analytical method.

26. 26. The method of claim 25, comprising adding a short nucleic acid sequence to the 3' end of the target nucleic acid prior to step (i) to facilitate transcription of the barcode.

27. 27. The method of claim 25 or 26, wherein steps (i) to (iii) are repeated at least once.

28. 28. The method of claim 27, wherein each time steps (i) to (iii) are repeated, a different nucleic acid binding molecule is used, or each time steps (i) to (iii) are repeated, the same nucleic acid binding molecule is used.

29. 26. The method of claim 25, wherein the nucleic acid barcode is enzymatically transferred to the target nucleic acid by single-stranded ligation, splint ligation, primer extension, or double-stranded ligation; the nucleic acid barcode is transferred to the target nucleic acid by primer extension, where primer extension is initiated by ligation of a nucleic acid having a universal sequence to the 3' end of the target nucleic acid; or the nucleic acid barcode is transferred to the target RNA by primer extension, where primer extension is initiated by enzymatic tailing of the 3' end of the target nucleic acid using E. coli poly(A) polymerase or Schizosaccharomyces pomby Cid1 poly(U) polymerase with one ribonucleotide and a competing complementary poly-dT, poly-dA, poly-dG, or poly-dC oligonucleotide.

30. 30. The method of any one of claims 25 to 29, comprising amplifying the barcoded target nucleic acid or a copy thereof prior to sequencing.

31. 31. The method of any one of claims 25 to 30, wherein the target nucleic acid comprises DNA, RNA or a mixture thereof.

32. 32. The method of any one of claims 25 to 31, wherein the target nucleic acid comprises at least one non-classical feature.

33. Non-classical features include 3-methylcytidine (m3C), 5-methylcytidine (m5C), N4-acetylcytidine (ac4C), pseudouridine (Ψ), 1-methyladenosine (m1A), N6-methyladenosine (m6A), inosine (I), 7-methylguanosine (m7G), dihydrouridine (D), 3-methyluridine (m3U), 5-methyluridine (m5U), 1-methylguanosine (m1G), N2-methylguanosine (m2G), 5-methyldeoxycytidine (m5dC), N4 33. The method of claim 32, wherein the modified nucleoside is selected from 5-methyldeoxycytidine, 5-hydroxymethylcytidine (5-hmC), 5-hydroxymethyldeoxycytidine (5hmdC), 5-carboxydeoxycytidine (5cadC), 5-formylcytidine (5fC), 5-formyldeoxycytidine (5fdC), 6-methyldeoxyadenosine, N 7 -methylguanosine (m7G), 2,7,2'-methylguanosine, or ribose methylated (Nm).

34. 33. The method of claim 32, wherein the non-classical characteristic is nucleic acid damage, the nucleic acid damage results from an oxidative process or exposure to ultraviolet light, the nucleic acid damage results from bulky adduct formation or base alkylation by an exogenous agent, or the damage is 8-oxoguanine (8-oxoG), one or more abasic sites, cis-platin crosslinks, benzo(a)pyrene diol epoxide (BPDE) adducts, cyclobutene pyrimidine dimers (CPD), pyrimidine-pyrimidone (6-4) photoproducts (6-4PP), 6-O-methylguanine (O 6 -MedG), or O6-(carboxymethyl)-2'-deoxyguanosine (O6-CMdG).

35. 33. The method of claim 32, wherein the non-classical feature is a structural element selected from a hairpin, a loop, a Z-DNA structure, a G-quadruplex, a triplex, an i-motif, a bulge, a triplex, a three-pronged bond, a cruciform structure, a quadruplex loop, a ribose zipper, or a pseudoknot.

36. 36. A method according to any one of claims 25 to 35, wherein the nucleic acid binding molecules are bound to the surface of the substrate and spatially separated from other nucleic acid binding molecules such that each target nucleic acid is contacted by only one target nucleic acid binding molecule.

37. 37. The method of any one of claims 25 to 36, wherein the nucleic acid barcode is transcribed to the target nucleic acid by covalently linking the barcode or its complement to the 5' or 3' end of the target nucleic acid, the nucleic acid barcode is enzymatically transferred to the target nucleic acid by single-stranded ligation, splint ligation, primer extension, or double-stranded ligation, or the nucleic acid barcode is transferred to the target nucleic acid by chemical ligation.

38. A method described in any one of claims 25 to 37, wherein the modification comprises photochemically or chemically linking the nucleic acid binding molecule to the target nucleic acid, or comprises editing a base at or near the site where the nucleic acid binding molecule binds to the target nucleic acid.

39. 39. The method of any one of claims 25 to 38, wherein the binding domain presents the chemical cross-linking moiety in an orientation that promotes a covalent binding reaction with a nucleic acid target.

40. 1. A method for detecting two or more non-classical features in a plurality of target nucleic acids, comprising: (i) contacting a target nucleic acid with at least two nucleic acid binding molecules, each nucleic acid binding molecule comprising a binding domain and an adapter, wherein the binding domain of each nucleic acid binding molecule binds to a different non-classical feature of DNA or RNA, and the adapter comprises a nucleic acid barcode sequence specific for the non-classical feature specifically bound by each binding domain; (ii) (a) transferring a nucleic acid barcode to a target nucleic acid to generate a barcoded target nucleic acid, or (b) generating a barcoded copy of the target nucleic acid, in an environment that substantially prevents off-target generation of the barcoded nucleic acid; (iii) modifying the barcoded target nucleic acid or a barcoded copy thereof such that the location of the non-classical feature is identifiable based on the primary nucleic acid sequence of the barcoded target nucleic acid or the barcoded copy thereof; and (vi) sequencing the barcoded target nucleic acid. A method comprising:

41. 41. The method of claim 40, comprising amplifying the barcoded target nucleic acid or a copy thereof prior to sequencing.

42. 42. The method of claim 40 or 41, wherein the target nucleic acid comprises DNA, RNA or a mixture thereof.

43. At least one of the non-classical features is 3-methylcytidine (m3C), 5-methylcytidine (m5C), N 4 -acetylcytidine (ac4C), pseudouridine (Ψ), 1-methyladenosine (m1A), N 6 -methyladenosine (m6A), inosine (I), 7-methylguanosine (m7G), dihydrouridine (D), 3-methyluridine (m3U), 5-methyluridine (m5U), 1-methylguanosine (m1G), N 2 -methylguanosine (m2G), 5-methyldeoxycytidine (m5dC), N 4 43. The method of any one of claims 40 to 42, wherein the modified nucleoside is selected from 5-methyldeoxycytidine, 5-hydroxymethylcytidine (5-hmC), 5-hydroxymethyldeoxycytidine (5hmdC), 5-carboxydeoxycytidine (5cadC), 5-formylcytidine (5fC), 5-formyldeoxycytidine (5fdC), 6-methyldeoxyadenosine, N 7 -methylguanosine (m7G), 2,7,2'-methylguanosine, or ribose methylated (Nm).

44. 43. The method of any one of claims 40 to 42, wherein the non-classical feature is nucleic acid damage, where the nucleic acid damage results from an oxidative process or contact with ultraviolet light, or results from bulky adduct formation or base alkylation by an exogenous agent, or where the damage is 8-oxoguanine (8-oxoG), one or more abasic sites, cis-platin crosslinks, benzo(a)pyrene diol epoxide (BPDE) adducts, cyclobutene pyrimidine dimers (CPD), pyrimidine-pyrimidone (6-4) photoproducts (6-4PP), 6-O-methylguanine (O 6 -MedG), or O6-(carboxymethyl)-2'-deoxyguanosine (O6-CMdG).

45. 43. The method of any one of claims 40 to 42, wherein at least one of the non-classical features is a structural element selected from a hairpin, a loop, a Z-DNA structure, a G-quadruplex, a triplex, an i-motif, a bulge, a triplex, a three-pronged bond, a cruciform structure, a quadruplex loop, a ribose zipper, or a pseudoknot.

46. 46. ​​The method of any one of claims 40 to 45, wherein the nucleic acid binding molecules are bound to the surface of a substrate and are spatially separated such that each target nucleic acid is contacted by only one target nucleic acid binding molecule.

47. 47. The method of any one of claims 40 to 46, wherein the nucleic acid barcode is transferred to the target nucleic acid by covalently linking the barcode or its complement to the 5' or 3' end of the target nucleic acid, enzymatically by single stranded ligation, splint ligation, primer extension, or double stranded ligation, or by chemical ligation.

48. A method described in any one of claims 40 to 47, wherein the modification comprises photochemically linking the nucleic acid binding molecule to the target nucleic acid or comprises editing a base at or near the site where the nucleic acid binding molecule binds to the target nucleic acid.

49. 1. A method for determining the location of a non-classical feature in a target nucleic acid at near or single base resolution, comprising: (i) contacting a target nucleic acid with a nucleic acid binding molecule according to any one of claims 1 to 14; (ii) transferring the nucleic acid barcode to the target nucleic acid in an environment that substantially prevents off-target generation of the barcoded nucleic acid to generate a barcoded target nucleic acid; and (iii) detecting the presence of the barcode in the target nucleic acid or a copy thereof; wherein the nucleic acid binding molecule comprises a binding domain which can be one or more of the following: (c) inducing a mutation in a target nucleic acid; or (d) causing cleavage between copies of the target nucleic acid by preventing polymerase bypass; A method comprising:

50. 50. The method of claim 49, wherein preventing polymerase bypass comprises chemically or photochemically linking a nucleic acid binding molecule to the target nucleic acid.